Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific AADAT KAT2, KATII ENSG00000109576 Aminoadipate aminotransferase 4 170060222-170091699 Enzymes, Predicted intracellular proteins Evidence at protein level HPA037502 Supported Approved Vesicles
Plasma membrane Colorectal cancer:5.59e-4 (favourable) Expressed in all Tissue enhanced liver: 34.6 prostate: 23.3 AAK1 DKFZp686K16132, KIAA1048 ENSG00000115977 AP2 associated kinase 1 2 69457997-69674349 Enzymes, Predicted intracellular proteins Evidence at protein level HPA017931, HPA020289 Approved Supported Plasma membrane
Cytosol Ovarian cancer:3.19e-4 (unfavourable) Expressed in all Tissue enriched 6 parathyroid gland: 382.6 thyroid gland: 59.1 ABCG2 ABCP, BCRP, CD338, EST157481, MXR ENSG00000118777 ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) 4 88090264-88231322 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037299, HPA054719 Supported Validated Nucleus
Plasma membrane Mixed Tissue enhanced small intestine: 116.1 seminal vesicle: 55.4 ABI1 ABI-1, E3B1, SSH3BP1 ENSG00000136754 Abl-interactor 1 10 26746593-26861087 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB008375, HPA029973, HPA068407 Approved Supported Plasma membrane
Cell Junctions Expressed in all Expressed in all cerebral cortex: 87.6 ACKR3 CMKOR1, CXCR7, GPR159, RDC1 ENSG00000144476 Atypical chemokine receptor 3 2 236567787-236582358 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA032003, HPA049718 Approved Supported Vesicles
Plasma membrane Renal cancer:1.76e-6 (unfavourable), Stomach cancer:2.01e-4 (unfavourable), Urothelial cancer:2.93e-4 (unfavourable), Cervical cancer:4.64e-4 (unfavourable) Expressed in all Expressed in all placenta: 175.2 ACTN1 ENSG00000072110 Actinin, alpha 1 14 68874143-68979440 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004303, HPA006035 Approved Validated Plasma membrane
Focal adhesion sites Renal cancer:9.08e-10 (unfavourable), Lung cancer:7.63e-5 (unfavourable), Head and neck cancer:2.49e-4 (unfavourable), Urothelial cancer:8.00e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 744.4 ACTR6 ARP6, FLJ13433 ENSG00000075089 ARP6 actin-related protein 6 homolog (yeast) 12 100199122-100241865 Predicted intracellular proteins Evidence at protein level HPA038587, HPA038588 Uncertain Approved Plasma membrane
Cytosol Liver cancer:7.70e-9 (unfavourable) Expressed in all Mixed testis: 16.2 ADAM10 CD156c, HsT18717, kuz, MADM ENSG00000137845 ADAM metallopeptidase domain 10 15 58588807-58749978 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB001709, HPA050670 Approved Supported Vesicles
Plasma membrane Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 47.8 ADAM28 ADAM23, eMDCII, MDC-Lm, MDC-Ls ENSG00000042980 ADAM metallopeptidase domain 28 8 24294040-24359018 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074034 Approved Plasma membrane
Mitochondria Endometrial cancer:3.17e-4 (favourable) Mixed Tissue enhanced epididymis: 428.3 stomach: 104.5 ADAM33 C20orf153, dJ964F7.1, DKFZp434K0521 ENSG00000149451 ADAM metallopeptidase domain 33 20 3667965-3682246 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA067152, HPA071758 Approved Uncertain Nuclear speckles
Plasma membrane Mixed Mixed endometrium: 102.9 ADAMTS2 ADAM-TS2, ADAMTS-3, hPCPNI, NPI, PCINP ENSG00000087116 ADAM metallopeptidase with thrombospondin type 1 motif, 2 5 179110851-179345430 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA028444 Uncertain Approved Vesicles
Plasma membrane Renal cancer:1.71e-8 (unfavourable) Expressed in all Mixed placenta: 27.2 ADAMTSL4 DKFZP434K1772, TSRC1 ENSG00000143382 ADAMTS-like 4 1 150549369-150560937 Disease related genes, Predicted secreted proteins Evidence at protein level HPA006279 Approved Approved Plasma membrane
Cytosol Renal cancer:4.35e-7 (unfavourable), Glioma:1.63e-4 (unfavourable), Colorectal cancer:1.86e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 89.1 lung: 32.7 ADAP1 CENTA1, GCS1L ENSG00000105963 ArfGAP with dual PH domains 1 7 897901-955407 Predicted intracellular proteins Evidence at protein level HPA007033, HPA012049 Supported Supported Plasma membrane
Cytosol Renal cancer:4.13e-5 (favourable), Colorectal cancer:5.25e-4 (unfavourable), Head and neck cancer:9.13e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 80.5 colon: 38.9 ADCK5 FLJ35454 ENSG00000173137 AarF domain containing kinase 5 8 144373101-144393242 Enzymes, Predicted membrane proteins Evidence at protein level HPA025692, HPA028679 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed duodenum: 9.9 ADD1 ENSG00000087274 Adducin 1 (alpha) 4 2843857-2930076 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009794, HPA035873, HPA035874 Supported Validated Nucleoplasm
Plasma membrane Renal cancer:1.29e-7 (favourable), Pancreatic cancer:3.94e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 201.7 ADGRG2 EDDM6, GPR64, HE6, TM7LN2 ENSG00000173698 Adhesion G protein-coupled receptor G2 X 18989309-19122637 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA001478, HPA050029 Supported Approved Plasma membrane
Cytosol Tissue enhanced Tissue enriched 6 epididymis: 1469.4 parathyroid gland: 235.5 ADGRL2 KIAA0786, LEC1, LPHH1, LPHN2 ENSG00000117114 Adhesion G protein-coupled receptor L2 1 81306160-81992436 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA043447 Approved Plasma membrane
Cell Junctions Endometrial cancer:1.33e-4 (unfavourable), Stomach cancer:3.00e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable) Expressed in all Mixed thyroid gland: 72.8 ADH1A ADH1 ENSG00000187758 Alcohol dehydrogenase 1A (class I), alpha polypeptide 4 99276367-99291028 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009562, HPA047814, HPA060902 Supported Approved Plasma membrane
Cytosol Liver cancer:2.38e-4 (favourable) Tissue enriched Tissue enriched 134 liver: 1364.4 gallbladder: 10.2 ADH1B ADH2 ENSG00000196616 Alcohol dehydrogenase 1B (class I), beta polypeptide 4 99304964-99321401 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047814, HPA060902 Supported Approved Plasma membrane
Cytosol Renal cancer:7.87e-4 (unfavourable) Tissue enriched Group enriched 6 adipose tissue: 1534.1;liver: 2889.4 lung: 371.7 ADH7 ADH-4 ENSG00000196344 Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide 4 99412261-99435737 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039695 Supported Supported Plasma membrane
Cytosol Group enriched Tissue enriched 6 esophagus: 216.3 tonsil: 35.9 ADRBK2 BARK2, GRK3 ENSG00000100077 Adrenergic, beta, receptor kinase 2 22 25564849-25729294 Enzymes, Predicted intracellular proteins Evidence at protein level HPA000804 Uncertain Approved Nucleus
Plasma membrane Urothelial cancer:1.29e-4 (favourable) Expressed in all Mixed adipose tissue: 32.7 ADSS ENSG00000035687 Adenylosuccinate synthase 1 244408494-244452134 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA024400 Supported Supported Plasma membrane
Cytosol Expressed in all Expressed in all testis: 116.4 AFAP1L2 Em:AC005383.4, FLJ14564, KIAA1914, XB130 ENSG00000169129 Actin filament associated protein 1-like 2 10 114294824-114404756 Predicted intracellular proteins Evidence at protein level HPA037843 Approved Supported Plasma membrane
Cytosol Renal cancer:1.55e-5 (unfavourable), Pancreatic cancer:3.76e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 137.4 parathyroid gland: 92.9 AGRN AGRIN ENSG00000188157 Agrin 1 1020123-1056118 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA040090 Approved Supported Plasma membrane
Cytosol Liver cancer:4.62e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 29.4 AHNAK MGC5395 ENSG00000124942 AHNAK nucleoprotein 11 62433542-62556235 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019010, HPA019070, HPA026643 Uncertain Supported Plasma membrane
Cytosol Urothelial cancer:3.47e-6 (unfavourable), Pancreatic cancer:2.42e-4 (unfavourable) Expressed in all Expressed in all skin: 398.0 AHNAK2 C14orf78 ENSG00000185567 AHNAK nucleoprotein 2 14 104937244-104978357 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA000878, HPA002940, HPA004145, HPA020111 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:4.05e-6 (unfavourable), Urothelial cancer:2.23e-5 (unfavourable), Lung cancer:2.79e-5 (unfavourable) Mixed Tissue enriched 8 skin: 346.3 smooth muscle: 45.9 AKAP10 D-AKAP2, MGC9414, PRKA10 ENSG00000108599 A kinase (PRKA) anchor protein 10 17 19904302-19978343 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA028901 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all testis: 26.1 AKAP12 AKAP250, SSeCKS ENSG00000131016 A kinase (PRKA) anchor protein 12 6 151239999-151358557 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006344, CAB026379, HPA056230 Supported Supported Plasma membrane
Cytosol Lung cancer:6.34e-5 (unfavourable), Endometrial cancer:7.08e-4 (unfavourable) Expressed in all Expressed in all testis: 183.8 AKR1B10 AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI ENSG00000198074 Aldo-keto reductase family 1, member B10 (aldose reductase) 7 134527592-134541408 Predicted intracellular proteins Evidence at protein level HPA020280, CAB070163, HPA073633 Supported Supported Plasma membrane
Cytosol Renal cancer:4.80e-9 (unfavourable), Colorectal cancer:1.91e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 653.4;gallbladder: 284.3;small intestine: 396.0;stomach: 417.4 esophagus: 90.2 AKR1B15 ENSG00000227471 Aldo-keto reductase family 1, member B15 7 134549136-134579875 Enzymes, Predicted intracellular proteins Evidence at protein level HPA020280, HPA073633 Uncertain Supported Plasma membrane
Cytosol Liver cancer:1.80e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Head and neck cancer:8.36e-4 (favourable) Mixed Tissue enriched 12 breast: 176.5 duodenum: 14.1 ALOXE3 E-LOX, eLOX3 ENSG00000179148 Arachidonate lipoxygenase 3 17 8095900-8119047 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA023120 Approved Plasma membrane
Cytosol Tissue enhanced Tissue enriched 17 skin: 36.6 breast: 2.2 ALS2CR12 ENSG00000155749 Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 12 2 201288271-201357398 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035793 Uncertain Approved Plasma membrane
Cytosol Not detected Group enriched 5 fallopian tube: 15.1;testis: 31.7 lung: 4.3 AMACR RACE ENSG00000242110 Alpha-methylacyl-CoA racemase 5 33986178-34008108 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB001809, HPA019527, HPA020912 Supported Supported Vesicles
Plasma membrane Colorectal cancer:7.11e-4 (favourable) Expressed in all Expressed in all kidney: 134.0 AMPH ENSG00000078053 Amphiphysin 7 38383704-38631567 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB008559, HPA019828, HPA019829 Supported Supported Plasma membrane
Cytosol Pancreatic cancer:9.96e-4 (favourable) Tissue enhanced Tissue enriched 9 cerebral cortex: 84.0 cervix, uterine: 8.9 ANKIB1 DKFZP434A0225, KIAA1386 ENSG00000001629 Ankyrin repeat and IBR domain containing 1 7 92246234-92401384 Predicted intracellular proteins Evidence at protein level HPA019358, HPA021780 Uncertain Supported Plasma membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 45.4 ANKLE2 KIAA0692, Lem4, LEMD7 ENSG00000176915 Ankyrin repeat and LEM domain containing 2 12 132725503-132761888 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003602, HPA074838 Uncertain Supported Endoplasmic reticulum
Plasma membrane Renal cancer:1.90e-8 (unfavourable), Liver cancer:3.97e-6 (unfavourable) Expressed in all Expressed in all testis: 80.1 ANKRA2 ENSG00000164331 Ankyrin repeat, family A (RFXANK-like), 2 5 73552335-73565686 Predicted intracellular proteins Evidence at protein level HPA065263 Approved Plasma membrane
Cell Junctions Expressed in all Expressed in all thyroid gland: 26.1 ANO2 C12orf3, TMEM16B ENSG00000047617 Anoctamin 2, calcium activated chloride channel 12 5531869-5946232 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036276 Supported Nucleoplasm
Plasma membrane Tissue enhanced Tissue enhanced testis: 17.7 placenta: 5.9 ANO6 DKFZp313M0720, TMEM16F ENSG00000177119 Anoctamin 6 12 45215987-45440404 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038958 Approved Approved Plasma membrane
Cytosol Breast cancer:7.56e-5 (unfavourable), Cervical cancer:3.82e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 90.8 ANPEP CD13, gp150, LAP1, p150, PEPN ENSG00000166825 Alanyl (membrane) aminopeptidase 15 89784889-89815401 CD markers, Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002417, HPA004625 Supported Supported Nucleus
Plasma membrane Expressed in all Group enriched 9 duodenum: 2451.4;small intestine: 2177.9 colon: 263.9 APBB1IP INAG1, RIAM ENSG00000077420 Amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 10 26438203-26567803 Predicted intracellular proteins Evidence at protein level HPA017009, HPA063903 Supported Validated Plasma membrane
Cytosol Endometrial cancer:7.48e-4 (favourable) Expressed in all Mixed appendix: 63.1 AQP3 GIL ENSG00000165272 Aquaporin 3 (Gill blood group) 9 33441154-33447611 Blood group antigen proteins, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA014924 Supported Supported Nucleus
Plasma membrane Cervical cancer:5.31e-4 (favourable) Expressed in all Expressed in all esophagus: 975.2 AQP4 MIWC ENSG00000171885 Aquaporin 4 18 26852038-26865818 Predicted membrane proteins, Transporters Evidence at protein level CAB005079, HPA014784, CAB058689 Supported Supported Supported Plasma membrane
Cell Junctions Tissue enriched Group enriched 17 cerebral cortex: 631.8;lung: 172.2 thyroid gland: 24.3 ARF1 ENSG00000143761 ADP-ribosylation factor 1 1 228082660-228099212 Predicted intracellular proteins Evidence at protein level CAB007742 Uncertain Approved Plasma membrane
Cytosol Head and neck cancer:1.55e-4 (unfavourable) Expressed in all Expressed in all placenta: 381.7 ARHGAP19 FLJ00194, MGC14258 ENSG00000213390 Rho GTPase activating protein 19 10 97222173-97292673 Predicted intracellular proteins Evidence at protein level HPA035777, HPA043231 Uncertain Approved Vesicles
Plasma membrane Renal cancer:7.47e-5 (unfavourable) Expressed in all Mixed testis: 34.1 ARHGAP24 DKFZP564B1162, FilGAP, FLJ33877 ENSG00000138639 Rho GTPase activating protein 24 4 85475114-86002670 Predicted intracellular proteins Evidence at protein level HPA014288 Approved Approved Plasma membrane
Cytosol Renal cancer:1.67e-11 (favourable) Expressed in all Expressed in all kidney: 105.5 ARHGEF1 LBCL2, P115-RHOGEF, SUB1.5 ENSG00000076928 Rho guanine nucleotide exchange factor (GEF) 1 19 41883161-41930150 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009502, HPA012924, HPA060784 Supported Validated Plasma membrane
Cytosol Renal cancer:3.36e-8 (unfavourable), Breast cancer:5.92e-4 (favourable) Expressed in all Expressed in all lymph node: 147.0 ARHGEF11 GTRAP48, KIAA0380, PDZ-RHOGEF ENSG00000132694 Rho guanine nucleotide exchange factor (GEF) 11 1 156934840-157045370 Predicted intracellular proteins Evidence at protein level HPA011026, HPA012037, HPA014658 Approved Approved Golgi apparatus
Plasma membrane Pancreatic cancer:1.72e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 43.6 ARID2 BAF200, DKFZp686G052, FLJ30619, KIAA1557 ENSG00000189079 AT rich interactive domain 2 (ARID, RFX-like) 12 45729665-45908040 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA063044 Supported Nucleoplasm
Plasma membrane Head and neck cancer:5.75e-4 (favourable) Expressed in all Expressed in all testis: 47.3 ARID5B FLJ21150, MRF2 ENSG00000150347 AT rich interactive domain 5B (MRF1-like) 10 61901300-62096944 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA015037 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all gallbladder: 62.1 ARL4C ARL7, LAK ENSG00000188042 ADP-ribosylation factor-like 4C 2 234493041-234497053 Predicted intracellular proteins Evidence at protein level HPA028927 Uncertain Supported Plasma membrane
Cytosol Renal cancer:3.69e-8 (unfavourable), Endometrial cancer:2.90e-7 (unfavourable), Urothelial cancer:6.99e-5 (unfavourable) Expressed in all Mixed spleen: 73.2 ARMC12 C6orf81, FLJ25390 ENSG00000157343 Armadillo repeat containing 12 6 35737032-35749079 Predicted intracellular proteins Evidence at protein level HPA030895 Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 8 testis: 62.9 epididymis: 7.4 ASGR2 CLEC4H2 ENSG00000161944 Asialoglycoprotein receptor 2 17 7101322-7115700 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014899, HPA015998 Supported Supported Endoplasmic reticulum
Plasma membrane Tissue enriched Tissue enriched 11 liver: 317.4 gallbladder: 28.1 ASH2L ASH2, ASH2L1, ASH2L2, Bre2 ENSG00000129691 Ash2 (absent, small, or homeotic)-like (Drosophila) 8 38105242-38144076 Predicted intracellular proteins Evidence at protein level HPA042289 Approved Supported Nucleoplasm
Plasma membrane Renal cancer:4.25e-4 (favourable) Expressed in all Expressed in all testis: 74.5 ASIC1 ACCN2, BNaC2, hBNaC2 ENSG00000110881 Acid sensing (proton gated) ion channel 1 12 50057548-50083611 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA058870 Approved Golgi apparatus
Plasma membrane Tissue enhanced Tissue enriched 10 cerebral cortex: 57.0 parathyroid gland: 5.5 ASPM ASP, Calmbp1, FLJ10517, FLJ10549, MCPH5 ENSG00000066279 Abnormal spindle microtubule assembly 1 197084128-197146694 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017816 Approved Approved Plasma membrane
Cytosol Liver cancer:1.25e-4 (unfavourable), Endometrial cancer:1.97e-4 (unfavourable), Pancreatic cancer:2.40e-4 (unfavourable), Lung cancer:2.41e-4 (unfavourable) Mixed Tissue enhanced bone marrow: 11.0 lymph node: 9.6 ATG3 APG3L, DKFZp564M1178, FLJ22125, MGC15201, PC3-96 ENSG00000144848 Autophagy related 3 3 112532509-112562046 Predicted intracellular proteins Evidence at protein level CAB037260, HPA040471 Supported Supported Plasma membrane
Cytosol Liver cancer:9.35e-6 (unfavourable), Prostate cancer:1.59e-4 (unfavourable), Cervical cancer:6.82e-4 (favourable) Expressed in all Expressed in all testis: 154.2 ATIC AICARFT, IMPCHASE, PURH ENSG00000138363 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase 2 215311817-215349773 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013462, HPA021012 Supported Validated Plasma membrane
Cytosol Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable) Expressed in all Expressed in all placenta,rectum: 44.5 ATOX1 HAH1 ENSG00000177556 Antioxidant 1 copper chaperone 5 151742316-151772532 Predicted intracellular proteins Evidence at protein level HPA055036 Approved Nucleoplasm
Plasma membrane Pancreatic cancer:9.57e-4 (favourable) Expressed in all Expressed in all thyroid gland: 151.1 ATP10D ATPVD, KIAA1487 ENSG00000145246 ATPase, class V, type 10D 4 47485288-47593486 Enzymes, Predicted membrane proteins Evidence at protein level HPA050808 Approved Supported Nucleoplasm
Plasma membrane Renal cancer:5.00e-8 (favourable) Expressed in all Mixed parathyroid gland: 22.1 ATP2B3 CFAP39, CLA2, PMCA3, SCAX1 ENSG00000067842 ATPase, Ca++ transporting, plasma membrane 3 X 153517676-153582939 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA001583 Supported Uncertain Golgi apparatus
Plasma membrane Not detected Group enriched 8 adrenal gland: 12.2;cerebral cortex: 19.1 fallopian tube: 2.0 ATP2C2 KIAA0703, SPCA2 ENSG00000064270 ATPase, Ca++ transporting, type 2C, member 2 16 84368527-84464187 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA052262, HPA075812 Approved Approved Plasma membrane
Focal adhesion sites Endometrial cancer:6.20e-6 (favourable) Mixed Tissue enhanced rectum: 39.0 skin: 30.1 ATP6V0A2 a2, ATP6a2, ATP6N1D, J6B7, Stv1, TJ6, TJ6M, TJ6s, Vph1 ENSG00000185344 ATPase, H+ transporting, lysosomal V0 subunit a2 12 123712318-123761755 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044279 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all skin: 15.2 ATP8A2 ATPIB, ML-1 ENSG00000132932 ATPase, aminophospholipid transporter, class I, type 8A, member 2 13 25372071-26025851 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA039926, HPA040033 Approved Supported Nucleoplasm
Plasma membrane Mixed Group enriched 6 cerebral cortex: 26.5;testis: 10.6 adrenal gland: 2.9 ATXN10 E46L, FLJ37990, SCA10 ENSG00000130638 Ataxin 10 22 45671798-45845307 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA049531 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all cerebral cortex: 83.7 ATXN7L3 DKFZp761G2113 ENSG00000087152 Ataxin 7-like 3 17 44191805-44200113 Predicted intracellular proteins Evidence at protein level HPA064316 Supported Approved Nuclear speckles
Plasma membrane Renal cancer:2.87e-4 (unfavourable), Liver cancer:4.03e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 84.0 AVPI1 PP5395, VIP32, VIT32 ENSG00000119986 Arginine vasopressin-induced 1 10 97677424-97687323 Predicted intracellular proteins Evidence at protein level HPA037649 Approved Approved Nucleus
Plasma membrane Expressed in all Mixed adrenal gland: 42.4 BAG3 ENSG00000151929 BCL2-associated athanogene 3 10 119651370-119677819 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA018493, HPA020586 Supported Validated Plasma membrane
Cytosol Expressed in all Expressed in all skeletal muscle: 98.2 BAIAP2 BAP2 ENSG00000175866 BAI1-associated protein 2 17 81035122-81117432 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA023310, HPA027421 Approved Validated Plasma membrane
Cytosol Urothelial cancer:7.58e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 125.1 BAIAP2L1 IRTKS ENSG00000006453 BAI1-associated protein 2-like 1 7 98291651-98401068 Predicted intracellular proteins Evidence at protein level HPA019484, HPA021257, HPA023874, HPA029503 Supported Validated Plasma membrane
Cytosol Mixed Mixed stomach: 55.7 BCAR1 CAS, CASS1, Crkas, P130Cas ENSG00000050820 Breast cancer anti-estrogen resistance 1 16 75228187-75268053 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000443, HPA042282 Approved Supported Approved Plasma membrane
Cytosol Renal cancer:4.55e-8 (favourable), Liver cancer:9.11e-5 (unfavourable), Lung cancer:1.24e-4 (unfavourable) Expressed in all Mixed spleen: 42.0 BCORL1 CXorf10, FLJ11362 ENSG00000085185 BCL6 corepressor-like 1 X 129981107-130058083 Predicted intracellular proteins Evidence at protein level HPA031775, HPA031777, HPA068568 Uncertain Approved Nucleoplasm
Plasma membrane Endometrial cancer:2.20e-5 (unfavourable), Renal cancer:5.00e-4 (unfavourable) Expressed in all Expressed in all placenta: 18.2 BEND6 bA203B9.1, C6orf65, FLJ30162 ENSG00000151917 BEN domain containing 6 6 56955126-57027342 Predicted intracellular proteins Evidence at protein level HPA052973 Approved Nucleus
Plasma membrane Tissue enriched Tissue enriched 6 cerebral cortex: 39.3 cervix, uterine: 6.7 BFSP1 CP115, CP94, filensin, LIFL-H ENSG00000125864 Beaded filament structural protein 1, filensin 20 17493905-17569220 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA040748, HPA042038 Supported Supported Plasma membrane
Cytosol Endometrial cancer:1.39e-4 (favourable) Mixed Mixed testis: 6.5 BFSP2 CP47, CP49, LIFL-L, phakinin ENSG00000170819 Beaded filament structural protein 2, phakinin 3 133399995-133475222 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA038464, HPA062959 Supported Uncertain Plasma membrane
Cytosol Tissue enriched Not detected epididymis,lymph node: 0.4 BMPR2 BMPR-II, BMPR3, BRK-3, PPH1, T-ALK ENSG00000204217 Bone morphogenetic protein receptor, type II (serine/threonine kinase) 2 202376936-202567751 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA017385, HPA049014 Approved Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all cerebral cortex: 36.5 BMX ETK, PSCTK3 ENSG00000102010 BMX non-receptor tyrosine kinase X 15464246-15556529 Enzymes, Predicted intracellular proteins Evidence at protein level HPA001048, CAB032495 Supported Supported Nucleoplasm
Plasma membrane Mixed Tissue enriched 18 epididymis: 122.9 placenta: 6.9 BOC CDON2 ENSG00000144857 BOC cell adhesion associated, oncogene regulated 3 113211003-113287459 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025806, HPA060778, HPA061787 Uncertain Supported Nucleoplasm
Plasma membrane Urothelial cancer:1.18e-5 (unfavourable), Head and neck cancer:4.89e-4 (favourable) Mixed Mixed fallopian tube: 56.6 BRPF1 BR140 ENSG00000156983 Bromodomain and PHD finger containing, 1 3 9731729-9748018 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003359 Supported Approved Plasma membrane
Cytosol Liver cancer:3.20e-5 (unfavourable), Prostate cancer:5.28e-4 (unfavourable) Expressed in all Expressed in all testis: 26.3 C12orf76 FLJ40142 ENSG00000174456 Chromosome 12 open reading frame 76 12 110027028-110073686 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA039713, HPA042013 Uncertain Approved Plasma membrane
Actin filaments Renal cancer:5.74e-5 (unfavourable), Lung cancer:6.44e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 106.1 C14orf93 FLJ12154 ENSG00000100802 Chromosome 14 open reading frame 93 14 22985908-23010166 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002569 Approved Approved Nucleus
Plasma membrane Breast cancer:5.05e-4 (favourable) Expressed in all Expressed in all skin: 21.7 C16orf74 MGC17624 ENSG00000154102 Chromosome 16 open reading frame 74 16 85690084-85751129 Predicted intracellular proteins Evidence at protein level HPA049367 Uncertain Approved Plasma membrane
Centrosome Pancreatic cancer:1.54e-5 (unfavourable), Head and neck cancer:1.71e-4 (unfavourable), Melanoma:4.08e-4 (unfavourable) Mixed Mixed urinary bladder: 13.8 C17orf58 ENSG00000186665 Chromosome 17 open reading frame 58 17 67991101-67993649 Predicted intracellular proteins Evidence at transcript level HPA023036 Uncertain Approved Plasma membrane
Cytosol Renal cancer:1.31e-10 (unfavourable), Liver cancer:8.99e-4 (unfavourable) Expressed in all Expressed in all placenta: 58.5 C17orf62 FLJ90469, MGC4368 ENSG00000178927 Chromosome 17 open reading frame 62 17 82442589-82450829 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045696 Uncertain Approved Plasma membrane
Cell Junctions Renal cancer:6.83e-11 (unfavourable) Expressed in all Expressed in all lymph node: 129.5 C18orf21 HsT3108, PNAS-124, PNAS-131 ENSG00000141428 Chromosome 18 open reading frame 21 18 35972083-35979286 Predicted intracellular proteins Evidence at protein level HPA065505, HPA067322 Uncertain Approved Nucleoli
Plasma membrane Liver cancer:1.38e-6 (unfavourable), Ovarian cancer:1.81e-6 (favourable) Expressed in all Expressed in all testis: 59.3 C1orf116 FLJ36507, MGC2742, MGC4309, SARG ENSG00000182795 Chromosome 1 open reading frame 116 1 207018521-207032756 Predicted intracellular proteins Evidence at protein level HPA011888, HPA011889 Supported Supported Plasma membrane
Cytosol Renal cancer:1.01e-5 (favourable) Mixed Tissue enhanced esophagus: 112.9;lung: 109.5;prostate: 80.5 stomach: 54.8 C1orf27 FLJ20505, odr-4, TTG1 ENSG00000157181 Chromosome 1 open reading frame 27 1 186375838-186421378 Predicted membrane proteins Evidence at protein level HPA015988, HPA031352 Uncertain Approved Nucleoplasm
Plasma membrane Ovarian cancer:9.92e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 75.0 C1orf74 FLJ25078 ENSG00000162757 Chromosome 1 open reading frame 74 1 209779208-209784559 Predicted intracellular proteins Evidence at protein level HPA028496 Uncertain Approved Plasma membrane
Cytosol Cervical cancer:8.52e-6 (unfavourable) Expressed in all Mixed lymph node: 5.1 C1QBP gC1Q-R, gC1qR, HABP1, p32, SF2p32 ENSG00000108561 Complement component 1, q subcomponent binding protein 17 5432777-5448830 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA026483 Supported Approved Plasma membrane
Mitochondria Expressed in all Expressed in all rectum: 159.4 C2orf72 LOC257407 ENSG00000204128 Chromosome 2 open reading frame 72 2 231037490-231049719 Predicted intracellular proteins Evidence at protein level HPA044962 Uncertain Approved Nucleus
Plasma membrane Renal cancer:4.74e-4 (unfavourable), Pancreatic cancer:5.27e-4 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 2.8;colon: 3.0;liver: 4.7 stomach: 1.3 C3orf14 HT021 ENSG00000114405 Chromosome 3 open reading frame 14 3 62318973-62336213 Predicted intracellular proteins Evidence at transcript level HPA048286 Approved Approved Plasma membrane
Cytosol Renal cancer:4.33e-5 (favourable) Expressed in all Mixed breast: 61.4 C4orf22 ENSG00000197826 Chromosome 4 open reading frame 22 4 80335720-80963756 Predicted intracellular proteins Evidence at transcript level HPA043383 Approved Approved Plasma membrane
Cytosol Not detected Group enriched 23 fallopian tube: 30.3;testis: 47.2 lung: 1.7 C5orf45 DKFZp686L2452, LOC51149, MGC65027, MGC78537 ENSG00000161010 Chromosome 5 open reading frame 45 5 179835133-179862173 Predicted intracellular proteins Evidence at protein level HPA043975 Uncertain Approved Plasma membrane
Cytosol Renal cancer:2.64e-5 (unfavourable) Expressed in all Mixed fallopian tube: 21.2 C8orf33 FLJ20989 ENSG00000182307 Chromosome 8 open reading frame 33 8 145052378-145056030 Predicted intracellular proteins Evidence at protein level HPA024812, HPA026104 Approved Uncertain Nucleoplasm
Plasma membrane Breast cancer:2.77e-4 (unfavourable), Liver cancer:8.95e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 25.8 C9 ENSG00000113600 Complement component 9 5 39284262-39424868 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB002151, HPA029577 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Tissue enriched 119 liver: 728.8 epididymis: 6.1 C9orf91 DKFZp547P234, FLJ38045 ENSG00000157693 Chromosome 9 open reading frame 91 9 114611206-114646422 Predicted membrane proteins Evidence at transcript level HPA017199 Approved Approved Plasma membrane
Cytosol Endometrial cancer:3.61e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 22.4 CA9 CAIX, MN ENSG00000107159 Carbonic anhydrase IX 9 35673856-35681159 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB005100, CAB017107, HPA055207 Supported Validated Plasma membrane
Cytosol Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable) Mixed Tissue enhanced gallbladder: 36.1;stomach: 92.4 small intestine: 14.8 CALD1 CDM, H-CAD, L-CAD ENSG00000122786 Caldesmon 1 7 134744252-134970728 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000006, HPA008066, HPA017330 Supported Validated Plasma membrane
Actin filaments Renal cancer:1.84e-5 (unfavourable), Melanoma:3.73e-4 (unfavourable) Expressed in all Tissue enhanced seminal vesicle: 1285.3 smooth muscle: 1186.8 CALML5 CLSP ENSG00000178372 Calmodulin-like 5 10 5498697-5499555 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA040725 Supported Approved Plasma membrane
Cytosol Head and neck cancer:2.59e-5 (favourable) Group enriched Group enriched 8 salivary gland: 262.7;skin: 651.2 breast: 55.1 CALN1 ENSG00000183166 Calneuron 1 7 71779491-72447151 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036278, HPA036708 Approved Uncertain Vesicles
Plasma membrane Mixed Group enriched 5 adrenal gland: 14.8;cerebral cortex: 46.5 testis: 6.0 CAMK2A CAMKA, CaMKIINalpha, KIAA0968 ENSG00000070808 Calcium/calmodulin-dependent protein kinase II alpha 5 150219491-150290291 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004330, HPA051783, HPA051785, HPA053973 Supported Supported Plasma membrane
Cell Junctions Tissue enriched Tissue enriched 9 cerebral cortex: 284.4 skeletal muscle: 33.3 CAMK2B CAM2, CAMK2, CAMKB ENSG00000058404 Calcium/calmodulin-dependent protein kinase II beta 7 44217150-44334577 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006849, HPA026307, HPA051783, HPA051785, HPA053973 Supported Supported Uncertain Plasma membrane
Cell Junctions Mixed Tissue enhanced cerebral cortex: 214.7 skeletal muscle: 46.1 CAMK2D CAMKD ENSG00000145349 Calcium/calmodulin-dependent protein kinase II delta 4 113451032-113761927 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026281, HPA051783, HPA051785, HPA053973 Approved Supported Plasma membrane
Cell Junctions Expressed in all Expressed in all parathyroid gland: 106.2 CASP4 ICE(rel)II, ICH-2, TX ENSG00000196954 Caspase 4, apoptosis-related cysteine peptidase 11 104942866-104969436 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA027588, CAB037167 Approved Approved Plasma membrane
Cytosol Renal cancer:3.27e-11 (unfavourable) Expressed in all Expressed in all placenta: 71.5 CAV3 LGMD1C, LQT9, VIP-21, VIP21 ENSG00000182533 Caveolin 3 3 8733800-8841808 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB017518, CAB018557, HPA054488 Supported Supported Vesicles
Plasma membrane Tissue enhanced Group enriched 6 heart muscle: 13.0;skeletal muscle: 63.3 esophagus: 6.0 CCBE1 FLJ30681, KIAA1983 ENSG00000183287 Collagen and calcium binding EGF domains 1 18 59430940-59697380 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041361, HPA041374 Uncertain Validated Plasma membrane
Cytosol Mixed Tissue enhanced ovary: 40.6 cervix, uterine: 15.9 CCDC107 MGC31967 ENSG00000159884 Coiled-coil domain containing 107 9 35658290-35661511 Predicted membrane proteins Evidence at protein level HPA016857, HPA050442 Validated Nucleoplasm
Plasma membrane Expressed in all Expressed in all adipose tissue: 63.0 CCDC115 ccp1, FLJ30131, MGC12981 ENSG00000136710 Coiled-coil domain containing 115 2 130338241-130342349 Predicted intracellular proteins Evidence at protein level HPA034598 Approved Supported Vesicles
Plasma membrane Breast cancer:7.59e-4 (favourable) Expressed in all Expressed in all ovary: 55.3 CCDC124 ENSG00000007080 Coiled-coil domain containing 124 19 17933016-17943991 Predicted intracellular proteins Evidence at protein level HPA041708, HPA046765 Supported Validated Plasma membrane
Cytosol Liver cancer:1.68e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 72.6 CCDC144NL MGC87631 ENSG00000205212 Coiled-coil domain containing 144 family, N-terminal like 17 20836447-20896140 Predicted intracellular proteins Evidence at transcript level HPA023457 Uncertain Approved Nucleus
Plasma membrane Not detected Tissue enriched 7 testis: 4.3 endometrium,prostate,seminal vesicle: 0.5 CCDC15 FLJ13215 ENSG00000149548 Coiled-coil domain containing 15 11 124954121-125041489 Predicted intracellular proteins Evidence at transcript level HPA040450, HPA041738 Uncertain Approved Plasma membrane
Cytosol Mixed Tissue enriched 5 testis: 18.8 breast: 3.5 CCDC154 C16orf29, LOC645811 ENSG00000197599 Coiled-coil domain containing 154 16 1434383-1444556 Predicted intracellular proteins Evidence at protein level HPA041158, HPA043535, HPA048237 Uncertain Approved Golgi apparatus
Plasma membrane Mixed Tissue enhanced testis: 6.5 prostate: 3.7 CCDC24 MGC45441 ENSG00000159214 Coiled-coil domain containing 24 1 43991359-43996528 Predicted intracellular proteins Evidence at protein level HPA035424, HPA061710 Uncertain Validated Plasma membrane
Cytosol Breast cancer:3.06e-5 (favourable), Liver cancer:1.70e-4 (unfavourable), Head and neck cancer:3.18e-4 (favourable) Expressed in all Tissue enhanced fallopian tube: 18.1 testis: 15.2 CCDC62 CT109, ERAP75, FLJ40344, TSP-NY ENSG00000130783 Coiled-coil domain containing 62 12 122774327-122827528 Predicted intracellular proteins Evidence at protein level HPA039021, HPA058741 Approved Approved Nucleoplasm
Plasma membrane Not detected Tissue enriched 143 testis: 115.3 spleen: 0.8 CCDC93 FLJ10996 ENSG00000125633 Coiled-coil domain containing 93 2 117915478-118014133 Predicted intracellular proteins Evidence at protein level HPA054183 Approved Supported Vesicles
Plasma membrane Liver cancer:2.97e-6 (unfavourable), Thyroid cancer:9.66e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 24.5 CCT3 Cctg, TRIC5 ENSG00000163468 Chaperonin containing TCP1, subunit 3 (gamma) 1 156308968-156367873 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006543 Approved Supported Plasma membrane
Cytosol Liver cancer:3.87e-7 (unfavourable), Renal cancer:6.34e-4 (unfavourable) Expressed in all Expressed in all testis: 205.6 CD248 CD164L1, TEM1 ENSG00000174807 CD248 molecule, endosialin 11 66314487-66317044 CD markers, Predicted membrane proteins Evidence at protein level HPA051856 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:2.69e-7 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 136.1 placenta: 96.3 CD2AP CMS ENSG00000198087 CD2-associated protein 6 47477789-47627263 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA003267, HPA003326, CAB004352 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:5.53e-5 (unfavourable), Urothelial cancer:7.57e-5 (favourable) Expressed in all Expressed in all small intestine: 66.9 CD33 FLJ00391, p67, SIGLEC-3, SIGLEC3 ENSG00000105383 CD33 molecule 19 51225064-51243860 CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011442, HPA035832, HPA064807 Approved Supported Nucleus
Plasma membrane Mixed Tissue enhanced spleen: 33.6 bone marrow: 20.9 CD44 CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1 ENSG00000026508 CD44 molecule (Indian blood group) 11 35138870-35232402 Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000112, CAB000316, HPA005785 Supported Validated Golgi apparatus
Plasma membrane Renal cancer:1.78e-8 (unfavourable) Expressed in all Expressed in all skin: 505.8 CD93 C1qR(P), C1QR1, C1qRP, CDw93, dJ737E23.1, ECSM3, MXRA4 ENSG00000125810 CD93 molecule 20 23079349-23086340 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA009300, HPA012368 Supported Approved Vesicles
Plasma membrane Renal cancer:2.74e-4 (unfavourable) Expressed in all Expressed in all placenta: 195.4 CDAN1 CDA-I, CDAI ENSG00000140326 Codanin 1 15 42723559-42737126 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039404, HPA040787 Supported Validated Plasma membrane
Cytosol Liver cancer:1.07e-4 (unfavourable) Expressed in all Expressed in all ovary: 15.1 CDC42EP1 Borg5, CEP1, MSE55 ENSG00000128283 CDC42 effector protein (Rho GTPase binding) 1 22 37560447-37569405 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006379 Approved Supported Plasma membrane
Actin filaments Expressed in all Expressed in all stomach: 107.7 CDH2 CD325, CDHN, NCAD ENSG00000170558 Cadherin 2, type 1, N-cadherin (neuronal) 18 27950966-28177446 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000141, CAB018580, HPA058574 Supported Supported Plasma membrane
Cell Junctions Expressed in all Tissue enhanced heart muscle: 125.8;parathyroid gland: 124.0 adrenal gland: 87.7 CDH26 VR20 ENSG00000124215 Cadherin 26 20 59958427-60034011 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015722, HPA047578 Uncertain Approved Plasma membrane
Microtubules Lung cancer:3.75e-4 (favourable), Cervical cancer:7.62e-4 (favourable) Group enriched Tissue enhanced prostate: 19.8 urinary bladder: 6.3 CEP162 C6orf84, KIAA1009, QN1 ENSG00000135315 Centrosomal protein 162kDa 6 84124241-84227635 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030170, HPA030171, HPA030172, HPA030173 Supported Validated Plasma membrane
Cytosol Expressed in all Mixed testis: 15.7 CEP295 KIAA1731 ENSG00000166004 Centrosomal protein 295kDa 11 93661639-93730358 Predicted intracellular proteins Evidence at protein level HPA038595, HPA038596, HPA038597 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all testis: 22.2 CEP55 C10orf3, CT111, FLJ10540 ENSG00000138180 Centrosomal protein 55kDa 10 93496632-93529092 Predicted intracellular proteins Evidence at protein level HPA023430 Approved Supported Plasma membrane
Microtubule organizing center Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.20e-9 (unfavourable), Pancreatic cancer:2.66e-5 (unfavourable), Lung cancer:1.45e-4 (unfavourable), Stomach cancer:3.15e-4 (favourable) Expressed in all Tissue enhanced testis: 39.1 lymph node: 17.8 CEP57L1 bA487F23.2, C6orf182, MGC21731 ENSG00000183137 Centrosomal protein 57kDa-like 1 6 109095110-109163932 Predicted intracellular proteins Evidence at protein level HPA040378 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all testis: 47.4 CEP89 CCDC123, FLJ14640 ENSG00000121289 Centrosomal protein 89kDa 19 32875925-32971991 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039382, HPA040056 Uncertain Supported Plasma membrane
Cytosol Liver cancer:8.78e-5 (unfavourable) Expressed in all Mixed fallopian tube: 14.8 CFAP157 C9orf117 ENSG00000160401 Cilia and flagella associated protein 157 9 127706989-127716002 Predicted intracellular proteins Evidence at protein level HPA021474, HPA021786 Supported Validated Plasma membrane
Cytosol Endometrial cancer:1.45e-4 (favourable) Mixed Tissue enriched 8 fallopian tube: 93.9 lung: 12.2 CGN KIAA1319 ENSG00000143375 Cingulin 1 151510510-151538692 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017193, HPA027586, HPA027587, HPA027657 Supported Supported Plasma membrane
Cell Junctions Renal cancer:5.84e-10 (favourable) Expressed in all Tissue enhanced parathyroid gland: 73.3 small intestine: 63.2 CHD9 BC022889, FLJ12178, KIAA0308 ENSG00000177200 Chromodomain helicase DNA binding protein 9 16 53055033-53329150 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA042053, HPA049420 Approved Approved Plasma membrane
Cytosol Renal cancer:1.84e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 26.8 CHRNA5 ENSG00000169684 Cholinergic receptor, nicotinic, alpha 5 (neuronal) 15 78565520-78595269 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054381 Approved Approved Plasma membrane
Focal adhesion sites Lung cancer:3.64e-5 (unfavourable) Mixed Mixed gallbladder: 6.9 CIB1 CALMYRIN, CIB, KIP, SIP2-28 ENSG00000185043 Calcium and integrin binding 1 (calmyrin) 15 90229975-90234047 Predicted intracellular proteins Evidence at protein level CAB012991, HPA048825 Approved Supported Nucleoplasm
Plasma membrane Endometrial cancer:2.26e-5 (favourable) Expressed in all Expressed in all fallopian tube: 204.7 CLCN6 CLC-6, KIAA0046 ENSG00000011021 Chloride channel, voltage-sensitive 6 1 11806096-11843144 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA032097 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed cerebral cortex: 31.2 CLDN23 CLDNL ENSG00000253958 Claudin 23 8 8701938-8704106 Predicted membrane proteins, Transporters Evidence at protein level HPA070578 Uncertain Nucleus
Plasma membrane Renal cancer:9.65e-8 (favourable), Colorectal cancer:3.46e-4 (favourable) Expressed in all Tissue enhanced colon: 24.1;stomach: 24.9 small intestine: 16.9 CLIC5 DFNB102 ENSG00000112782 Chloride intracellular channel 5 6 45898451-46080395 Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA074371 Supported Nuclear speckles
Plasma membrane Tissue enhanced Tissue enhanced lung: 116.4;skeletal muscle: 119.2 heart muscle: 72.3 CNGA1 CNCG, CNCG1, CNG1, RCNC1, RCNCa, RP49 ENSG00000198515 Cyclic nucleotide gated channel alpha 1 4 47935977-48016672 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA076168 Approved Vesicles
Plasma membrane Mixed Mixed liver: 14.2 CNKSR2 CNK2, KIAA0902, KSR2 ENSG00000149970 Connector enhancer of kinase suppressor of Ras 2 X 21374418-21654695 Predicted intracellular proteins Evidence at protein level HPA001502 Approved Golgi apparatus
Plasma membrane Tissue enhanced Tissue enriched 9 cerebral cortex: 54.1 adrenal gland: 5.8 CNNM1 ACDP1 ENSG00000119946 Cyclin and CBS domain divalent metal cation transport mediator 1 10 99329099-99394330 Predicted membrane proteins Evidence at protein level HPA040408 Approved Uncertain Plasma membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 10.2;testis: 16.7 ovary: 3.0 CNNM4 ACDP4, KIAA1592 ENSG00000158158 Cyclin and CBS domain divalent metal cation transport mediator 4 2 96760902-96811891 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA017732 Supported Uncertain Plasma membrane
Actin filaments Ovarian cancer:8.75e-4 (unfavourable), Endometrial cancer:9.14e-4 (unfavourable) Expressed in all Expressed in all rectum: 37.5 CNR1 CANN6, CB-R, CB1, CB1A, CB1K5, CNR ENSG00000118432 Cannabinoid receptor 1 (brain) 6 88139864-88166359 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB005603, HPA042256 Approved Approved Plasma membrane
Actin filaments Tissue enriched Tissue enhanced cerebral cortex: 32.2 adipose tissue: 12.1 COBL KIAA0633 ENSG00000106078 Cordon-bleu WH2 repeat protein 7 51016212-51316818 Predicted intracellular proteins Evidence at protein level HPA019033, HPA019167 Supported Approved Plasma membrane
Cell Junctions Renal cancer:5.21e-12 (favourable) Mixed Mixed cerebral cortex: 61.6 COL6A2 ENSG00000142173 Collagen, type VI, alpha 2 21 46098097-46132849 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007029, HPA030920, HPA038799 Supported Approved Plasma membrane
Cytosol Renal cancer:8.72e-14 (unfavourable) Expressed in all Expressed in all placenta: 470.8 COLQ EAD ENSG00000206561 Collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase 3 15450133-15521751 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA045876 Approved Plasma membrane
Cell Junctions Mixed Tissue enhanced parathyroid gland: 19.2 fallopian tube: 17.4 COMMD10 PTD002 ENSG00000145781 COMM domain containing 10 5 116084991-116412762 Predicted intracellular proteins Evidence at protein level HPA045441, HPA075641 Approved Uncertain Plasma membrane
Cytosol Stomach cancer:2.99e-4 (unfavourable), Thyroid cancer:6.93e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 46.7 COMMD4 FLJ20452 ENSG00000140365 COMM domain containing 4 15 75335891-75343224 Predicted intracellular proteins Evidence at protein level HPA066957 Uncertain Supported Nucleus
Plasma membrane Expressed in all Expressed in all testis: 76.3 COQ7 CAT5, CLK-1 ENSG00000167186 Coenzyme Q7 homolog, ubiquinone (yeast) 16 19067599-19080095 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067252, HPA071922 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:8.23e-12 (favourable) Expressed in all Expressed in all parathyroid gland: 38.6 CORO1B coronin-2 ENSG00000172725 Coronin, actin binding protein, 1B 11 67435510-67443821 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017616, HPA040113, HPA070456 Supported Validated Plasma membrane
Cytosol Endometrial cancer:1.65e-4 (favourable) Expressed in all Expressed in all prostate: 77.2 CORO2A IR10, WDR2 ENSG00000106789 Coronin, actin binding protein, 2A 9 98120975-98192640 Predicted intracellular proteins Evidence at protein level HPA041161, HPA041302 Supported Approved Plasma membrane
Cytosol Renal cancer:6.56e-4 (unfavourable) Mixed Mixed small intestine: 39.4 CORO2B ClipinC, KIAA0925 ENSG00000103647 Coronin, actin binding protein, 2B 15 68578969-68727806 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017960 Approved Approved Plasma membrane
Focal adhesion sites Group enriched Tissue enhanced cerebral cortex: 73.5;fallopian tube: 36.2 ovary: 17.8 CPPED1 CSTP1, FLJ11151 ENSG00000103381 Calcineurin-like phosphoesterase domain containing 1 16 12659799-12804017 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040938, HPA041970 Uncertain Supported Plasma membrane
Cytosol Renal cancer:1.62e-9 (favourable), Breast cancer:9.72e-4 (unfavourable) Expressed in all Expressed in all spleen: 41.6 CREB3L1 OASIS ENSG00000157613 CAMP responsive element binding protein 3-like 1 11 46277661-46321422 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA024069, CAB026151 Supported Uncertain Plasma membrane
Cytosol Renal cancer:2.97e-4 (unfavourable), Endometrial cancer:3.92e-4 (favourable), Thyroid cancer:8.59e-4 (unfavourable) Expressed in all Mixed stomach: 66.1 CRLF3 CREME9, CYTOR4 ENSG00000176390 Cytokine receptor-like factor 3 17 30769388-30824776 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA007596 Supported Supported Plasma membrane
Cytosol Renal cancer:1.31e-7 (unfavourable) Expressed in all Mixed lymph node: 39.9 CROCC ROLT, rootletin ENSG00000058453 Ciliary rootlet coiled-coil, rootletin 1 16740273-16972979 Predicted intracellular proteins Evidence at protein level HPA021191, HPA021762 Supported Supported Plasma membrane
Centrosome Endometrial cancer:8.34e-5 (favourable), Lung cancer:7.92e-4 (favourable), Renal cancer:7.97e-4 (unfavourable) Expressed in all Mixed skin: 11.7 CRYAB CRYA2, HSPB5 ENSG00000109846 Crystallin, alpha B 11 111908565-111923722 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002053, CAB040560, HPA057100 Supported Validated Plasma membrane
Cytosol Urothelial cancer:1.70e-5 (unfavourable), Colorectal cancer:4.90e-5 (unfavourable) Group enriched Tissue enhanced heart muscle: 3940.2 cerebral cortex: 1892.7 CSF1R C-FMS, CD115, CSFR, FMS ENSG00000182578 Colony stimulating factor 1 receptor 5 150053291-150113372 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB008970, HPA012323 Uncertain Supported Vesicles
Plasma membrane Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable) Expressed in all Mixed spleen: 150.2 CSPG4 HMW-MAA, MCSP, MCSPG, MEL-CSPG, MSK16, NG2 ENSG00000173546 Chondroitin sulfate proteoglycan 4 15 75674322-75712848 Predicted membrane proteins Evidence at protein level HPA002951, CAB016189, HPA042785, HPA050008 Approved Approved Nucleus
Plasma membrane Renal cancer:7.60e-6 (unfavourable), Urothelial cancer:4.93e-5 (unfavourable) Expressed in all Mixed adipose tissue: 31.9 CST6 ENSG00000175315 Cystatin E/M 11 66011841-66013505 Cancer-related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB019316, HPA044963 Supported Approved Plasma membrane
Cytosol Tissue enhanced Tissue enriched 9 skin: 213.3 breast: 24.7 CTNNA1 CAP102 ENSG00000044115 Catenin (cadherin-associated protein), alpha 1, 102kDa 5 138610967-138935034 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB021089, HPA046119, HPA063535 Approved Validated Plasma membrane
Cell Junctions Renal cancer:7.34e-7 (favourable), Pancreatic cancer:8.02e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 215.4 CUTA ACHAP, C6orf82 ENSG00000112514 CutA divalent cation tolerance homolog (E. coli) 6 33416442-33418317 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016787, HPA064369 Uncertain Approved Plasma membrane
Focal adhesion sites Lung cancer:8.50e-4 (favourable) Expressed in all Expressed in all thyroid gland: 292.6 CXADR CAR ENSG00000154639 Coxsackie virus and adenovirus receptor 21 17512382-17593579 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003342, CAB005103, HPA030411, HPA030412 Supported Validated Plasma membrane
Cell Junctions Head and neck cancer:3.50e-4 (favourable) Expressed in all Mixed skin: 59.6 DAAM1 KIAA0666 ENSG00000100592 Dishevelled associated activator of morphogenesis 1 14 59188646-59371405 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026605, HPA064789 Uncertain Approved Plasma membrane
Cytosol Renal cancer:3.77e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 51.1 DBN1 D0S117E ENSG00000113758 Drebrin 1 5 177456608-177474401 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051452, HPA056940 Supported Supported Plasma membrane
Actin filaments Renal cancer:8.28e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 83.2 DCAF16 C4orf30, FLJ20280 ENSG00000163257 DDB1 and CUL4 associated factor 16 4 17800655-17810758 Predicted intracellular proteins Evidence at protein level HPA042487 Uncertain Approved Plasma membrane
Cytosol Lung cancer:5.78e-4 (favourable), Liver cancer:6.40e-4 (unfavourable), Urothelial cancer:7.67e-4 (favourable) Expressed in all Expressed in all endometrium: 22.9 DCHS2 CDH27, CDHJ, CDHR7, FLJ20047, PCDH23, PCDHJ ENSG00000197410 Dachsous cadherin-related 2 4 154232037-154491716 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA064159 Uncertain Approved Vesicles
Plasma membrane Not detected Mixed endometrium: 4.0 DCUN1D2 C13orf17, FLJ10704, FLJ20092 ENSG00000150401 DCN1, defective in cullin neddylation 1, domain containing 2 13 113455819-113490952 Predicted intracellular proteins Evidence at protein level HPA039349 Uncertain Approved Plasma membrane
Cytosol Pancreatic cancer:5.65e-5 (favourable) Expressed in all Expressed in all heart muscle: 65.3 DDIAS C11orf82, FLJ25416, FLJ38838, noxin ENSG00000165490 DNA damage-induced apoptosis suppressor 11 82899975-82958277 Predicted secreted proteins Evidence at protein level HPA038540, HPA038541 Approved Approved Plasma membrane
Cytosol Mixed Tissue enhanced testis: 20.1 skeletal muscle: 6.4 DDR2 NTRKR3, TKT, TYRO10 ENSG00000162733 Discoidin domain receptor tyrosine kinase 2 1 162631373-162787400 CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA070112 Supported Plasma membrane
Actin filaments Renal cancer:1.73e-7 (unfavourable) Expressed in all Mixed adrenal gland: 94.0 DDX60L FLJ31033 ENSG00000181381 DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like 4 168356735-168537786 Enzymes, Predicted intracellular proteins Evidence at protein level HPA043211, HPA055501 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:3.04e-5 (unfavourable), Renal cancer:2.94e-4 (unfavourable) Expressed in all Mixed bone marrow: 33.7 DFFA DFF-45, DFF1, DFF45, ICAD ENSG00000160049 DNA fragmentation factor, 45kDa, alpha polypeptide 1 10456522-10472526 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002679, HPA018859, HPA019938, HPA025230 Supported Supported Plasma membrane
Cytosol Renal cancer:1.57e-9 (favourable), Liver cancer:9.46e-4 (unfavourable) Expressed in all Expressed in all placenta: 28.8 DGKG DAGK3 ENSG00000058866 Diacylglycerol kinase, gamma 90kDa 3 186105668-186362237 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036577 Approved Approved Vesicles
Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 21.3 placenta: 11.1 DIAPH3 AN, AUNA1, DRF3, FLJ34705, NSDAN ENSG00000139734 Diaphanous-related formin 3 13 59665583-60163987 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA032151 Supported Plasma membrane
Microtubules Lung cancer:3.72e-4 (unfavourable), Endometrial cancer:4.18e-4 (unfavourable), Colorectal cancer:9.04e-4 (favourable) Mixed Tissue enriched 7 testis: 33.9 placenta: 5.0 DLEU1 BCMS, BCMS1, DLB1, LEU1, LINC00021, NCRNA00021, XTP6 ENSG00000176124 Deleted in lymphocytic leukemia 1 (non-protein coding) 13 50082171-50723236 Predicted intracellular proteins Evidence at protein level CAB017848, HPA039465 Uncertain Approved Plasma membrane
Cytosol Mixed Mixed testis: 9.3 DLG1 dJ1061C18.1.1, DLGH1, hdlg, SAP-97, SAP97 ENSG00000075711 Discs, large homolog 1 (Drosophila) 3 197042560-197299300 Predicted intracellular proteins Evidence at protein level CAB016307, HPA069593 Supported Uncertain Vesicles
Plasma membrane Expressed in all Expressed in all thyroid gland: 94.5 DLG2 chapsyn-110, PPP1R58, PSD-93, PSD93 ENSG00000150672 Discs, large homolog 2 (Drosophila) 11 83455012-85627922 Predicted intracellular proteins Evidence at protein level HPA021307, HPA023896, CAB072341 Approved Approved Vesicles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 73.0 thyroid gland: 25.9 DMWD D19S593E, DMR-N9, gene59 ENSG00000185800 Dystrophia myotonica, WD repeat containing 19 45782947-45792802 Predicted intracellular proteins Evidence at protein level HPA068172, HPA069843 Approved Approved Plasma membrane
Actin filaments Liver cancer:1.47e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 39.8 DNAJA4 PRO1472 ENSG00000140403 DnaJ (Hsp40) homolog, subfamily A, member 4 15 78264086-78282196 Predicted intracellular proteins Evidence at protein level CAB004646, HPA041790 Uncertain Approved Plasma membrane
Cytosol Renal cancer:1.08e-7 (favourable), Glioma:8.35e-4 (unfavourable) Expressed in all Expressed in all testis: 95.2 DNAJC9 JDD1, SB73 ENSG00000213551 DnaJ (Hsp40) homolog, subfamily C, member 9 10 73183362-73248862 Predicted intracellular proteins Evidence at protein level HPA035215, HPA035216 Supported Supported Nucleoplasm
Plasma membrane Prostate cancer:7.07e-5 (unfavourable), Lung cancer:3.26e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 37.4 DPYSL2 CRMP2, DHPRP2, DRP-2, DRP2 ENSG00000092964 Dihydropyrimidinase-like 2 8 26514275-26658178 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002381, CAB018719 Supported Supported Plasma membrane
Cytosol Urothelial cancer:5.41e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 381.2 DQX1 FLJ23757 ENSG00000144045 DEAQ box RNA-dependent ATPase 1 2 74518131-74526336 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039158 Supported Approved Plasma membrane
Cytosol Mixed Tissue enhanced duodenum: 14.8;small intestine: 13.8 colon: 5.6 DROSHA Etohi2, HSA242976, RN3, RNASE3L, RNASEN ENSG00000113360 Drosha, ribonuclease type III 5 31400497-31532196 Enzymes, Predicted intracellular proteins Evidence at protein level HPA031150 Approved Nucleoplasm
Plasma membrane Liver cancer:1.39e-4 (unfavourable), Endometrial cancer:6.79e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 30.0 DSC3 CDHF3, DSC, DSC1, DSC2, DSC4 ENSG00000134762 Desmocollin 3 18 30990008-31042815 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB037328, HPA049265, HPA073937 Supported Validated Plasma membrane
Cell Junctions Urothelial cancer:1.04e-5 (unfavourable) Tissue enhanced Group enriched 11 esophagus: 119.5;skin: 455.7 tonsil: 25.9 DSEL C18orf4, FLJ11477, NCAG1 ENSG00000171451 Dermatan sulfate epimerase-like 18 67506582-67516980 Predicted membrane proteins Evidence at protein level HPA060942 Approved Nucleoplasm
Plasma membrane Tissue enhanced Mixed cerebral cortex: 5.3 DUSP15 bA243J16.5, bA243J16.6, C20orf57, FLJ20645, VHY ENSG00000149599 Dual specificity phosphatase 15 20 31847637-31870747 Enzymes, Predicted intracellular proteins Evidence at protein level HPA076649 Approved Plasma membrane
Cytosol Renal cancer:5.40e-7 (favourable) Mixed Tissue enhanced testis: 77.1 parathyroid gland: 16.0 DYSF FER1L1, LGMD2B ENSG00000135636 Dysferlin 2 71453722-71686768 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002510, HPA017071, HPA021945 Supported Supported Plasma membrane
Microtubule organizing center Expressed in all Mixed skeletal muscle: 32.8 DYX1C1 CILD25, DNAAF4, EKN1, FLJ37882 ENSG00000256061 Dyslexia susceptibility 1 candidate 1 15 55410525-55508234 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA051048 Uncertain Approved Plasma membrane
Cytosol Mixed Tissue enhanced testis: 20.4 fallopian tube: 17.5 EDNRB ETB, HSCR, HSCR2 ENSG00000136160 Endothelin receptor type B 13 77895481-77919768 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB017842, HPA027546 Approved Approved Plasma membrane
Cytosol Renal cancer:7.20e-5 (favourable) Group enriched Tissue enhanced placenta: 178.8 cerebral cortex: 89.1 EEF2 EEF-2, EF2 ENSG00000167658 Eukaryotic translation elongation factor 2 19 3976056-3985469 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB007795, HPA040534, HPA057351 Approved Validated Plasma membrane
Cytosol Endometrial cancer:1.81e-6 (favourable), Renal cancer:1.25e-5 (favourable) Expressed in all Expressed in all ovary: 1621.9 EFCAB1 FLJ11767 ENSG00000034239 EF-hand calcium binding domain 1 8 48710789-48735311 Predicted intracellular proteins Evidence at protein level HPA023527, HPA069955 Supported Approved Nucleoplasm
Plasma membrane Tissue enhanced Tissue enhanced fallopian tube: 148.1;testis: 46.9 ovary: 23.8 EFCAB2 CFAP200, DRC8, MGC12458 ENSG00000203666 EF-hand calcium binding domain 2 1 244969705-245127164 Predicted intracellular proteins Evidence at protein level HPA031206, HPA031207 Approved Approved Plasma membrane
Cytosol Thyroid cancer:6.51e-4 (unfavourable) Mixed Expressed in all fallopian tube: 57.4 EFHC1 EJM, EJM1, FLJ10466 ENSG00000096093 EF-hand domain (C-terminal) containing 1 6 52420308-52495785 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA035307 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:2.33e-4 (favourable), Renal cancer:3.29e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 27.2 thyroid gland: 7.5 EFR3A KIAA0143 ENSG00000132294 EFR3 homolog A 8 131904088-132013642 Predicted intracellular proteins Evidence at protein level HPA022859, HPA023092, HPA023402 Supported Supported Plasma membrane
Cytosol Expressed in all Expressed in all cerebral cortex: 67.5 EHBP1 KIAA0903, NACSIN ENSG00000115504 EH domain binding protein 1 2 62673851-63046487 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035468, HPA035469 Supported Supported Plasma membrane
Cytosol Urothelial cancer:1.95e-8 (unfavourable), Lung cancer:9.03e-4 (unfavourable) Expressed in all Expressed in all testis: 67.5 EIF5 ENSG00000100664 Eukaryotic translation initiation factor 5 14 103333544-103345025 Predicted intracellular proteins Evidence at protein level HPA000867, CAB004226 Supported Supported Plasma membrane
Cytosol Renal cancer:5.67e-7 (favourable) Expressed in all Expressed in all testis: 173.0 EIF5B DKFZp434I036, FLJ10524, IF2, KIAA0741 ENSG00000158417 Eukaryotic translation initiation factor 5B 2 99337353-99401326 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA034648, HPA040095 Approved Approved Plasma membrane
Cytosol Liver cancer:7.15e-10 (unfavourable), Renal cancer:1.42e-6 (unfavourable), Ovarian cancer:8.99e-4 (favourable) Expressed in all Expressed in all testis: 67.2 ELMO3 CED-12, CED12, ELMO-3, FLJ13824 ENSG00000102890 Engulfment and cell motility 3 16 67199111-67204029 Predicted intracellular proteins Evidence at protein level HPA021484 Approved Approved Plasma membrane
Cell Junctions Renal cancer:2.77e-5 (favourable) Expressed in all Mixed skin: 39.4 ENC1 ENC-1, KLHL37, NRPB, PIG10, TP53I10 ENSG00000171617 Ectodermal-neural cortex 1 (with BTB domain) 5 74627406-74641424 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA078061 Uncertain Plasma membrane
Cytoplasmic bodies Renal cancer:2.95e-5 (unfavourable), Breast cancer:3.88e-4 (unfavourable) Expressed in all Tissue enriched 15 cerebral cortex: 462.7 gallbladder: 30.9 ENO3 ENSG00000108515 Enolase 3 (beta, muscle) 17 4948092-4957131 Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000793, HPA068284 Approved Validated Plasma membrane
Cytosol Colorectal cancer:7.33e-4 (unfavourable) Expressed in all Tissue enriched 19 skeletal muscle: 5975.8 heart muscle: 311.9 EPB41L4A NBL4 ENSG00000129595 Erythrocyte membrane protein band 4.1 like 4A 5 112142441-112419316 Predicted intracellular proteins Evidence at protein level HPA036580 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:3.65e-5 (favourable) Mixed Expressed in all parathyroid gland: 26.9 EPB41L4B EHM2 ENSG00000095203 Erythrocyte membrane protein band 4.1 like 4B 9 109171975-109320964 Predicted intracellular proteins Evidence at protein level HPA042862 Approved Approved Plasma membrane
Cytosol Breast cancer:1.02e-4 (unfavourable) Mixed Mixed thyroid gland: 74.5 EPHB2 DRT, EPHT3, ERK, Hek5, Tyro5 ENSG00000133216 EPH receptor B2 1 22710839-22921500 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013647, HPA071200 Approved Supported Nucleus
Plasma membrane Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable) Tissue enhanced Mixed rectum: 27.8 EPS8L2 FLJ21935, FLJ22171, MGC3088 ENSG00000177106 EPS8-like 2 11 694438-727727 Predicted intracellular proteins Evidence at protein level HPA041143 Approved Supported Plasma membrane
Cytosol Glioma:1.80e-4 (unfavourable) Expressed in all Mixed small intestine: 112.7 ERBB2 CD340, HER-2, HER2, NEU, NGL ENSG00000141736 Erb-b2 receptor tyrosine kinase 2 17 39687914-39730426 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555 Approved Supported Plasma membrane
Cytosol Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 122.9 ERBB2IP ERBIN, LAP2 ENSG00000112851 Erbb2 interacting protein 5 65926475-66082549 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA048606, HPA059863 Approved Supported Nuclear speckles
Plasma membrane Expressed in all Expressed in all testis: 49.9 ERBB3 HER3, LCCS2 ENSG00000065361 Erb-b2 receptor tyrosine kinase 3 12 56079857-56103505 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025331, HPA045396 Uncertain Approved Plasma membrane
Actin filaments Expressed in all Mixed small intestine: 88.5 ETS2 ENSG00000157557 V-ets avian erythroblastosis virus E26 oncogene homolog 2 21 38805307-38824955 Predicted intracellular proteins, RAS pathway related proteins, Transcription factors Evidence at protein level HPA003176 Supported Nucleoplasm
Plasma membrane Expressed in all Expressed in all spleen: 256.3 EVA1A FAM176A, FLJ13391, TMEM166 ENSG00000115363 Eva-1 homolog A (C. elegans) 2 75469302-75569722 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008055 Approved Supported Vesicles
Plasma membrane Ovarian cancer:5.67e-4 (favourable), Renal cancer:5.80e-4 (favourable) Mixed Tissue enhanced liver: 98.5 lung: 31.1 EXOC3L1 EXOC3L, FLJ35539, FLJ35587 ENSG00000179044 Exocyst complex component 3-like 1 16 67184366-67190204 Predicted intracellular proteins Evidence at transcript level HPA029574 Uncertain Approved Vesicles
Plasma membrane Expressed in all Tissue enhanced spleen: 30.6 placenta: 8.4 FABP5 E-FABP, KFABP, PA-FABP ENSG00000164687 Fatty acid binding protein 5 (psoriasis-associated) 8 81280363-81284777 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB017831, CAB040577, HPA051895 Supported Supported Plasma membrane
Cytosol Renal cancer:4.69e-10 (unfavourable) Expressed in all Expressed in all esophagus: 1671.2 FAIM FAIM1, FLJ10582 ENSG00000158234 Fas apoptotic inhibitory molecule 3 138608606-138633376 Predicted intracellular proteins Evidence at protein level HPA042440, HPA052209 Approved Approved Plasma membrane
Cytosol Liver cancer:3.96e-5 (unfavourable), Renal cancer:6.63e-4 (favourable) Expressed in all Expressed in all fallopian tube: 60.5 FAM126A DRCTNNB1A , HCC, HYCC1, hyccin ENSG00000122591 Family with sequence similarity 126, member A 7 22889371-23014130 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA042873 Approved Supported Plasma membrane
Cytosol Renal cancer:6.04e-7 (unfavourable), Stomach cancer:5.99e-4 (unfavourable), Urothelial cancer:9.03e-4 (unfavourable) Expressed in all Expressed in all testis: 33.2 FAM129A C1orf24, GIG39, NIBAN ENSG00000135842 Family with sequence similarity 129, member A 1 184790724-184974550 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA028172, HPA028231, HPA028657 Approved Supported Plasma membrane
Cytosol Urothelial cancer:4.52e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 105.0 FAM171A1 C10orf38, FLJ12884 ENSG00000148468 Family with sequence similarity 171, member A1 10 15211643-15371062 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051345 Approved Approved Nucleoplasm
Plasma membrane Thyroid cancer:4.90e-6 (unfavourable), Renal cancer:2.71e-5 (favourable) Expressed in all Mixed cerebral cortex: 73.4 FAM193A C4orf8, RES4-22 ENSG00000125386 Family with sequence similarity 193, member A 4 2625261-2732565 Predicted intracellular proteins Evidence at protein level HPA043116 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:4.80e-4 (favourable) Expressed in all Expressed in all testis: 41.5 FAM210B C20orf108, dJ1167H4.1, DKFZP434A1114 ENSG00000124098 Family with sequence similarity 210, member B 20 56358915-56368663 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042652 Approved Approved Plasma membrane
Cytosol Renal cancer:1.44e-10 (favourable), Lung cancer:4.26e-4 (favourable), Cervical cancer:5.44e-4 (favourable) Expressed in all Expressed in all ovary: 131.1 FAM47E FLJ42946, LOC100129583 ENSG00000189157 Family with sequence similarity 47, member E 4 76214040-76283780 Predicted intracellular proteins Evidence at transcript level HPA053331 Uncertain Uncertain Plasma membrane
Cytosol Mixed Tissue enhanced fallopian tube: 26.5 thyroid gland: 13.8 FAM47E-STBD1 ENSG00000272414 FAM47E-STBD1 readthrough 4 76251721-76311129 Predicted intracellular proteins Evidence at transcript level HPA053331 Approved Uncertain Plasma membrane
Cytosol Not detected Expressed in all adipose tissue: 33.0 FAS APO-1, APT1, CD95, FAS1, TNFRSF6 ENSG00000026103 Fas cell surface death receptor 10 88990531-89015785 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027444 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed lung: 39.5 FASN FAS, SDR27X1 ENSG00000169710 Fatty acid synthase 17 82078333-82098332 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005192, HPA006461, CAB015417, HPA056108 Supported Validated Plasma membrane
Cytosol Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 283.6 FBLN5 ARMD3, DANCE, EVEC, UP50 ENSG00000140092 Fibulin 5 14 91869412-91947987 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA000848, HPA000868, CAB025843 Supported Approved Plasma membrane
Cytosol Liver cancer:6.75e-4 (favourable) Expressed in all Expressed in all gallbladder: 221.9 FBLN7 FLJ37440, TM14 ENSG00000144152 Fibulin 7 2 112138385-112188216 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA034992 Uncertain Approved Plasma membrane
Cell Junctions Mixed Mixed parathyroid gland: 18.3 FBP2 ENSG00000130957 Fructose-1,6-bisphosphatase 2 9 94558720-94593793 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA012513, HPA055286 Approved Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 8 skeletal muscle: 266.1 stomach: 32.9 FGD1 FGDY, ZFYVE3 ENSG00000102302 FYVE, RhoGEF and PH domain containing 1 X 54445454-54496166 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000911 Uncertain Approved Plasma membrane
Cytosol Endometrial cancer:2.10e-4 (unfavourable) Expressed in all Mixed endometrium: 10.1 FGR c-fgr, p55c-fgr, SRC2 ENSG00000000938 FGR proto-oncogene, Src family tyrosine kinase 1 27612064-27635277 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA002024 Supported Approved Plasma membrane
Aggresome Expressed in all Tissue enhanced appendix: 87.8;bone marrow: 137.2;spleen: 92.1 lung: 56.3 FHIT AP3Aase, FRA3B ENSG00000189283 Fragile histidine triad 3 59749310-61251459 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB002684, HPA018840, HPA018909 Supported Approved Nucleoli fibrillar center
Plasma membrane Renal cancer:1.36e-4 (favourable) Mixed Expressed in all kidney: 26.6 FHL1 bA535K18.1, FHL1B, FLH1A, KYO-T, MGC111107, SLIM1, XMPMA ENSG00000022267 Four and a half LIM domains 1 X 136146702-136211359 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001040, HPA001391, CAB020817 Supported Supported Plasma membrane
Cytosol Urothelial cancer:2.11e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 3805.6 FILIP1 FILIP, KIAA1275 ENSG00000118407 Filamin A interacting protein 1 6 75291859-75493738 Predicted intracellular proteins Evidence at protein level HPA053564 Approved Uncertain Plasma membrane
Actin filaments Mixed Tissue enhanced heart muscle: 34.9 smooth muscle: 19.4 FLAD1 FAD1, PP591 ENSG00000160688 Flavin adenine dinucleotide synthetase 1 1 154983338-154993111 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028476, HPA028486, HPA028563 Approved Supported Plasma membrane
Cytosol Renal cancer:2.55e-6 (unfavourable), Liver cancer:3.04e-4 (unfavourable) Expressed in all Expressed in all skin: 28.6 FLCN BHD, MGC17998, MGC23445 ENSG00000154803 Folliculin 17 17212212-17237188 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB015158, HPA028760 Supported Supported Plasma membrane
Cytosol Pancreatic cancer:4.49e-4 (favourable) Expressed in all Expressed in all endometrium: 30.7 FLNC ABP-280, ABPL, FLN2 ENSG00000128591 Filamin C, gamma 7 128830377-128859274 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006135 Supported Supported Plasma membrane
Cytosol Lung cancer:2.17e-5 (unfavourable), Urothelial cancer:3.73e-5 (unfavourable), Glioma:2.14e-4 (unfavourable), Renal cancer:5.69e-4 (unfavourable) Expressed in all Tissue enhanced skeletal muscle: 384.8 smooth muscle: 158.7 FLT1 FLT, VEGFR1 ENSG00000102755 Fms-related tyrosine kinase 1 13 28300344-28495128 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA011740, HPA014290, CAB068189, CAB068190 Supported Supported Plasma membrane
Actin filaments Renal cancer:2.19e-4 (unfavourable) Expressed in all Tissue enriched 8 placenta: 617.5 thyroid gland: 81.7 FMN2 ENSG00000155816 Formin 2 1 240014348-240475189 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA050649 Approved Plasma membrane
Actin filaments Group enriched Group enriched 6 cerebral cortex: 54.0;parathyroid gland: 32.9 adrenal gland: 7.0 FSCN1 FLJ38511, p55, SNL ENSG00000075618 Fascin actin-bundling protein 1 7 5592823-5606655 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000121, HPA005723, CAB035991, HPA050654 Supported Supported Plasma membrane
Cytosol Renal cancer:8.15e-7 (unfavourable), Lung cancer:2.28e-4 (unfavourable), Head and neck cancer:5.76e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 85.7 spleen: 55.9 FSD1L CCDC10, CSDUFD1, FSD1CL, FSD1NL ENSG00000106701 Fibronectin type III and SPRY domain containing 1-like 9 105447796-105552433 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035138 Approved Approved Plasma membrane
Actin filaments Mixed Tissue enhanced cerebral cortex: 17.8 testis: 13.4 FTCD ENSG00000160282 Formimidoyltransferase cyclodeaminase 21 46136262-46155567 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA020073, HPA030928, HPA030929, HPA036114 Supported Approved Plasma membrane
Cytosol Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable) Tissue enriched Group enriched 18 kidney: 100.1;liver: 184.7 testis: 7.7 FUT2 SE, Se2, SEC2, sej ENSG00000176920 Fucosyltransferase 2 (secretor status included) 19 48695971-48705950 Blood group antigen proteins, Enzymes, Predicted membrane proteins Evidence at transcript level HPA014402 Uncertain Uncertain Plasma membrane
Cytosol Head and neck cancer:5.83e-4 (favourable) Mixed Tissue enhanced duodenum: 52.9 stomach: 32.5 FYN MGC45350, SLK, SYN ENSG00000010810 FYN proto-oncogene, Src family tyrosine kinase 6 111660332-111873452 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005034, CAB018387, HPA023887, HPA063770 Approved Validated Plasma membrane
Cytosol Renal cancer:1.43e-4 (unfavourable), Liver cancer:1.84e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 166.6 GADL1 ENSG00000144644 Glutamate decarboxylase-like 1 3 30726200-30894765 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039160, HPA040229 Uncertain Approved Plasma membrane
Cytosol Not detected Tissue enhanced skeletal muscle: 9.0 thyroid gland: 2.5 GALNT15 GALNT7, GALNTL2, pp-GalNAc-T15 ENSG00000131386 Polypeptide N-acetylgalactosaminyltransferase 15 3 16174649-16231992 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA017076, HPA051551 Uncertain Approved Vesicles
Plasma membrane Tissue enriched Tissue enhanced adipose tissue: 36.2;cerebral cortex: 41.4;placenta: 42.6 breast: 18.3 GAPDH GAPD ENSG00000111640 Glyceraldehyde-3-phosphate dehydrogenase 12 6533927-6538374 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005197, CAB016392, HPA040067, HPA061280 Supported Validated Plasma membrane
Cytosol Renal cancer:6.25e-10 (unfavourable), Liver cancer:1.79e-6 (unfavourable) Expressed in all Expressed in all skeletal muscle: 9875.4 GAS2L1 GAR22 ENSG00000185340 Growth arrest-specific 2 like 1 22 29306582-29312785 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019858 Approved Approved Plasma membrane
Cell Junctions Renal cancer:8.44e-4 (favourable) Expressed in all Expressed in all testis: 32.2 GAS8 DRC4, GAS11 ENSG00000141013 Growth arrest-specific 8 16 90019629-90044975 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041311, HPA048238 Approved Approved Plasma membrane
Cytosol Renal cancer:1.09e-7 (favourable), Endometrial cancer:3.01e-4 (favourable), Pancreatic cancer:7.67e-4 (favourable) Expressed in all Mixed fallopian tube: 22.6 GCA GCL ENSG00000115271 Grancalcin, EF-hand calcium binding protein 2 162318840-162371595 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035033, HPA035034 Supported Supported Plasma membrane
Cytosol Expressed in all Tissue enhanced bone marrow: 214.9 appendix: 90.2 GFRA3 GFRa-3 ENSG00000146013 GDNF family receptor alpha 3 5 138252379-138274671 Predicted membrane proteins Evidence at protein level HPA020731 Approved Uncertain Plasma membrane
Cytosol Mixed Mixed seminal vesicle: 8.0 GINM1 C6orf72, dJ12G14.2 ENSG00000055211 Glycoprotein integral membrane 1 6 149566294-149591748 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017210, HPA041679 Approved Approved Nucleoli fibrillar center
Plasma membrane Expressed in all Expressed in all thyroid gland: 118.1 GLRX GRX, GRX1 ENSG00000173221 Glutaredoxin (thioltransferase) 5 95751319-95823005 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008634, HPA046431, CAB069419 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all kidney: 217.3 GNB1 ENSG00000078369 Guanine nucleotide binding protein (G protein), beta polypeptide 1 1 1785285-1891117 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA040736 Supported Uncertain Golgi apparatus
Plasma membrane Liver cancer:3.61e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 448.5 GNB3 ENSG00000111664 Guanine nucleotide binding protein (G protein), beta polypeptide 3 12 6839954-6847393 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA040736 Approved Uncertain Golgi apparatus
Plasma membrane Tissue enhanced Mixed smooth muscle: 3.7 GPAT3 AGPAT10, AGPAT9, HMFN0839, LPAAT-theta, MAG1, MGC11324 ENSG00000138678 Glycerol-3-phosphate acyltransferase 3 4 83535914-83605875 Enzymes, Predicted membrane proteins Evidence at protein level HPA029414, CAB033749 Approved Uncertain Plasma membrane
Cytosol Renal cancer:2.71e-9 (favourable), Urothelial cancer:8.21e-4 (unfavourable) Mixed Tissue enhanced kidney: 89.3 duodenum: 41.9 GPC1 glypican ENSG00000063660 Glypican 1 2 240435671-240468078 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030571 Approved Supported Plasma membrane
Cytosol Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:5.78e-5 (unfavourable), Endometrial cancer:1.55e-4 (unfavourable) Expressed in all Tissue enhanced skin: 266.0 prostate: 57.7 GPR1 ENSG00000183671 G protein-coupled receptor 1 2 206175316-206218047 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010525 Uncertain Supported Vesicles
Plasma membrane Mixed Tissue enhanced placenta: 11.2 esophagus: 5.5 GPR173 SREB3 ENSG00000184194 G protein-coupled receptor 173 X 53049091-53080615 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA003905 Approved Plasma membrane
Cytosol Endometrial cancer:2.88e-6 (unfavourable), Pancreatic cancer:2.33e-5 (favourable), Renal cancer:2.47e-4 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 19.1 ovary: 9.0 GPR50 H9, Mel1c ENSG00000102195 G protein-coupled receptor 50 X 151176653-151181465 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA049862, HPA054678 Supported Supported Nucleoplasm
Plasma membrane Mixed Not detected placenta: 0.6 GPRC5A PEIG-1, RAI3, RAIG1, TIG1 ENSG00000013588 G protein-coupled receptor, class C, group 5, member A 12 12890782-12917937 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007928, HPA046526 Approved Validated Vesicles
Plasma membrane Pancreatic cancer:4.63e-6 (unfavourable), Renal cancer:9.02e-5 (unfavourable) Mixed Tissue enhanced lung: 302.3 thyroid gland: 90.7 GPRIN1 GRIN1, KIAA1893 ENSG00000169258 G protein regulated inducer of neurite outgrowth 1 5 176595802-176610133 Predicted intracellular proteins Evidence at protein level HPA036478, HPA070892 Supported Supported Vesicles
Plasma membrane Renal cancer:2.79e-7 (unfavourable), Lung cancer:6.83e-6 (unfavourable) Expressed in all Tissue enriched 7 cerebral cortex: 27.9 duodenum: 3.9 GRAMD1A FLJ90346, KIAA1533 ENSG00000089351 GRAM domain containing 1A 19 34994784-35026471 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008852, HPA012570 Approved Approved Plasma membrane
Cytosol Renal cancer:7.95e-12 (unfavourable) Expressed in all Expressed in all appendix: 36.8 GRAMD1C DKFZp434C0328 ENSG00000178075 GRAM domain containing 1C 3 113828182-113947174 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012316 Approved Uncertain Plasma membrane
Cytosol Renal cancer:4.22e-15 (favourable) Mixed Mixed testis: 28.3 GSR ENSG00000104687 Glutathione reductase 8 30678061-30727926 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001538, CAB008632 Approved Supported Plasma membrane
Cytosol Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 77.8 GTSE1 B99, GTSE-1 ENSG00000075218 G-2 and S-phase expressed 1 22 46296741-46330810 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029457, HPA060544 Uncertain Approved Plasma membrane
Centrosome Liver cancer:1.90e-10 (unfavourable), Pancreatic cancer:1.29e-4 (unfavourable), Lung cancer:4.66e-4 (unfavourable) Mixed Tissue enhanced testis: 12.5 lymph node: 10.7 HAPLN3 EXLD1, HsT19883 ENSG00000140511 Hyaluronan and proteoglycan link protein 3 15 88877288-88895626 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA039237 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.18e-13 (unfavourable) Expressed in all Tissue enhanced appendix: 14.3;lymph node: 11.0 spleen: 4.0 HARBI1 C11orf77, FLJ32675 ENSG00000180423 Harbinger transposase derived 1 11 46602861-46617909 Predicted intracellular proteins Evidence at protein level HPA038671, HPA045457 Uncertain Validated Plasma membrane
Cytosol Expressed in all Tissue enhanced testis: 21.7 parathyroid gland: 5.2 HAS1 HAS ENSG00000105509 Hyaluronan synthase 1 19 51713112-51723994 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA067602 Approved Approved Nucleoplasm
Plasma membrane Mixed Tissue enhanced adipose tissue: 26.9 appendix: 9.1 HAUS4 C14orf94, FLJ20424 ENSG00000092036 HAUS augmin-like complex, subunit 4 14 22946228-22957161 Predicted intracellular proteins Evidence at protein level HPA029803, HPA071195 Approved Supported Plasma membrane
Focal adhesion sites Urothelial cancer:2.24e-4 (unfavourable) Expressed in all Expressed in all ovary: 61.7 HCK JTK9 ENSG00000101336 HCK proto-oncogene, Src family tyrosine kinase 20 32052188-32101856 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB005195, HPA063768 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:1.66e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 142.6;spleen: 108.6 lung: 67.5 HCLS1 CTTNL, HS1 ENSG00000180353 Hematopoietic cell-specific Lyn substrate 1 3 121631399-121660927 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019143 Supported Supported Plasma membrane
Cytosol Expressed in all Expressed in all spleen: 275.8 HDAC8 HDACL1, MRXS6, RPD3, WTS ENSG00000147099 Histone deacetylase 8 X 72329516-72573103 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA048560 Supported Supported Nucleus
Plasma membrane Expressed in all Expressed in all epididymis: 26.9 HENMT1 C1orf59, FLJ30525, HEN1 ENSG00000162639 HEN1 methyltransferase homolog 1 (Arabidopsis) 1 108648290-108661526 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028464, HPA028497 Uncertain Approved Plasma membrane
Focal adhesion sites Renal cancer:2.48e-5 (unfavourable), Cervical cancer:2.56e-4 (favourable), Colorectal cancer:9.95e-4 (favourable) Expressed in all Tissue enriched 8 testis: 127.7 lymph node: 15.0 HERPUD1 HERP, KIAA0025, Mif1, SUP ENSG00000051108 Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 16 56932048-56944863 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037041, CAB037104, HPA040754, HPA041219 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.41e-9 (favourable) Expressed in all Expressed in all prostate: 379.0 HLA-A ENSG00000206503 Major histocompatibility complex, class I, A 6 29941260-29945884 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB078470 Supported Golgi apparatus
Plasma membrane Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable) Expressed in all Mixed gallbladder: 342.4 HMOX1 bK286B10, HO-1 ENSG00000100292 Heme oxygenase 1 22 35380361-35394214 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000635, CAB017444 Supported Uncertain Golgi apparatus
Plasma membrane Liver cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all spleen: 435.2 HN1L C16orf34, FLJ13092, KIAA1426, L11 ENSG00000206053 Hematological and neurological expressed 1-like 16 1678256-1702280 Predicted intracellular proteins Evidence at protein level HPA041888, HPA041908 Approved Validated Plasma membrane
Cytosol Endometrial cancer:7.85e-4 (favourable), Liver cancer:9.14e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 100.6 HPS3 BLOC2S1, SUTAL ENSG00000163755 Hermansky-Pudlak syndrome 3 3 149129584-149173732 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046281, HPA052778 Approved Approved Golgi apparatus
Plasma membrane Renal cancer:4.38e-4 (unfavourable), Liver cancer:6.04e-4 (unfavourable) Expressed in all Mixed spleen: 22.5 HRH1 ENSG00000196639 Histamine receptor H1 3 11137093-11263557 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029740 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:1.27e-5 (unfavourable) Mixed Mixed cerebral cortex: 12.4 HSPB1 CMT2F, Hs.76067, Hsp25, HSP27, HSP28 ENSG00000106211 Heat shock 27kDa protein 1 7 76302544-76304295 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000497, CAB004439, CAB047330, CAB047331, CAB047332 Supported Validated Plasma membrane
Cytosol Colorectal cancer:9.94e-5 (unfavourable) Expressed in all Expressed in all esophagus: 1622.3 HUNK ENSG00000142149 Hormonally up-regulated Neu-associated kinase 21 31873315-32044633 Enzymes, Predicted intracellular proteins Evidence at protein level HPA027295, HPA027372 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:7.48e-5 (favourable) Mixed Mixed placenta: 6.8 HYDIN CILD5, DKFZp434D0513, KIAA1864, PPP1R31 ENSG00000157423 HYDIN, axonemal central pair apparatus protein 16 70807378-71230722 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA067155, HPA074129 Supported Approved Plasma membrane
Cytosol Not detected Tissue enhanced fallopian tube: 9.3;testis: 6.4 parathyroid gland: 5.3 HYLS1 FLJ32915 ENSG00000198331 Hydrolethalus syndrome 1 11 125883614-125900648 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA041210 Uncertain Supported Plasma membrane
Cytosol Liver cancer:1.92e-4 (unfavourable) Expressed in all Tissue enriched 6 testis: 37.4 smooth muscle: 6.6 ICAM1 BB2, CD54 ENSG00000090339 Intercellular adhesion molecule 1 19 10270835-10286615 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002126, CAB002142, HPA004877 Supported Uncertain Plasma membrane
Cytosol Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable) Expressed in all Expressed in all lung: 256.0 IFFO2 ENSG00000169991 Intermediate filament family orphan 2 1 18904281-18956686 Predicted intracellular proteins Evidence at protein level HPA015987, HPA064603 Approved Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all skin: 72.6 IFIT5 RI58 ENSG00000152778 Interferon-induced protein with tetratricopeptide repeats 5 10 89414586-89421001 Predicted intracellular proteins Evidence at protein level HPA037957, HPA062180 Uncertain Supported Vesicles
Plasma membrane Expressed in all Mixed parathyroid gland: 35.6 IFRD1 PC4, TIS7 ENSG00000006652 Interferon-related developmental regulator 1 7 112422968-112481017 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024122 Approved Approved Plasma membrane
Cytosol Ovarian cancer:5.45e-4 (favourable) Expressed in all Expressed in all bone marrow: 130.1 IGFL2 UNQ645 ENSG00000204866 IGF-like family member 2 19 46143106-46161299 Predicted intracellular proteins, Predicted secreted proteins Evidence at transcript level HPA059137 Uncertain Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 6 skin: 35.5 parathyroid gland: 5.7 IKZF3 Aiolos, ZNFN1A3 ENSG00000161405 IKAROS family zinc finger 3 (Aiolos) 17 39757715-39864188 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017105, HPA024377 Supported Uncertain Plasma membrane
Cytosol Cervical cancer:6.85e-6 (favourable), Head and neck cancer:4.16e-4 (favourable), Melanoma:5.42e-4 (favourable), Renal cancer:7.38e-4 (unfavourable) Mixed Tissue enhanced lymph node: 45.2;spleen: 32.2;tonsil: 40.9 appendix: 26.4 IL12RB2 ENSG00000081985 Interleukin 12 receptor, beta 2 1 67307364-67396900 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA024168 Uncertain Uncertain Plasma membrane
Cytosol Tissue enhanced Tissue enhanced placenta: 11.7 cerebral cortex: 4.5 IL13 ALRH, BHR1, IL-13, MGC116786, MGC116788, MGC116789, P600 ENSG00000169194 Interleukin 13 5 132656263-132661110 Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA042421 Approved Plasma membrane
Cytosol Not detected Tissue enriched 10 testis: 19.9 gallbladder: 2.0 IL15RA CD215, IL-15RA ENSG00000134470 Interleukin 15 receptor, alpha 10 5937569-5978187 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026215 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.27e-12 (unfavourable), Liver cancer:2.67e-6 (unfavourable), Pancreatic cancer:5.35e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 33.5 IL21R CD360 ENSG00000103522 Interleukin 21 receptor 16 27402162-27452042 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA042296 Uncertain Uncertain Plasma membrane
Cytosol Head and neck cancer:7.29e-4 (favourable) Mixed Tissue enhanced appendix: 16.4;lymph node: 29.2;tonsil: 18.0 spleen: 7.7 IL6ST CD130, GP130 ENSG00000134352 Interleukin 6 signal transducer 5 55935095-55994993 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010558, CAB025784 Uncertain Supported Golgi apparatus
Plasma membrane Renal cancer:5.05e-4 (unfavourable) Expressed in all Expressed in all placenta: 327.1 IQGAP1 HUMORFA01, KIAA0051, p195, SAR1 ENSG00000140575 IQ motif containing GTPase activating protein 1 15 90388218-90502243 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013302, HPA014055 Supported Supported Plasma membrane
Cell Junctions Pancreatic cancer:5.67e-5 (unfavourable) Expressed in all Expressed in all endometrium: 119.6 IQGAP2 ENSG00000145703 IQ motif containing GTPase activating protein 2 5 76403249-76708132 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004241, HPA037403, HPA037404 Approved Approved Vesicles
Plasma membrane Renal cancer:9.44e-12 (favourable), Liver cancer:5.65e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 124.6 testis: 91.6 ISLR HsT17563 ENSG00000129009 Immunoglobulin superfamily containing leucine-rich repeat 15 74173671-74176872 Predicted secreted proteins Evidence at protein level HPA040326, HPA050811 Approved Approved Golgi apparatus
Plasma membrane Renal cancer:4.89e-8 (unfavourable) Expressed in all Mixed endometrium: 198.5 ITGA7 ENSG00000135424 Integrin, alpha 7 12 55684568-55716043 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008427 Uncertain Approved Plasma membrane
Cytosol Urothelial cancer:9.59e-5 (unfavourable), Pancreatic cancer:1.75e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 154.2 smooth muscle: 135.5 ITGB5 ENSG00000082781 Integrin, beta 5 3 124761948-124901418 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001820, CAB022050 Approved Approved Plasma membrane
Mitochondria Pancreatic cancer:1.40e-4 (unfavourable) Expressed in all Expressed in all placenta: 116.8 ITGB7 ENSG00000139626 Integrin, beta 7 12 53191318-53207307 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042277 Approved Plasma membrane
Cytosol Mixed Mixed spleen: 32.8 ITGB8 ENSG00000105855 Integrin, beta 8 7 20330702-20415754 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA027796, HPA027797 Approved Approved Plasma membrane
Cytosol Renal cancer:1.77e-4 (favourable) Mixed Mixed cerebral cortex: 30.9 ITSN2 KIAA1256, PRO2015, SH3D1B, SH3P18, SWA, SWAP ENSG00000198399 Intersectin 2 2 24202864-24360714 Predicted intracellular proteins Evidence at protein level HPA036475 Approved Approved Vesicles
Plasma membrane Head and neck cancer:2.98e-4 (favourable) Expressed in all Expressed in all thyroid gland: 84.6 JAG1 AGS, AHD, AWS, CD339, HJ1, JAGL1 ENSG00000101384 Jagged 1 20 10637684-10674107 CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB010343, HPA021555 Supported Supported Golgi apparatus
Plasma membrane Pancreatic cancer:4.10e-6 (unfavourable) Expressed in all Expressed in all placenta: 96.3 JMJD4 FLJ12517 ENSG00000081692 Jumonji domain containing 4 1 227730425-227735411 Predicted intracellular proteins Evidence at protein level HPA027260, HPA052861 Uncertain Approved Vesicles
Plasma membrane Renal cancer:3.16e-4 (unfavourable) Expressed in all Expressed in all testis: 12.9 KCNC2 Kv3.2 ENSG00000166006 Potassium channel, voltage gated Shaw related subfamily C, member 2 12 75040077-75209868 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA019664, CAB022571 Uncertain Supported Plasma membrane
Cytosol Group enriched Tissue enriched 11 cerebral cortex: 46.5 prostate: 4.2 KIAA0556 ENSG00000047578 KIAA0556 16 27550133-27780369 Predicted intracellular proteins Evidence at protein level HPA035089, HPA035090 Supported Approved Nuclear speckles
Plasma membrane Head and neck cancer:3.00e-4 (favourable) Expressed in all Tissue enhanced fallopian tube: 47.1 thyroid gland: 26.8 KIAA1524 CIP2A ENSG00000163507 KIAA1524 3 108549869-108589644 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039570 Approved Supported Plasma membrane
Cytosol Endometrial cancer:6.24e-5 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:9.18e-4 (unfavourable) Expressed in all Mixed testis: 10.2 KIAA1958 FLJ39294 ENSG00000165185 KIAA1958 9 112486847-112669397 Predicted intracellular proteins Evidence at protein level HPA020625 Approved Approved Plasma membrane
Cytosol Mixed Mixed ovary: 12.1 KIF17 KIAA1405, KIF17B, KIF3X, KLP-2, OSM-3 ENSG00000117245 Kinesin family member 17 1 20664014-20718017 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA032085 Uncertain Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 6 testis: 23.7 cerebral cortex: 3.8 KIF21A FEOM1, FLJ20052 ENSG00000139116 Kinesin family member 21A 12 39293228-39443390 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB022079, HPA058432 Approved Supported Plasma membrane
Cytosol Renal cancer:8.07e-8 (favourable) Expressed in all Tissue enhanced cerebral cortex: 79.6 fallopian tube: 59.5 KIF26B FLJ10157 ENSG00000162849 Kinesin family member 26B 1 245154985-245709431 Predicted intracellular proteins Evidence at protein level HPA027709, HPA028478, HPA028561, HPA028562 Approved Approved Plasma membrane
Microtubules Ovarian cancer:1.24e-4 (unfavourable) Mixed Mixed cerebral cortex: 2.3 KISS1R AXOR12, GPR54, HOT7T175 ENSG00000116014 KISS1 receptor 19 917287-921015 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA071913 Supported Vesicles
Plasma membrane Renal cancer:3.33e-6 (unfavourable) Tissue enhanced Tissue enriched 5 cerebral cortex: 1.2 appendix,lymph node,placenta: 0.2 KLK10 NES1, PRSSL1 ENSG00000129451 Kallikrein-related peptidase 10 19 51012739-51020175 Cancer-related genes, Enzymes, Predicted secreted proteins Evidence at protein level HPA017195 Uncertain Plasma membrane
Cytosol Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable) Mixed Tissue enhanced esophagus: 138.7;skin: 52.8 tonsil: 47.4 KNTC1 KIAA0166, ROD ENSG00000184445 Kinetochore associated 1 12 122527246-122626396 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA025241 Approved Supported Plasma membrane
Cytosol Renal cancer:7.89e-8 (unfavourable), Liver cancer:4.79e-6 (unfavourable), Head and neck cancer:8.69e-4 (favourable) Expressed in all Tissue enhanced testis: 43.2 bone marrow: 27.2 KRT75 K6HF ENSG00000170454 Keratin 75, type II 12 52424070-52434525 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019367, HPA076201 Supported Approved Plasma membrane
Cytosol Tissue enhanced Not detected breast: 0.9 KRT77 KRT1B ENSG00000189182 Keratin 77, type II 12 52689626-52703463 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA045934 Supported Approved Nuclear membrane
Plasma membrane Mixed Tissue enriched 12 skin: 309.5 breast: 25.9 L1CAM CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1 ENSG00000198910 L1 cell adhesion molecule X 153861514-153909223 CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005830, CAB010896 Approved Approved Nucleoplasm
Plasma membrane Endometrial cancer:8.51e-10 (unfavourable), Lung cancer:2.36e-6 (unfavourable), Renal cancer:1.17e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable) Tissue enhanced Tissue enhanced adrenal gland: 36.2;cerebral cortex: 67.1 seminal vesicle: 12.7 L3MBTL1 dJ138B7.3, DKFZp586P1522, KIAA0681, L3MBTL, ZC2HC3 ENSG00000185513 L(3)mbt-like 1 (Drosophila) 20 43507680-43550950 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA056389 Supported Nucleus
Plasma membrane Mixed Mixed testis: 10.1 LACE1 AFG1 ENSG00000135537 Lactation elevated 1 6 108294894-108526796 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA030154, HPA030155, HPA030659 Approved Approved Plasma membrane
Cytosol Mixed Tissue enhanced testis: 17.5 parathyroid gland: 8.1 LAMA4 LAMA3 ENSG00000112769 Laminin, alpha 4 6 112108760-112254939 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA015693, CAB078156 Approved Approved Plasma membrane
Cytosol Renal cancer:2.00e-4 (unfavourable) Expressed in all Mixed smooth muscle: 144.6 LAMC1 LAMB2 ENSG00000135862 Laminin, gamma 1 (formerly LAMB2) 1 183023460-183145592 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001908, HPA001909, CAB004486, CAB078163 Supported Approved Endoplasmic reticulum
Plasma membrane Urothelial cancer:8.85e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 330.2 smooth muscle: 145.7 LCTL FLJ33279, KLG, KLPH ENSG00000188501 Lactase-like 15 66547179-66565979 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA071640 Approved Endoplasmic reticulum
Plasma membrane Group enriched Mixed cerebral cortex: 1.0 LENG1 ENSG00000105617 Leukocyte receptor cluster (LRC) member 1 19 54155161-54159882 Predicted intracellular proteins Evidence at protein level HPA043541 Uncertain Approved Nucleus
Plasma membrane Renal cancer:3.72e-4 (favourable), Pancreatic cancer:8.12e-4 (favourable) Expressed in all Tissue enhanced spleen: 1.8 endometrium: 1.0 LGR6 FLJ14471 ENSG00000133067 Leucine-rich repeat containing G protein-coupled receptor 6 1 202193901-202319781 G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008556 Approved Approved Nucleoplasm
Plasma membrane Glioma:2.00e-4 (unfavourable) Tissue enhanced Tissue enhanced fallopian tube: 14.1 gallbladder: 9.6 LHX6 LHX6.1 ENSG00000106852 LIM homeobox 6 9 122202577-122229626 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA047854, HPA058319 Approved Uncertain Nucleoli fibrillar center
Plasma membrane Mixed Mixed cerebral cortex: 8.1 LNX2 MGC46315, PDZRN1 ENSG00000139517 Ligand of numb-protein X 2 13 27545911-27620404 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040698 Approved Approved Vesicles
Plasma membrane Renal cancer:7.09e-13 (favourable) Expressed in all Expressed in all testis: 23.2 LONRF3 FLJ22612, RNF127 ENSG00000175556 LON peptidase N-terminal domain and ring finger 3 X 118974614-119018355 Predicted intracellular proteins Evidence at protein level HPA050422 Uncertain Approved Nucleus
Plasma membrane Pancreatic cancer:4.32e-4 (unfavourable) Mixed Mixed thyroid gland: 12.5 LPAR1 edg-2, EDG2, Gpcr26, GPR26, LPA1, Mrec1.3, rec.1.3, vzg-1 ENSG00000198121 Lysophosphatidic acid receptor 1 9 110873263-111038458 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA050667 Approved Nuclear speckles
Plasma membrane Expressed in all Mixed cervix, uterine: 90.9 LPAR6 P2RY5, P2Y5 ENSG00000139679 Lysophosphatidic acid receptor 6 13 48389567-48444704 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA028934, HPA076273 Approved Supported Vesicles
Plasma membrane Renal cancer:3.60e-4 (unfavourable), Lung cancer:6.22e-4 (favourable) Expressed in all Expressed in all placenta: 100.1 LRCH2 KIAA1495 ENSG00000130224 Leucine-rich repeats and calponin homology (CH) domain containing 2 X 115110616-115234072 Predicted intracellular proteins Evidence at protein level HPA003233 Approved Approved Nucleoli
Plasma membrane Mixed Mixed prostate: 13.3 LRRC15 LIB ENSG00000172061 Leucine rich repeat containing 15 3 194355247-194369743 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA035503 Uncertain Approved Vesicles
Plasma membrane Tissue enhanced Mixed cervix, uterine,tonsil: 4.7 LRRFIP2 HUFI-2 ENSG00000093167 Leucine rich repeat (in FLII) interacting protein 2 3 37052656-37183689 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA035956, HPA042023 Uncertain Approved Plasma membrane
Actin filaments Cervical cancer:6.31e-4 (favourable) Expressed in all Expressed in all testis: 130.5 LTB4R2 BLT2, BLTR2, JULF2, NOP9 ENSG00000213906 Leukotriene B4 receptor 2 14 24305734-24312053 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022689, HPA029680, HPA072921 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced skin: 40.6 spleen: 11.2 LY6K CT97, FLJ35226, HSJ001348 ENSG00000160886 Lymphocyte antigen 6 complex, locus K 8 142700111-142705127 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017770, CAB075742, CAB075743 Supported Supported Nucleoplasm
Plasma membrane Lung cancer:9.17e-5 (unfavourable) Mixed Tissue enriched 5 testis: 30.4 adipose tissue: 5.9 LZTS1 FEZ1 ENSG00000061337 Leucine zipper, putative tumor suppressor 1 8 20246165-20303963 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006294, HPA022046 Approved Approved Nucleoli
Plasma membrane Renal cancer:9.28e-6 (unfavourable), Endometrial cancer:3.03e-4 (unfavourable) Expressed in all Tissue enriched 10 parathyroid gland: 123.3 cerebral cortex,testis: 12.4 LZTS2 KIAA1813, LAPSER1 ENSG00000107816 Leucine zipper, putative tumor suppressor 2 10 100996618-101007836 Predicted intracellular proteins Evidence at protein level HPA044956 Approved Approved Plasma membrane
Cytosol Renal cancer:3.39e-4 (unfavourable), Colorectal cancer:8.23e-4 (unfavourable) Expressed in all Expressed in all endometrium: 57.8 MADD DENN, KIAA0358, RAB3GEP ENSG00000110514 MAP-kinase activating death domain 11 47269161-47330031 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038568 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:5.69e-5 (favourable), Endometrial cancer:6.62e-5 (favourable), Urothelial cancer:8.25e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 104.2 MAP2K1 MAPKK1, MEK1, PRKMK1 ENSG00000169032 Mitogen-activated protein kinase kinase 1 15 66386817-66492312 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003834, HPA026430 Approved Validated Plasma membrane
Cytosol Glioma:2.68e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.8 MAP4K1 HPK1 ENSG00000104814 Mitogen-activated protein kinase kinase kinase kinase 1 19 38587641-38618882 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007419, CAB007754 Supported Uncertain Nucleoplasm
Plasma membrane Renal cancer:7.99e-10 (unfavourable), Cervical cancer:6.17e-5 (favourable), Head and neck cancer:3.26e-4 (favourable) Expressed in all Tissue enhanced lymph node: 37.7;spleen: 24.2;tonsil: 28.3 appendix: 19.9 MAP4K5 GCKR, KHS, KHS1 ENSG00000012983 Mitogen-activated protein kinase kinase kinase kinase 5 14 50418501-50561126 Predicted intracellular proteins Evidence at protein level HPA036696 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all endometrium: 54.9 MAPT DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau ENSG00000186868 Microtubule-associated protein tau 17 45894382-46028334 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000151, HPA048895, HPA069524, HPA069570 Supported Supported Nuclear speckles
Plasma membrane Group enriched Tissue enriched 8 cerebral cortex: 116.6 skeletal muscle: 13.7 MARCH10 FLJ35757, MARCH-X, RNF190 ENSG00000173838 Membrane-associated ring finger (C3HC4) 10, E3 ubiquitin protein ligase 17 62701314-62808344 Predicted intracellular proteins Evidence at protein level HPA023322 Supported Approved Plasma membrane
Cytosol Mixed Tissue enriched 7 testis: 145.2 fallopian tube: 20.2 MARCH7 AXOT, MARCH-VII, RNF177 ENSG00000136536 Membrane-associated ring finger (C3HC4) 7, E3 ubiquitin protein ligase 2 159712457-159771027 Predicted intracellular proteins Evidence at protein level HPA014275, HPA022152 Approved Supported Plasma membrane
Cytosol Renal cancer:1.84e-4 (unfavourable), Liver cancer:2.41e-4 (unfavourable) Expressed in all Expressed in all testis: 111.7 MARK2 EMK1, PAR-1, PAR-1B, Par1b ENSG00000072518 MAP/microtubule affinity-regulating kinase 2 11 63838928-63911019 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038790, HPA074905 Approved Supported Nucleoplasm
Plasma membrane Liver cancer:1.30e-4 (unfavourable), Endometrial cancer:3.21e-4 (unfavourable) Expressed in all Expressed in all skin: 46.2 MCF2L2 ARHGEF22, KIAA0861 ENSG00000053524 MCF.2 cell line derived transforming sequence-like 2 3 183178043-183428778 Disease related genes, Predicted intracellular proteins Evidence at transcript level HPA038946, HPA038947 Uncertain Approved Plasma membrane
Cytosol Not detected Group enriched 8 adrenal gland: 10.3;cerebral cortex: 17.1;parathyroid gland: 7.4;spleen: 3.5;testis: 4.6 prostate: 1.0 MCOLN1 ML4, MLIV, MST080, MSTP080, TRPM-L1, TRPML1 ENSG00000090674 Mucolipin 1 19 7522626-7534009 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA031763, CAB032637 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:5.60e-5 (favourable), Renal cancer:5.67e-4 (favourable) Expressed in all Expressed in all spleen: 49.0 MCTS1 MCT-1 ENSG00000232119 Malignant T cell amplified sequence 1 X 120594010-120621074 Predicted intracellular proteins Evidence at protein level HPA001045 Supported Plasma membrane
Cytosol Head and neck cancer:3.27e-5 (unfavourable), Renal cancer:4.35e-5 (unfavourable), Breast cancer:1.38e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 50.5 MDGA1 GPIM, MAMDC3 ENSG00000112139 MAM domain containing glycosylphosphatidylinositol anchor 1 6 37630679-37699306 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA031235, HPA050382 Approved Supported Golgi apparatus
Plasma membrane Mixed Mixed parathyroid gland: 10.5 MEI1 MGC40042, SPATA38 ENSG00000167077 Meiotic double-stranded break formation protein 1 22 41699499-41799456 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA049240 Approved Uncertain Nucleoplasm
Plasma membrane Cervical cancer:1.59e-6 (favourable) Tissue enhanced Mixed testis: 18.7 MET DFNB97, HGFR, RCCP2 ENSG00000105976 MET proto-oncogene, receptor tyrosine kinase 7 116672390-116798386 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005282, CAB018577, HPA055607 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable) Expressed in all Mixed placenta: 38.7 METAP2 MAP2, MNPEP, p67 ENSG00000111142 Methionyl aminopeptidase 2 12 95473520-95515839 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013025, HPA019095 Supported Supported Plasma membrane
Cytosol Liver cancer:4.51e-6 (unfavourable) Expressed in all Expressed in all seminal vesicle: 141.9 MISP C19orf21, Caprice, DKFZp686H18209 ENSG00000099812 Mitotic spindle positioning 19 751126-764318 Predicted intracellular proteins Evidence at protein level HPA049511, HPA062232 Supported Validated Plasma membrane
Focal adhesion sites Tissue enhanced Group enriched 6 colon: 96.4;duodenum: 178.1;rectum: 53.5;small intestine: 221.5 stomach: 22.1 MMP10 STMY2 ENSG00000166670 Matrix metallopeptidase 10 11 102770503-102780628 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002159 Uncertain Approved Plasma membrane
Cytosol Urothelial cancer:7.12e-4 (favourable) Tissue enhanced Tissue enriched 39 endometrium: 443.1 appendix: 11.3 MMP24 MT5-MMP ENSG00000125966 Matrix metallopeptidase 24 (membrane-inserted) 20 35226654-35277000 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA049280 Approved Nucleoli
Plasma membrane Renal cancer:8.17e-11 (favourable) Mixed Tissue enhanced cerebral cortex: 10.6 lung: 7.1 MOCS1 MOCOD ENSG00000124615 Molybdenum cofactor synthesis 1 6 39899578-39934551 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA045783, HPA058177, HPA075505 Uncertain Approved Plasma membrane
Cytosol Cervical cancer:1.07e-5 (unfavourable), Pancreatic cancer:6.07e-5 (favourable) Expressed in all Mixed placenta: 59.8 MPI ENSG00000178802 Mannose phosphate isomerase 15 74890005-74902219 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA007200 Approved Approved Plasma membrane
Cytosol Head and neck cancer:2.39e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 51.1 MPV17L2 FKSG24, MGC12972 ENSG00000254858 MPV17 mitochondrial membrane protein-like 2 19 18193182-18196948 Predicted membrane proteins Evidence at protein level HPA043111 Uncertain Approved Plasma membrane
Cytosol Renal cancer:2.30e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 16.2 MPZL1 FLJ21047, PZR ENSG00000197965 Myelin protein zero-like 1 1 167721192-167791919 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026966, HPA063538 Approved Supported Vesicles
Plasma membrane Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable) Expressed in all Expressed in all breast: 111.3 MRGPRF GPR140, GPR168, MGC21621, mrgF ENSG00000172935 MAS-related GPR, member F 11 69004395-69013409 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA028811 Approved Supported Nuclear membrane
Plasma membrane Expressed in all Mixed smooth muscle: 77.8 MRPL42 HSPC204, MRP-L31, MRPL31, MRPS32, PTD007, RPML31 ENSG00000198015 Mitochondrial ribosomal protein L42 12 93467488-93516213 Predicted intracellular proteins Evidence at protein level HPA039398 Approved Supported Plasma membrane
Mitochondria Liver cancer:7.49e-4 (unfavourable), Urothelial cancer:8.12e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 56.2 MTCP1 P13MTCP1, p8MTCP1 ENSG00000214827 Mature T-cell proliferation 1 X 155061622-155147937 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA032040 Approved Nucleoplasm
Plasma membrane Renal cancer:4.52e-8 (unfavourable) Mixed Mixed testis: 8.7 MTPN GCDP, MYOTROPHIN, V-1 ENSG00000105887 Myotrophin 7 135926761-135977353 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA019735 Approved Approved Plasma membrane
Cytosol Liver cancer:1.19e-4 (unfavourable), Pancreatic cancer:3.05e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 194.2 MUC1 ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM ENSG00000185499 Mucin 1, cell surface associated 1 155185824-155192916 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000036, CAB001986, HPA004179, HPA007235, HPA008855 Supported Validated Vesicles
Plasma membrane Pancreatic cancer:4.60e-4 (unfavourable) Expressed in all Tissue enhanced lung: 447.5;stomach: 650.2 cervix, uterine: 286.5 MYB c-myb ENSG00000118513 V-myb avian myeloblastosis viral oncogene homolog 6 135181315-135219173 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017704 Approved Approved Nucleus
Plasma membrane Prostate cancer:9.65e-4 (favourable), Stomach cancer:9.87e-4 (favourable) Tissue enhanced Tissue enhanced breast: 25.9;rectum: 29.6 colon: 25.7 MYH11 SMHC, SMMHC ENSG00000133392 Myosin, heavy chain 11, smooth muscle 16 15703135-15857033 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002302, HPA014539, HPA015310 Supported Approved Plasma membrane
Cytosol Liver cancer:1.10e-5 (favourable) Tissue enhanced Tissue enhanced seminal vesicle: 1365.9;smooth muscle: 1008.5 prostate: 841.6 MYO1C myr2 ENSG00000197879 Myosin IC 17 1464098-1492812 Predicted intracellular proteins, Transporters Evidence at protein level HPA001768, HPA005924, CAB037023 Supported Validated Nuclear bodies
Plasma membrane Lung cancer:5.22e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 191.9 MYOF FER1L3, KIAA1207 ENSG00000138119 Myoferlin 10 93306429-93482317 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014245 Approved Supported Vesicles
Plasma membrane Pancreatic cancer:1.40e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 100.7 MYSM1 KIAA1915 ENSG00000162601 Myb-like, SWIRM and MPN domains 1 1 58654739-58700092 Enzymes, Predicted intracellular proteins Evidence at protein level HPA054291, HPA067133 Approved Supported Nucleoplasm
Plasma membrane Head and neck cancer:5.09e-5 (favourable) Expressed in all Mixed skin: 11.1 N6AMT2 ENSG00000150456 N-6 adenine-specific DNA methyltransferase 2 (putative) 13 20728731-20773958 Predicted intracellular proteins Evidence at protein level HPA040417, HPA042543 Uncertain Approved Plasma membrane
Cytosol Endometrial cancer:1.82e-4 (favourable) Expressed in all Expressed in all endometrium: 18.0 NAIF1 bA379C10.2, C9orf90, DKFZp762G199 ENSG00000171169 Nuclear apoptosis inducing factor 1 9 128061233-128068206 Predicted intracellular proteins Evidence at protein level HPA054898 Supported Nucleoplasm
Plasma membrane Pancreatic cancer:1.02e-5 (favourable), Renal cancer:8.30e-5 (favourable), Liver cancer:1.61e-4 (unfavourable) Expressed in all Mixed testis: 4.6 NAPG ENSG00000134265 N-ethylmaleimide-sensitive factor attachment protein, gamma 18 10525905-10552761 Predicted intracellular proteins Evidence at protein level HPA008208, HPA011389 Approved Approved Plasma membrane
Cytosol Renal cancer:8.14e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 50.6 NARFL FLJ21988, HPRN, IOP1, PRN ENSG00000103245 Nuclear prelamin A recognition factor-like 16 729753-741329 Predicted intracellular proteins Evidence at protein level HPA040851 Approved Approved Plasma membrane
Cytosol Cervical cancer:1.32e-5 (favourable), Renal cancer:9.83e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 19.4 NCAM1 CD56, NCAM ENSG00000149294 Neural cell adhesion molecule 1 11 112961247-113278436 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000142, CAB018071, HPA039835 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable) Tissue enriched Tissue enhanced cerebral cortex: 335.9 adrenal gland: 87.0 NCAM2 MGC51008, NCAM21 ENSG00000154654 Neural cell adhesion molecule 2 21 20998315-21543329 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA030900, HPA030901 Approved Supported Nuclear bodies
Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 69.0 adrenal gland: 15.9 NCK1 NCK, NCKalpha ENSG00000158092 NCK adaptor protein 1 3 136862208-136949823 Predicted intracellular proteins Evidence at protein level CAB005063, HPA030766 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:9.14e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable) Expressed in all Expressed in all lymph node: 49.5 NCKAP1L HEM1 ENSG00000123338 NCK-associated protein 1-like 12 54497711-54548238 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA039490, HPA040772 Approved Uncertain Plasma membrane
Cytosol Expressed in all Mixed spleen: 55.8 NCKIPSD AF3P21, DIP1, ORF1, SPIN90, WASLBP, WISH ENSG00000213672 NCK interacting protein with SH3 domain 3 48673844-48686364 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB019267, HPA050005 Validated Plasma membrane
Cytosol Renal cancer:1.20e-5 (favourable), Liver cancer:8.57e-4 (unfavourable) Expressed in all Tissue enriched 9 parathyroid gland: 300.2 cerebral cortex: 35.1 NGEF ARHGEF27 ENSG00000066248 Neuronal guanine nucleotide exchange factor 2 232878686-233013272 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008160 Approved Uncertain Plasma membrane
Cytosol Mixed Tissue enhanced adrenal gland: 66.8;cerebral cortex: 151.9 duodenum: 44.0 NGFR CD271, p75NTR, TNFRSF16 ENSG00000064300 Nerve growth factor receptor 17 49495293-49515017 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB000143, CAB001995, HPA004765 Supported Approved Nucleoplasm
Plasma membrane Urothelial cancer:3.40e-4 (unfavourable) Expressed in all Mixed adipose tissue: 32.2 NKX2-8 Nkx2-9, NKX2.8, NKX2H ENSG00000136327 NK2 homeobox 8 14 36580579-36582607 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA062879 Uncertain Approved Nucleoplasm
Plasma membrane Mixed Tissue enhanced testis: 3.1 lung: 0.6 NLGN1 KIAA1070 ENSG00000169760 Neuroligin 1 3 173396284-174286644 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006572, HPA006680 Approved Uncertain Nuclear bodies
Plasma membrane Group enriched Tissue enhanced cerebral cortex: 25.5 testis: 12.5 NMBR BB1 ENSG00000135577 Neuromedin B receptor 6 142058330-142088799 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA026665 Supported Plasma membrane
Cytosol Not detected Group enriched 5 fallopian tube: 1.3;testis: 2.6 cerebral cortex: 0.3 NMT1 NMT ENSG00000136448 N-myristoyltransferase 1 17 45051610-45109016 Enzymes, Predicted intracellular proteins Evidence at protein level HPA022949, HPA022963 Supported Supported Plasma membrane
Cytosol Liver cancer:4.94e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 58.8 NOS1 nNOS, NOS ENSG00000089250 Nitric oxide synthase 1 (neuronal) 12 117208142-117452170 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002167, HPA058312 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced skeletal muscle: 12.9 cerebral cortex: 3.0 NOTCH2 ENSG00000134250 Notch 2 1 119911553-120069626 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046392, HPA048743 Uncertain Supported Nucleoplasm
Plasma membrane Ovarian cancer:5.24e-4 (unfavourable), Pancreatic cancer:9.48e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 46.5 NPFFR2 GPR74, NPFF2, NPGPR ENSG00000056291 Neuropeptide FF receptor 2 4 72031804-72148067 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026825 Approved Plasma membrane
Actin filaments Mixed Tissue enhanced placenta: 2.3;seminal vesicle: 4.5 epididymis: 1.1 NPL C1orf13, DHDPS1, NPL1 ENSG00000135838 N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase) 1 182789293-182830384 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028345 Approved Vesicles
Plasma membrane Renal cancer:6.63e-4 (unfavourable), Liver cancer:8.05e-4 (unfavourable) Expressed in all Mixed placenta: 63.2 NRP2 VEGF165R2 ENSG00000118257 Neuropilin 2 2 205681990-205798133 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA039980, HPA054974 Approved Supported Vesicles
Plasma membrane Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable) Expressed in all Mixed smooth muscle: 83.5 NSD1 ARA267, FLJ22263, KMT3B, STO ENSG00000165671 Nuclear receptor binding SET domain protein 1 5 177133025-177300215 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA048431, HPA070333 Supported Nucleus
Plasma membrane Expressed in all Expressed in all testis: 43.2 NT5E CALJA, CD73, eN, eNT, NT5 ENSG00000135318 5'-nucleotidase, ecto (CD73) 6 85449584-85495791 CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017357 Approved Supported Plasma membrane
Cytosol Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable) Expressed in all Tissue enhanced cervix, uterine: 171.7 smooth muscle: 104.9 NUDT16L1 SDOS ENSG00000168101 Nudix (nucleoside diphosphate linked moiety X)-type motif 16-like 1 16 4693694-4695859 Predicted intracellular proteins Evidence at protein level HPA044186, HPA063605 Approved Approved Plasma membrane
Cytosol Renal cancer:1.02e-6 (favourable), Lung cancer:2.79e-4 (favourable) Expressed in all Expressed in all prostate: 28.4 NUS1 C6orf68, MGC7199, NgBR, TANGO14 ENSG00000153989 NUS1 dehydrodolichyl diphosphate synthase subunit 6 117675502-117710640 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA027504 Supported Approved Vesicles
Plasma membrane Cervical cancer:6.99e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 91.7 OBSCN ARHGEF30, KIAA1556, KIAA1639, UNC89 ENSG00000154358 Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 1 228208130-228378876 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA019497, HPA021186 Approved Approved Plasma membrane
Cytosol Endometrial cancer:1.64e-4 (unfavourable) Mixed Tissue enriched 6 skeletal muscle: 249.2 heart muscle: 38.3 OCLN PPP1R115 ENSG00000197822 Occludin 5 69492292-69558104 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA005933, CAB013075, CAB068212, CAB068213, CAB068214 Supported Supported Plasma membrane
Cell Junctions Renal cancer:6.59e-11 (favourable) Mixed Tissue enhanced thyroid gland: 78.3 lung: 39.9 ODC1 ODC ENSG00000115758 Ornithine decarboxylase 1 2 10439968-10448504 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001536, CAB035996 Approved Approved Plasma membrane
Cytosol Liver cancer:3.07e-5 (unfavourable) Expressed in all Expressed in all testis: 240.7 OLIG2 BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17 ENSG00000205927 Oligodendrocyte lineage transcription factor 2 21 33025845-33029196 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003254, CAB019381 Supported Uncertain Nucleoplasm
Plasma membrane Tissue enriched Tissue enriched 239 cerebral cortex: 91.2 duodenum: 0.3 OPHN1 ARHGAP41, MRX60, OPN1 ENSG00000079482 Oligophrenin 1 X 68042344-68433913 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002919 Approved Approved Nucleus
Plasma membrane Mixed Mixed cerebral cortex: 20.3 OSGEP GCPL1, KAE1, OSGEP1, PRSMG1 ENSG00000092094 O-sialoglycoprotein endopeptidase 14 20446411-20455105 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039751 Uncertain Supported Nucleoplasm
Plasma membrane Renal cancer:4.64e-6 (unfavourable), Breast cancer:1.48e-4 (favourable) Expressed in all Mixed thyroid gland: 12.7 OSR2 FLJ90037 ENSG00000164920 Odd-skipped related transciption factor 2 8 98944403-98952104 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA052425, HPA063486 Uncertain Approved Nucleus
Plasma membrane Head and neck cancer:2.44e-5 (favourable) Mixed Tissue enhanced endometrium: 204.6;fallopian tube: 143.0 ovary: 102.5 OTULIN FAM105B, FLJ34884 ENSG00000154124 OTU deubiquitinase with linear linkage specificity 5 14664664-14699711 Enzymes, Predicted intracellular proteins Evidence at protein level HPA051074 Uncertain Approved Plasma membrane
Mitochondria Renal cancer:2.59e-7 (unfavourable) Expressed in all Expressed in all bone marrow: 17.2 PACSIN3 SDPIII ENSG00000165912 Protein kinase C and casein kinase substrate in neurons 3 11 47177525-47186443 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039480, HPA043904 Approved Supported Plasma membrane
Cytosol Ovarian cancer:2.09e-4 (favourable) Expressed in all Tissue enhanced skeletal muscle: 164.2 heart muscle: 89.5 PAG1 CBP, PAG ENSG00000076641 Phosphoprotein membrane anchor with glycosphingolipid microdomains 1 8 80967810-81112068 Predicted intracellular proteins Evidence at protein level HPA001632, HPA066527 Uncertain Supported Vesicles
Plasma membrane Renal cancer:1.24e-6 (unfavourable), Testis cancer:6.82e-4 (unfavourable) Expressed in all Mixed placenta: 22.8 PAIP1 ENSG00000172239 Poly(A) binding protein interacting protein 1 5 43526267-43557758 Predicted intracellular proteins Evidence at protein level HPA076187 Approved Plasma membrane
Cytosol Pancreatic cancer:4.79e-4 (unfavourable) Expressed in all Expressed in all testis: 152.3 PAK1 ENSG00000149269 P21 protein (Cdc42/Rac)-activated kinase 1 11 77321707-77474635 Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA003565, CAB005312 Supported Supported Validated Plasma membrane
Cytosol Glioma:9.48e-5 (unfavourable), Colorectal cancer:5.87e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 186.8 PAK4 ENSG00000130669 P21 protein (Cdc42/Rac)-activated kinase 4 19 39125770-39182816 Enzymes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB025747, CAB044670, HPA070175, HPA072220 Uncertain Supported Plasma membrane
Cell Junctions Renal cancer:5.29e-5 (favourable), Prostate cancer:9.85e-4 (unfavourable) Expressed in all Expressed in all prostate: 42.2 PALM KIAA0270 ENSG00000099864 Paralemmin 19 708939-748329 Predicted intracellular proteins Evidence at protein level HPA041713, HPA049578 Approved Validated Nucleus
Plasma membrane Renal cancer:5.44e-4 (favourable), Pancreatic cancer:9.81e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 85.1 adipose tissue: 52.9 PAPPA ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1 ENSG00000182752 Pregnancy-associated plasma protein A, pappalysin 1 9 116153804-116402322 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001667, CAB016724 Supported Uncertain Plasma membrane
Cytosol Mixed Tissue enriched 7 placenta: 103.9 parathyroid gland: 14.6 PAQR8 C6orf33, LMPB1, MPRB ENSG00000170915 Progestin and adipoQ receptor family member VIII 6 52361421-52407777 Predicted membrane proteins Evidence at protein level HPA064625 Supported Golgi apparatus
Plasma membrane Breast cancer:4.61e-4 (favourable), Urothelial cancer:6.40e-4 (favourable) Expressed in all Mixed cerebral cortex: 65.1 PAWR par-4, PAR4 ENSG00000177425 PRKC, apoptosis, WT1, regulator 12 79574979-79691097 Predicted intracellular proteins Evidence at protein level HPA012640, CAB020779 Approved Validated Plasma membrane
Actin filaments Expressed in all Mixed endometrium: 45.3 PCDH7 BH-Pcdh, PPP1R120 ENSG00000169851 Protocadherin 7 4 30720415-31146805 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011866, HPA046521 Uncertain Validated Plasma membrane
Cell Junctions Lung cancer:6.46e-5 (unfavourable), Stomach cancer:6.42e-4 (unfavourable) Mixed Mixed cerebral cortex: 46.1 PCDHB10 ENSG00000120324 Protocadherin beta 10 5 141182560-141195642 Predicted membrane proteins Evidence at protein level HPA013445, HPA014668, HPA029441 Approved Approved Vesicles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 8.3 endometrium: 5.1 PCDHB16 KIAA1621, ME1, PCDH-BETA16, PCDH3X, PCDHB8a ENSG00000272674 Protocadherin beta 16 5 141181399-141186399 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014668 Supported Vesicles
Plasma membrane Mixed Mixed parathyroid gland: 10.6 PCDHGA7 PCDH-GAMMA-A7 ENSG00000253537 Protocadherin gamma subfamily A, 7 5 141382739-141512979 Predicted membrane proteins Evidence at transcript level HPA008755, HPA077995 Uncertain Uncertain Plasma membrane
Cell Junctions Mixed Tissue enhanced cerebral cortex: 7.4 thyroid gland: 3.2 PCLO ACZ, DKFZp779G1236, KIAA0559 ENSG00000186472 Piccolo presynaptic cytomatrix protein 7 82754013-83162930 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015858, HPA029579 Approved Approved Nuclear speckles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 17.5 parathyroid gland: 9.6 PCMTD1 FLJ10883 ENSG00000168300 Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 8 51817575-51899186 Predicted intracellular proteins Evidence at protein level HPA025696, HPA061444 Approved Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all parathyroid gland: 184.0 PDAP1 HASPP28, PAP, PAP1 ENSG00000106244 PDGFA associated protein 1 7 99392048-99408829 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB021103, HPA050294, HPA060836 Approved Validated Plasma membrane
Cytosol Liver cancer:6.67e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 37.3 PDCD7 ES18, HES18 ENSG00000090470 Programmed cell death 7 15 65117379-65133836 Predicted intracellular proteins Evidence at protein level HPA049388 Approved Approved Nucleoli
Plasma membrane Renal cancer:1.00e-4 (unfavourable) Expressed in all Expressed in all testis: 30.7 PDGFC fallotein, SCDGF ENSG00000145431 Platelet derived growth factor C 4 156760454-156971394 Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA009134 Approved Supported Plasma membrane
Cytosol Renal cancer:1.35e-5 (favourable), Stomach cancer:3.05e-4 (unfavourable), Urothelial cancer:3.17e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 39.8 endometrium: 16.7 PDZD2 KIAA0300, PDZK3 ENSG00000133401 PDZ domain containing 2 5 31639410-32110931 Predicted intracellular proteins Evidence at protein level CAB020784, HPA036503, HPA036504, HPA064387 Uncertain Approved Plasma membrane
Cytosol Mixed Mixed ovary: 18.2 PDZD8 bA129M16.2, FLJ34427, PDZK8 ENSG00000165650 PDZ domain containing 8 10 117277274-117375467 Predicted secreted proteins Evidence at protein level HPA015716, HPA051610 Uncertain Approved Nucleoli fibrillar center
Plasma membrane Pancreatic cancer:6.10e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 46.6 PEBP1 HCNP, PBP, PEBP, RKIP ENSG00000089220 Phosphatidylethanolamine binding protein 1 12 118135858-118145584 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008819, CAB009906, CAB013493 Supported Approved Plasma membrane
Cytosol Renal cancer:2.15e-13 (favourable), Pancreatic cancer:1.52e-4 (favourable) Expressed in all Expressed in all adrenal gland: 1649.3 PFAS FGARAT, KIAA0361, PURL ENSG00000178921 Phosphoribosylformylglycinamidine synthase 17 8247618-8270491 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA022140, HPA022886 Supported Approved Nucleoplasm
Plasma membrane Liver cancer:9.19e-4 (unfavourable) Expressed in all Expressed in all lymph node: 11.8 PGAP3 CAB2, MGC9753, PER1, PERLD1, PP1498 ENSG00000161395 Post-GPI attachment to proteins 3 17 39671122-39696797 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA016591 Approved Approved Plasma membrane
Cytosol Renal cancer:3.89e-4 (favourable), Liver cancer:3.94e-4 (favourable), Ovarian cancer:6.82e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 35.5 PGLYRP4 PGLYRPIbeta, PGRP-Ibeta, PGRPIB, SBBI67 ENSG00000163218 Peptidoglycan recognition protein 4 1 153330120-153348840 Predicted secreted proteins Evidence at protein level CAB025879 Approved Vesicles
Plasma membrane Group enriched Group enriched 5 esophagus: 5.8;skin: 18.2 tonsil: 2.2 PHF20L1 CGI-72, FLJ13649, FLJ21615, MGC64923, TDRD20B ENSG00000129292 PHD finger protein 20-like 1 8 132775358-132848807 Predicted intracellular proteins Evidence at protein level HPA025060, HPA028417 Uncertain Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all thyroid gland: 37.9 PHLDB2 FLJ21791, LL5b, LL5beta ENSG00000144824 Pleckstrin homology-like domain, family B, member 2 3 111732497-111976517 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035146, HPA035147 Approved Supported Plasma membrane
Cytosol Renal cancer:7.03e-8 (favourable), Head and neck cancer:2.59e-4 (unfavourable) Expressed in all Mixed placenta: 59.4 PI4KA PI4K-ALPHA, pi4K230, PIK4CA ENSG00000241973 Phosphatidylinositol 4-kinase, catalytic, alpha 22 20707691-20859417 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009092, HPA075515 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:7.22e-5 (favourable), Lung cancer:5.24e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 114.0 PIGB ENSG00000069943 Phosphatidylinositol glycan anchor biosynthesis, class B 15 55318960-55355648 Predicted membrane proteins Evidence at protein level HPA039929 Uncertain Uncertain Plasma membrane
Cytosol Expressed in all Mixed parathyroid gland: 22.8 PIGN MDC4, PIG-N ENSG00000197563 Phosphatidylinositol glycan anchor biosynthesis, class N 18 62043567-62187118 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039922, HPA040374 Approved Supported Plasma membrane
Cytosol Colorectal cancer:6.51e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 31.3 PIRT ENSG00000233670 Phosphoinositide-interacting regulator of transient receptor potential channels 17 10822475-10838445 Predicted membrane proteins, Transporters Evidence at transcript level HPA042337 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Tissue enhanced adrenal gland: 3.1;cerebral cortex: 2.7;rectum: 2.7 colon: 2.1 PKD2L2 TRPP5 ENSG00000078795 Polycystic kidney disease 2-like 2 5 137887968-137942747 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level HPA041903, HPA043634 Approved Approved Plasma membrane
Cytosol Not detected Tissue enriched 11 testis: 15.6 thyroid gland: 1.4 PKP4 p0071 ENSG00000144283 Plakophilin 4 2 158456964-158682879 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB037334, HPA066647, HPA070648 Approved Validated Plasma membrane
Cell Junctions Renal cancer:3.29e-7 (favourable), Endometrial cancer:5.80e-4 (favourable) Expressed in all Expressed in all kidney: 65.1 PLAU UPA, URK ENSG00000122861 Plasminogen activator, urokinase 10 73909177-73917497 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008719 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable) Expressed in all Expressed in all appendix: 61.3 PLS3 T-plastin ENSG00000102024 Plastin 3 X 115561174-115650861 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA020433, HPA076083 Approved Approved Plasma membrane
Cytosol Head and neck cancer:6.07e-5 (unfavourable), Renal cancer:1.01e-4 (unfavourable), Thyroid cancer:3.72e-4 (favourable), Pancreatic cancer:4.59e-4 (unfavourable), Urothelial cancer:7.04e-4 (unfavourable) Expressed in all Mixed thyroid gland: 291.7 POLE POLE1 ENSG00000177084 Polymerase (DNA directed), epsilon, catalytic subunit 12 132623753-132687365 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA058210, HPA067385 Validated Nucleus
Plasma membrane Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable) Expressed in all Expressed in all testis: 22.0 PPEF1 PPEF, PPP7CA ENSG00000086717 Protein phosphatase, EF-hand calcium binding domain 1 X 18675909-18827921 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA034577 Uncertain Uncertain Plasma membrane
Cytokinetic bridge Mixed Tissue enriched 7 testis: 26.2 cerebral cortex: 3.6 PPFIBP1 hSGT2, hSgt2p, L2, SGT2 ENSG00000110841 PTPRF interacting protein, binding protein 1 (liprin beta 1) 12 27523431-27695564 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001924 Uncertain Approved Plasma membrane
Cytosol Renal cancer:5.11e-7 (favourable), Pancreatic cancer:2.56e-4 (unfavourable), Lung cancer:5.11e-4 (unfavourable), Endometrial cancer:6.29e-4 (unfavourable) Expressed in all Expressed in all ovary: 106.2 PPM1A MGC9201, PP2CA, PP2Calpha ENSG00000100614 Protein phosphatase, Mg2+/Mn2+ dependent, 1A 14 60245752-60299087 Enzymes, Predicted intracellular proteins Evidence at protein level HPA029209 Approved Supported Plasma membrane
Cytosol Renal cancer:1.57e-9 (favourable) Expressed in all Expressed in all testis: 99.7 PPM1F CAMKP, CaMKPase, FEM-2, KIAA0015, POPX2 ENSG00000100034 Protein phosphatase, Mg2+/Mn2+ dependent, 1F 22 21919420-21952837 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030989, HPA030990 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:6.03e-5 (unfavourable) Expressed in all Expressed in all placenta: 39.4 PPP1R12B MGC131980, MGC87886, MYPT2, PP1bp55 ENSG00000077157 Protein phosphatase 1, regulatory subunit 12B 1 202348699-202592706 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA024171, HPA024640 Supported Supported Plasma membrane
Actin filaments Expressed in all Expressed in all endometrium: 363.9 PPP1R16B ANKRD4, KIAA0823, TIMAP ENSG00000101445 Protein phosphatase 1, regulatory subunit 16B 20 38805705-38923024 Predicted intracellular proteins Evidence at protein level HPA049571 Supported Nuclear speckles
Plasma membrane Head and neck cancer:7.87e-5 (favourable), Cervical cancer:2.11e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 51.0 lymph node: 44.7 PPP1R18 KIAA1949, phostensin ENSG00000146112 Protein phosphatase 1, regulatory subunit 18 6 30676389-30687895 Predicted intracellular proteins Evidence at protein level HPA044745, HPA051000 Supported Approved Nucleoplasm
Plasma membrane Renal cancer:1.11e-16 (unfavourable), Colorectal cancer:4.71e-4 (unfavourable) Expressed in all Tissue enhanced lymph node: 54.0 spleen: 35.7 PPP3R1 CALNB1, CNB, CNB1 ENSG00000221823 Protein phosphatase 3, regulatory subunit B, alpha 2 68178857-68256237 Predicted intracellular proteins Evidence at protein level CAB005610, HPA047157 Approved Approved Plasma membrane
Cytosol Endometrial cancer:9.08e-6 (unfavourable), Renal cancer:1.70e-5 (unfavourable), Liver cancer:5.37e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 198.1 PPP3R2 PPP3RL ENSG00000188386 Protein phosphatase 3, regulatory subunit B, beta 9 101591615-101595001 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047157 Uncertain Approved Plasma membrane
Cytosol Not detected Tissue enriched 755 testis: 75.4 all non-specific tissues: 0.0 PPTC7 TA-PP2C ENSG00000196850 PTC7 protein phosphatase homolog 12 110533245-110583320 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039335, HPA040614 Approved Approved Plasma membrane
Cytosol Ovarian cancer:1.43e-5 (unfavourable), Renal cancer:4.48e-5 (favourable), Pancreatic cancer:6.76e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 33.7 PRDX6 1-Cys, aiPLA2, AOP2, KIAA0106, MGC46173, NSGPx, p29, PRX ENSG00000117592 Peroxiredoxin 6 1 173477266-173488807 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006983, CAB008663 Supported Supported Plasma membrane
Cytosol Head and neck cancer:1.23e-5 (unfavourable), Renal cancer:9.51e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 363.4 PRKCA PKCA ENSG00000154229 Protein kinase C, alpha 17 66302636-66810743 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003844, HPA006563, HPA006564, CAB016290 Approved Validated Plasma membrane
Cytosol Expressed in all Mixed cerebral cortex: 45.1 PRKCH PKC-L, PKCL, PRKCL ENSG00000027075 Protein kinase C, eta 14 61187559-61550976 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA026294, HPA053709 Approved Approved Plasma membrane
Cytosol Head and neck cancer:8.55e-6 (favourable) Expressed in all Expressed in all lymph node: 62.3 PRKCZ PKC2 ENSG00000067606 Protein kinase C, zeta 1 2050470-2185395 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021851 Supported Approved Plasma membrane
Cytosol Renal cancer:1.64e-9 (favourable) Expressed in all Tissue enhanced cerebral cortex: 100.0 placenta: 59.9 PRKD1 PKC-mu, PKCM, PKD, PRKCM ENSG00000184304 Protein kinase D1 14 29576479-30191898 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB018367, HPA029834 Uncertain Supported Plasma membrane
Cytosol Renal cancer:2.44e-5 (favourable), Thyroid cancer:2.91e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 49.5 prostate: 29.0 PROSER2 C10orf47, MGC35403 ENSG00000148426 Proline and serine rich 2 10 11823339-11872277 Predicted intracellular proteins Evidence at protein level HPA041337 Uncertain Uncertain Plasma membrane
Cytosol Mixed Mixed placenta: 10.8 PRRG1 PRGP1 ENSG00000130962 Proline rich Gla (G-carboxyglutamic acid) 1 X 37349275-37457295 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056029, HPA078129 Uncertain Approved Vesicles
Plasma membrane Renal cancer:2.05e-7 (favourable), Pancreatic cancer:1.22e-4 (unfavourable), Cervical cancer:4.65e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 21.6 PSMC5 p45, p45/SUG, S8, SUG-1, SUG1, TBP10, TRIP1 ENSG00000087191 Proteasome 26S subunit, ATPase 5 17 63827152-63832026 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017871, HPA064293 Uncertain Supported Plasma membrane
Cytosol Renal cancer:3.13e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 245.8 PSMD9 p27, Rpn4 ENSG00000110801 Proteasome 26S subunit, non-ATPase 9 12 121888731-121918297 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA040512, HPA044220 Supported Supported Plasma membrane
Cytosol Liver cancer:1.32e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 17.9 PTCHD4 C6orf138, dJ402H5.2, FLJ41841 ENSG00000244694 Patched domain containing 4 6 47878028-48068689 Predicted membrane proteins Evidence at transcript level HPA041276 Uncertain Approved Plasma membrane
Cytosol Renal cancer:1.49e-6 (favourable) Group enriched Mixed seminal vesicle: 2.8 PTK2B CADTK, CAKB, FAK2, PTK, PYK2, RAFTK ENSG00000120899 Protein tyrosine kinase 2 beta 8 27311482-27459391 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB003850, HPA026091, HPA026276 Approved Validated Plasma membrane
Cytosol Cervical cancer:3.32e-4 (favourable), Thyroid cancer:5.11e-4 (favourable) Expressed in all Expressed in all lymph node: 100.2 PTPN12 PTP-PEST, PTPG1 ENSG00000127947 Protein tyrosine phosphatase, non-receptor type 12 7 77537275-77640071 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007097 Approved Approved Plasma membrane
Cytosol Renal cancer:7.27e-6 (unfavourable), Cervical cancer:1.15e-4 (unfavourable), Pancreatic cancer:2.01e-4 (unfavourable), Liver cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all placenta: 106.3 PTPN13 PTP-BAS, PTP-BL, PTP1E, PTPL1 ENSG00000163629 Protein tyrosine phosphatase, non-receptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) 4 86594315-86815171 Enzymes, Predicted intracellular proteins Evidence at protein level CAB002213, HPA065290 Approved Approved Plasma membrane
Cytosol Mixed Mixed skin: 66.1 PTPRN2 IA-2beta, ICAAR, KIAA0387, phogrin ENSG00000155093 Protein tyrosine phosphatase, receptor type, N polypeptide 2 7 157539056-158587788 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006900, HPA026656 Approved Uncertain Vesicles
Plasma membrane Glioma:7.72e-5 (unfavourable), Renal cancer:8.68e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 82.5 stomach: 39.0 PTPRS ENSG00000105426 Protein tyrosine phosphatase, receptor type, S 19 5158495-5340803 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054747 Approved Plasma membrane
Cytosol Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 70.8 PTRF cavin-1, CAVIN1 ENSG00000177469 Polymerase I and transcript release factor 17 42402452-42423517 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA049838, HPA074213 Supported Supported Vesicles
Plasma membrane Urothelial cancer:5.87e-4 (unfavourable), Ovarian cancer:5.92e-4 (unfavourable), Colorectal cancer:6.36e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 342.2 PYGL ENSG00000100504 Phosphorylase, glycogen, liver 14 50857891-50944736 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA000962, HPA004119 Supported Supported Plasma membrane
Cytosol Pancreatic cancer:2.63e-4 (unfavourable), Head and neck cancer:5.97e-4 (unfavourable) Expressed in all Mixed adipose tissue: 116.1 RAB13 ENSG00000143545 RAB13, member RAS oncogene family 1 153981617-153986358 Predicted intracellular proteins Evidence at protein level HPA003996 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all prostate: 153.9 RAB23 ENSG00000112210 RAB23, member RAS oncogene family 6 57186992-57222314 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA029135, HPA029136 Approved Validated Plasma membrane
Cytosol Expressed in all Mixed smooth muscle: 101.8 RAB3GAP2 DKFZP434D245, KIAA0839, RAB3-GAP150, SPG69 ENSG00000118873 RAB3 GTPase activating protein subunit 2 (non-catalytic) 1 220148293-220272454 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA026273, HPA027299 Approved Supported Plasma membrane
Cytosol Breast cancer:3.05e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 34.7 RAB8A MEL, RAB8 ENSG00000167461 RAB8A, member RAS oncogene family 19 16111629-16134234 Predicted intracellular proteins Evidence at protein level HPA041945 Supported Nucleus
Plasma membrane Renal cancer:6.56e-5 (unfavourable), Thyroid cancer:1.71e-4 (favourable) Expressed in all Expressed in all small intestine: 65.9 RABL2A ENSG00000144134 RAB, member of RAS oncogene family-like 2A 2 113627229-113643396 Predicted intracellular proteins Evidence at protein level HPA042700, HPA044007 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.20e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 31.0 cerebral cortex: 8.1 RABL2B ENSG00000079974 RAB, member of RAS oncogene family-like 2B 22 50767501-50783663 Predicted intracellular proteins Evidence at protein level HPA042700, HPA044007 Approved Uncertain Plasma membrane
Cytosol Liver cancer:4.58e-5 (unfavourable), Endometrial cancer:5.58e-4 (favourable) Expressed in all Expressed in all epididymis: 109.0 RAD52 ENSG00000002016 RAD52 homolog, DNA repair protein 12 912077-990053 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA028957 Approved Nuclear speckles
Plasma membrane Renal cancer:2.22e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 13.5 RALGAPA2 AS250, C20orf74, dJ1049G11.4, KIAA1272, RapGAPalpha2 ENSG00000188559 Ral GTPase activating protein, alpha subunit 2 (catalytic) 20 20389552-20712488 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042707, HPA043622 Uncertain Supported Plasma membrane
Cytosol Renal cancer:3.77e-5 (favourable) Expressed in all Expressed in all thyroid gland: 39.8 RASAL2 nGAP ENSG00000075391 RAS protein activator like 2 1 178094141-178484147 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA018805, HPA020453 Approved Approved Plasma membrane
Focal adhesion sites Urothelial cancer:2.05e-4 (unfavourable) Expressed in all Mixed esophagus: 19.5 RASD1 AGS1, DEXRAS1 ENSG00000108551 RAS, dexamethasone-induced 1 17 17494437-17496395 Predicted intracellular proteins Evidence at protein level HPA047896 Uncertain Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all adipose tissue: 112.9 RASD2 MGC:4834, Rhes, TEM2 ENSG00000100302 RASD family, member 2 22 35540868-35554001 Predicted intracellular proteins Evidence at protein level HPA005839 Approved Approved Plasma membrane
Cytosol Renal cancer:2.22e-5 (unfavourable) Mixed Tissue enhanced seminal vesicle: 31.8 epididymis: 18.2 RASGRP1 CalDAG-GEFII, RASGRP ENSG00000172575 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 15 38488103-38565575 Disease related genes, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA046216 Supported Plasma membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 28.5;lymph node: 25.3 tonsil: 15.8 RASSF3 ENSG00000153179 Ras association (RalGDS/AF-6) domain family member 3 12 64610513-64697567 Predicted intracellular proteins Evidence at protein level CAB022664, CAB034035, HPA038469 Supported Supported Plasma membrane
Cytosol Expressed in all Expressed in all smooth muscle: 85.0 RC3H1 KIAA2025, RNF198, roquin, RP5-1198E17.5 ENSG00000135870 Ring finger and CCCH-type domains 1 1 173931214-174022297 Predicted intracellular proteins Evidence at protein level HPA027428, HPA027434, HPA027448 Approved Supported Plasma membrane
Cytosol Renal cancer:7.96e-4 (unfavourable) Expressed in all Mixed bone marrow: 12.9 RCCD1 MGC14386 ENSG00000166965 RCC1 domain containing 1 15 90954870-90963125 Predicted intracellular proteins Evidence at protein level HPA039683, HPA040776 Approved Validated Plasma membrane
Cytosol Expressed in all Mixed parathyroid gland: 8.8 RCSD1 CapZIP, MGC21854, MK2S4 ENSG00000198771 RCSD domain containing 1 1 167630093-167706249 Predicted intracellular proteins Evidence at protein level HPA016597 Supported Uncertain Nucleoplasm
Plasma membrane Head and neck cancer:2.97e-4 (favourable) Expressed in all Tissue enhanced lymph node: 108.5 tonsil: 74.2 RELL1 ENSG00000181826 RELT-like 1 4 37590800-37686376 Predicted membrane proteins Evidence at protein level HPA013377 Approved Supported Plasma membrane
Microtubules Expressed in all Mixed thyroid gland: 27.6 RELN PRO1598, RL ENSG00000189056 Reelin 7 103471784-103989516 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA046512 Approved Plasma membrane
Focal adhesion sites Tissue enhanced Tissue enhanced liver: 17.8 cerebral cortex: 7.3 RFPL1 RNF78 ENSG00000128250 Ret finger protein-like 1 22 29438583-29442455 Predicted intracellular proteins Evidence at transcript level HPA048320, HPA072380 Approved Nuclear speckles
Plasma membrane Not detected Tissue enriched 6 cerebral cortex: 27.3 ovary: 4.4 RFPL2 RNF79 ENSG00000128253 Ret finger protein-like 2 22 32190435-32203477 Predicted intracellular proteins Evidence at transcript level HPA048320, HPA072380 Approved Nuclear speckles
Plasma membrane Prostate cancer:4.16e-4 (favourable) Tissue enriched Tissue enriched 9 prostate: 7.0 cerebral cortex: 0.8 RFPL3 ENSG00000128276 Ret finger protein-like 3 22 32354885-32361161 Predicted intracellular proteins Evidence at protein level HPA048320, HPA072380 Approved Nuclear speckles
Plasma membrane Not detected Tissue enriched 7 testis: 4.0 epididymis: 0.5 RGP1 KIAA0258 ENSG00000107185 RGP1 homolog, RAB6A GEF complex partner 1 9 35749287-35758575 Predicted intracellular proteins Evidence at protein level HPA020414, HPA021085 Approved Validated Plasma membrane
Cytosol Renal cancer:8.55e-13 (favourable), Liver cancer:7.09e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 35.4 RGS10 ENSG00000148908 Regulator of G-protein signaling 10 10 119499828-119542708 Predicted intracellular proteins Evidence at protein level CAB004559, HPA021305, HPA058485 Supported Supported Nucleus
Plasma membrane Renal cancer:4.20e-10 (unfavourable), Endometrial cancer:6.32e-4 (favourable), Cervical cancer:6.81e-4 (favourable) Expressed in all Expressed in all lymph node: 139.8 RIMBP3 KIAA1666, RIMBP3.1, RIMBP3A ENSG00000275793 RIMS binding protein 3 22 18605815-18611919 Predicted intracellular proteins Evidence at protein level HPA001183 Supported Uncertain Vesicles
Plasma membrane Not detected Tissue enriched 38 testis: 45.4 parathyroid gland: 1.2 RIMBP3B ENSG00000274600 RIMS binding protein 3B 22 21383374-21389478 Predicted intracellular proteins Evidence at protein level HPA001183 Supported Uncertain Vesicles
Plasma membrane Not detected Tissue enriched 26 testis: 12.1 appendix,parathyroid gland: 0.4 RIMBP3C ENSG00000183246 RIMS binding protein 3C 22 21545357-21551461 Predicted intracellular proteins Evidence at protein level HPA001183 Supported Uncertain Vesicles
Plasma membrane Not detected Tissue enriched 32 testis: 15.7 spleen: 0.4 RIOK2 FLJ11159 ENSG00000058729 RIO kinase 2 5 97160867-97183260 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005681 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all testis: 22.0 RIPK1 RIP ENSG00000137275 Receptor (TNFRSF)-interacting serine-threonine kinase 1 6 3063991-3115187 Enzymes, Predicted intracellular proteins Evidence at protein level CAB010302, HPA015257 Supported Validated Plasma membrane
Cytosol Urothelial cancer:6.71e-4 (favourable) Expressed in all Expressed in all skin: 26.1 RNF114 PSORS12, ZNF313 ENSG00000124226 Ring finger protein 114 20 49936336-49953892 Predicted intracellular proteins Evidence at protein level HPA021184 Approved Supported Plasma membrane
Cytosol Endometrial cancer:8.10e-6 (unfavourable), Thyroid cancer:3.01e-4 (favourable), Liver cancer:3.11e-4 (unfavourable) Expressed in all Expressed in all testis: 149.3 RNF149 FLJ90504 ENSG00000163162 Ring finger protein 149 2 101271219-101308701 Predicted membrane proteins Evidence at protein level HPA011424 Approved Approved Vesicles
Plasma membrane Renal cancer:2.04e-8 (unfavourable), Urothelial cancer:2.91e-4 (favourable) Expressed in all Expressed in all appendix: 69.4 RNF165 ARKL2, RNF111L2 ENSG00000141622 Ring finger protein 165 18 46326809-46463140 Predicted intracellular proteins Evidence at protein level HPA041615, HPA047798 Uncertain Approved Nucleus
Plasma membrane Mixed Tissue enhanced cerebral cortex: 9.3;parathyroid gland: 9.6 thyroid gland: 6.9 ROM1 ROM, TSPAN23 ENSG00000149489 Retinal outer segment membrane protein 1 11 62611722-62615120 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028910 Supported Approved Plasma membrane
Cytosol Renal cancer:2.85e-6 (unfavourable), Lung cancer:2.20e-4 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 25.5 ovary: 13.2 RP11-298I3.5 ENSG00000259132 14 22946270-22982258 Predicted intracellular proteins Evidence at protein level HPA029803 Approved Approved Plasma membrane
Focal adhesion sites Not detected Mixed lymph node: 9.2 RP11-385D13.1 ENSG00000251537 17 15571491-15651653 Predicted intracellular proteins Evidence at protein level HPA023623, HPA066431 Uncertain Approved Plasma membrane
Cytosol Not detected Not detected skin: 0.5 RP5-862P8.2 ENSG00000143674 Mitogen-activated protein kinase kinase kinase MLK4 1 233327768-233385148 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007636 Uncertain Approved Plasma membrane
Cytosol Mixed Mixed testis: 17.7 RPGRIP1L CORS3, FTM, JBTS7, KIAA1005, MKS5, NPHP8, PPP1R134 ENSG00000103494 RPGRIP1-like 16 53597683-53703938 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA039405, HPA040530 Uncertain Approved Plasma membrane
Cytosol Renal cancer:5.95e-4 (unfavourable), Breast cancer:6.93e-4 (unfavourable) Mixed Tissue enhanced testis: 27.8 parathyroid gland: 19.1 RPL36A L36A, RPL44 ENSG00000241343 Ribosomal protein L36a X 101390824-101396154 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA063979, HPA077586 Uncertain Supported Plasma membrane
Cytosol Renal cancer:8.81e-11 (unfavourable) Expressed in all Expressed in all ovary: 3443.9 RPL36A-HNRNPH2 ENSG00000257529 RPL36A-HNRNPH2 readthrough X 101391011-101412297 Predicted intracellular proteins Evidence at transcript level HPA077586 Approved Plasma membrane
Cytosol Not detected Mixed ovary: 2.6 RPL36AL RPL36A ENSG00000165502 Ribosomal protein L36a-like 14 49618519-49620685 Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA077586 Approved Plasma membrane
Cytosol Thyroid cancer:2.83e-4 (favourable) Expressed in all Expressed in all ovary: 528.8 RPSA 37LRP, LAMR1, LRP, p40, SA ENSG00000168028 Ribosomal protein SA 3 39406689-39412542 Plasma proteins, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level CAB009561 Approved Supported Plasma membrane
Cytosol Expressed in all Expressed in all ovary: 2079.5 RSBN1L FLJ42526, FLJ45813, MGC71764 ENSG00000187257 Round spermatid basic protein 1-like 7 77696443-77783022 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA020406, HPA020413 Approved Supported Nuclear speckles
Plasma membrane Lung cancer:3.74e-4 (favourable) Expressed in all Expressed in all testis: 47.0 S100A16 DT1P1A7, MGC17528, S100F ENSG00000188643 S100 calcium binding protein A16 1 153606886-153613145 Predicted intracellular proteins Evidence at protein level HPA045841 Supported Validated Plasma membrane
Cytosol Lung cancer:3.14e-5 (unfavourable), Renal cancer:3.91e-5 (unfavourable), Pancreatic cancer:2.04e-4 (unfavourable), Liver cancer:3.18e-4 (unfavourable) Expressed in all Tissue enhanced esophagus: 1495.4 skin: 395.2 SAMHD1 AGS5, HDDC1, Mg11, MOP-5, SBBI88 ENSG00000101347 SAM domain and HD domain 1 20 36890229-36951843 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047072 Supported Supported Nucleoplasm
Plasma membrane Renal cancer:5.12e-4 (unfavourable) Expressed in all Expressed in all spleen: 135.3 SCIN KIAA1905 ENSG00000006747 Scinderin 7 12570577-12660179 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA020518, HPA024264 Supported Approved Plasma membrane
Cytosol Renal cancer:4.26e-8 (favourable) Tissue enhanced Tissue enhanced placenta: 116.3 small intestine: 52.7 SCNN1D dNaCh, ENaCdelta ENSG00000162572 Sodium channel, non voltage gated 1 delta subunit 1 1280436-1292029 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009540, HPA026884 Approved Supported Plasma membrane
Actin filaments Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable) Mixed Tissue enhanced testis: 13.8 cerebral cortex: 7.3 SDC2 CD362, fibroglycan, HSPG, HSPG1, SYND2 ENSG00000169439 Syndecan 2 8 96493351-96611780 CD markers, Predicted membrane proteins Evidence at protein level CAB025123, HPA044416 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all thyroid gland: 708.5 SDC4 amphiglycan, ryudocan, SYND4 ENSG00000124145 Syndecan 4 20 45325288-45348424 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA005716, CAB013240 Supported Approved Golgi apparatus
Plasma membrane Renal cancer:2.44e-7 (favourable), Thyroid cancer:2.67e-4 (favourable), Pancreatic cancer:4.20e-4 (unfavourable) Expressed in all Expressed in all lung: 250.5 SDPR cavin-2, CAVIN2, PS-p68, SDR ENSG00000168497 Serum deprivation response 2 191834302-191847255 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039325, HPA062122 Supported Supported Plasma membrane
Cytosol Renal cancer:8.45e-5 (favourable), Stomach cancer:3.69e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 165.5 SEMA3D coll-2, Sema-Z2 ENSG00000153993 Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D 7 84995553-85186855 Predicted intracellular proteins Evidence at protein level HPA037522 Uncertain Approved Golgi apparatus
Plasma membrane Mixed Group enriched 5 spleen: 67.1;thyroid gland: 76.0 prostate: 13.5 SEMA6D FLJ11598, KIAA1479 ENSG00000137872 Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D 15 47184101-47774223 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043109 Approved Golgi apparatus
Plasma membrane Renal cancer:5.96e-5 (favourable) Tissue enhanced Tissue enhanced placenta: 64.3 small intestine: 45.7 SERPINB3 HsT1196, SCC, SCCA1, T4-A ENSG00000057149 Serpin peptidase inhibitor, clade B (ovalbumin), member 3 18 63637719-63661963 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB018772, CAB036006, CAB036007, HPA048341, HPA049988, HPA055992 Supported Approved Plasma membrane
Cytosol Pancreatic cancer:3.19e-4 (unfavourable) Tissue enhanced Group enriched 6 cervix, uterine: 297.6;esophagus: 851.2 urinary bladder: 90.5 SH3BGR 21-GARP ENSG00000185437 SH3 domain binding glutamate-rich protein 21 39445855-39515506 Predicted intracellular proteins Evidence at protein level CAB003685, HPA030690 Supported Approved Plasma membrane
Cytosol Expressed in all Group enriched 7 heart muscle: 89.7;skeletal muscle: 436.1 prostate: 40.2 SH3D21 C1orf113, FLJ22938 ENSG00000214193 SH3 domain containing 21 1 36306387-36324886 Predicted intracellular proteins Evidence at protein level HPA042212, HPA042456, HPA066168 Approved Approved Nucleus
Plasma membrane Renal cancer:1.76e-6 (unfavourable), Breast cancer:2.60e-4 (favourable) Mixed Tissue enhanced small intestine: 28.3 skin: 17.8 SIN3B KIAA0700 ENSG00000127511 SIN3 transcription regulator family member B 19 16829400-16880353 Predicted intracellular proteins Evidence at protein level HPA050329 Uncertain Approved Nucleoplasm
Plasma membrane Prostate cancer:3.58e-4 (unfavourable), Pancreatic cancer:4.37e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 110.4 SIPA1L1 E6TP1, KIAA0440 ENSG00000197555 Signal-induced proliferation-associated 1 like 1 14 71320449-71741229 Predicted intracellular proteins Evidence at protein level HPA002875 Approved Approved Plasma membrane
Actin filaments Renal cancer:6.80e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 46.2 SKA3 C13orf3, MGC4832, RAMA1 ENSG00000165480 Spindle and kinetochore associated complex subunit 3 13 21153595-21176602 Predicted intracellular proteins Evidence at protein level HPA039272 Approved Uncertain Plasma membrane
Cytosol Liver cancer:9.73e-6 (unfavourable), Pancreatic cancer:3.77e-4 (unfavourable), Melanoma:8.71e-4 (unfavourable) Mixed Tissue enhanced testis: 10.2 lymph node: 5.1 SLC12A2 BSC, BSC2, NKCC1, PPP1R141 ENSG00000064651 Solute carrier family 12 (sodium/potassium/chloride transporter), member 2 5 128083766-128189688 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA020130, HPA063697 Approved Approved Vesicles
Plasma membrane Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable) Expressed in all Expressed in all rectum: 66.4 SLC16A1 MCT, MCT1 ENSG00000155380 Solute carrier family 16 (monocarboxylate transporter), member 1 1 112911847-112957013 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA003324, CAB017489, HPA071055 Supported Validated Plasma membrane
Cell Junctions Renal cancer:6.78e-8 (unfavourable), Endometrial cancer:8.37e-6 (unfavourable), Pancreatic cancer:2.10e-4 (unfavourable), Lung cancer:4.05e-4 (unfavourable) Expressed in all Mixed testis: 32.0 SLC16A3 MCT3, MCT4 ENSG00000141526 Solute carrier family 16 (monocarboxylate transporter), member 3 17 82228397-82261129 Predicted membrane proteins, Transporters Evidence at protein level CAB017490, HPA021451 Approved Supported Nuclear membrane
Plasma membrane Liver cancer:1.19e-7 (unfavourable), Renal cancer:3.71e-7 (unfavourable), Lung cancer:2.02e-5 (unfavourable), Cervical cancer:6.07e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 74.4 SLC16A7 MCT2 ENSG00000118596 Solute carrier family 16 (monocarboxylate transporter), member 7 12 59596067-59789855 Predicted membrane proteins, Transporters Evidence at protein level HPA005911 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:8.85e-5 (favourable) Mixed Mixed adipose tissue: 24.8 SLC17A5 AST, ISSD, NSD, SD, SIALIN, SIASD, SLD ENSG00000119899 Solute carrier family 17 (acidic sugar transporter), member 5 6 73593379-73654155 Disease related genes, Predicted membrane proteins Evidence at protein level HPA044479 Supported Plasma membrane
Cytosol Thyroid cancer:3.52e-4 (favourable) Expressed in all Tissue enriched 9 parathyroid gland: 640.5 thyroid gland: 69.8 SLC2A12 GLUT12, GLUT8 ENSG00000146411 Solute carrier family 2 (facilitated glucose transporter), member 12 6 133988697-134052636 Predicted membrane proteins, Transporters Evidence at protein level HPA031593, HPA031594 Approved Validated Plasma membrane
Cell Junctions Tissue enriched Tissue enhanced prostate: 38.8 endometrium: 15.7 SLC30A1 ZNT1, ZRC1 ENSG00000170385 Solute carrier family 30 (zinc transporter), member 1 1 211571568-211578742 Predicted membrane proteins, Transporters Evidence at protein level HPA015275, HPA049000 Uncertain Supported Vesicles
Plasma membrane Expressed in all Mixed liver: 47.3 SLC46A1 HCP1, MGC9564, PCFT ENSG00000076351 Solute carrier family 46 (folate transporter), member 1 17 28394756-28407197 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB011614 Approved Supported Plasma membrane
Cytosol Glioma:3.90e-4 (unfavourable) Expressed in all Expressed in all duodenum: 97.7 SLC4A7 NBC3, SBC2, SLC4A6 ENSG00000033867 Solute carrier family 4, sodium bicarbonate cotransporter, member 7 3 27372721-27484420 Predicted membrane proteins, Transporters Evidence at protein level CAB022494, HPA035857 Supported Supported Plasma membrane
Focal adhesion sites Renal cancer:7.91e-6 (unfavourable) Expressed in all Tissue enhanced duodenum: 59.2 breast: 23.6 SLC5A3 SMIT, SMIT1 ENSG00000198743 Solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 21 34073570-34106260 Predicted membrane proteins, Transporters Evidence at protein level HPA029791 Approved Plasma membrane
Cytosol Pancreatic cancer:1.98e-5 (unfavourable), Renal cancer:4.72e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 42.0 kidney: 32.9 SLC7A2 ATRC2, CAT-2, HCAT2 ENSG00000003989 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 8 17497088-17570573 Predicted membrane proteins, Transporters Evidence at protein level HPA009277 Supported Plasma membrane
Cell Junctions Renal cancer:2.65e-7 (unfavourable), Stomach cancer:3.08e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 373.7 liver: 92.6 SLC7A6 KIAA0245, LAT-2, LAT3, y+LAT-2 ENSG00000103064 Solute carrier family 7 (amino acid transporter light chain, y+L system), member 6 16 68264516-68301823 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050713 Uncertain Approved Vesicles
Plasma membrane Urothelial cancer:1.84e-4 (unfavourable) Expressed in all Mixed adipose tissue: 35.1 SLC8A1 NCX1 ENSG00000183023 Solute carrier family 8 (sodium/calcium exchanger), member 1 2 40097270-40611053 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB022694, HPA070007 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced heart muscle: 79.5 seminal vesicle: 38.2 SLC9A4 NHE4 ENSG00000180251 Solute carrier family 9, subfamily A (NHE4, cation proton antiporter 4), member 4 2 102473303-102533972 Predicted membrane proteins, Transporters Evidence at protein level HPA036096 Approved Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 5 stomach: 51.1 kidney: 9.5 SLK KIAA0204, se20-9, STK2 ENSG00000065613 STE20-like kinase 10 103967201-104029233 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA015757 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:2.77e-5 (unfavourable), Renal cancer:3.95e-5 (favourable) Expressed in all Expressed in all esophagus: 61.2 SMAGP hSMAGP, MGC149453, MGC149454 ENSG00000170545 Small cell adhesion glycoprotein 12 51244558-51270890 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039711 Approved Supported Nucleoplasm
Plasma membrane Renal cancer:2.24e-4 (favourable), Pancreatic cancer:4.38e-4 (unfavourable), Glioma:7.05e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 144.1 esophagus: 83.7 SNCG BCSG1, persyn, SR ENSG00000173267 Synuclein, gamma (breast cancer-specific protein 1) 10 86958618-86963260 Predicted intracellular proteins Evidence at protein level CAB001452, HPA014404, CAB040581 Supported Approved Approved Golgi apparatus
Plasma membrane Renal cancer:2.29e-8 (unfavourable), Stomach cancer:7.15e-4 (unfavourable) Group enriched Tissue enhanced adipose tissue: 174.4;adrenal gland: 199.0;urinary bladder: 190.7 seminal vesicle: 113.6 SNX9 SDP1, SH3PX1, SH3PXD3A ENSG00000130340 Sorting nexin 9 6 157700387-157945077 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031410, HPA057203 Approved Validated Plasma membrane
Cytosol Lung cancer:3.77e-4 (unfavourable), Cervical cancer:5.95e-4 (unfavourable), Renal cancer:9.95e-4 (favourable) Expressed in all Expressed in all gallbladder: 71.1 SORCS1 sorCS1 ENSG00000108018 Sortilin-related VPS10 domain containing receptor 1 10 106573663-107164534 Predicted membrane proteins Evidence at protein level HPA011948 Approved Approved Plasma membrane
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 12.2;thyroid gland: 18.0 kidney: 4.8 SPAG16 DKFZp666P1710, FLJ22724, PF20, WDR29 ENSG00000144451 Sperm associated antigen 16 2 213284379-214410501 Predicted intracellular proteins Evidence at protein level HPA037542 Uncertain Approved Plasma membrane
Cytosol Renal cancer:3.82e-4 (favourable), Prostate cancer:4.90e-4 (unfavourable) Expressed in all Expressed in all testis: 83.8 SPERT CBY2, NURIT ENSG00000174015 Spermatid associated 13 45702311-45714559 Predicted intracellular proteins Evidence at protein level HPA039359, HPA040046 Supported Approved Plasma membrane
Cell Junctions Mixed Tissue enriched 175 testis: 49.2 fallopian tube,urinary bladder: 0.2 SPG20 KIAA0610, TAHCCP1 ENSG00000133104 Spastic paraplegia 20 (Troyer syndrome) 13 36301638-36370180 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA039053, HPA039054, HPA061519 Approved Validated Plasma membrane
Cytosol Expressed in all Expressed in all epididymis: 80.0 SPHK1 SPHK ENSG00000176170 Sphingosine kinase 1 17 76376584-76387860 Enzymes, Predicted intracellular proteins Evidence at protein level HPA022829, HPA028761 Uncertain Supported Plasma membrane
Cytosol Renal cancer:5.14e-6 (unfavourable) Expressed in all Mixed gallbladder: 19.0 SPINK13 HBVDNAPTP1, HESPINTOR, LiESP6, MGC149260, SPINK5L3 ENSG00000214510 Serine peptidase inhibitor, Kazal type 13 (putative) 5 148268180-148286254 Predicted intracellular proteins, Predicted secreted proteins Evidence at transcript level HPA036456 Uncertain Approved Nucleus
Plasma membrane Renal cancer:4.03e-10 (unfavourable) Group enriched Tissue enriched 8 epididymis: 304.8 seminal vesicle: 36.9 SPINT1 HAI, MANSC2 ENSG00000166145 Serine peptidase inhibitor, Kunitz type 1 15 40844018-40858207 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA006903 Uncertain Uncertain Plasma membrane
Cytosol Renal cancer:1.37e-7 (favourable), Breast cancer:6.97e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 219.8 SPPL3 DKFZP586C1324, IMP2, MGC126674, MGC126676, MGC90402, PSL4 ENSG00000157837 Signal peptide peptidase like 3 12 120762510-120904371 Enzymes, Predicted membrane proteins Evidence at protein level HPA004194, HPA059958 Uncertain Supported Vesicles
Plasma membrane Liver cancer:1.29e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 82.3 SPSB4 SSB-4 ENSG00000175093 SplA/ryanodine receptor domain and SOCS box containing 4 3 141051402-141148611 Predicted intracellular proteins Evidence at protein level HPA073015 Approved Nucleoplasm
Plasma membrane Glioma:2.57e-4 (favourable) Group enriched Tissue enhanced cerebral cortex: 1.3;spleen: 1.5;testis: 2.4 pancreas: 1.2 SRC ASV, c-src, SRC1 ENSG00000197122 SRC proto-oncogene, non-receptor tyrosine kinase 20 37344685-37406050 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004023, HPA030875 Approved Validated Plasma membrane
Cytosol Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable) Expressed in all Mixed gallbladder,small intestine: 43.7 SRD5A3 FLJ13352, SRD5A2L, SRD5A2L1 ENSG00000128039 Steroid 5 alpha-reductase 3 4 55346109-55373096 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA027006 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable) Expressed in all Expressed in all gallbladder: 28.3 ST8SIA5 SIAT8E ENSG00000101638 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 18 46667821-46759257 Predicted membrane proteins Evidence at protein level HPA043813, HPA046771 Approved Approved Plasma membrane
Midbody Tissue enriched Tissue enhanced adrenal gland: 5.5;cerebral cortex: 11.5 parathyroid gland: 3.4 STAC STAC1 ENSG00000144681 SH3 and cysteine rich domain 3 36380344-36548007 Predicted intracellular proteins, Transporters Evidence at protein level HPA035143 Uncertain Uncertain Nucleoplasm
Plasma membrane Mixed Tissue enhanced parathyroid gland: 23.0;prostate: 20.0 lung: 15.8 STAT2 STAT113 ENSG00000170581 Signal transducer and activator of transcription 2, 113kDa 12 56341597-56360155 Predicted intracellular proteins, Transcription factors Evidence at protein level CAB003858, HPA018888 Approved Supported Plasma membrane
Cytosol Renal cancer:4.78e-13 (unfavourable), Endometrial cancer:4.75e-4 (unfavourable) Expressed in all Expressed in all spleen: 48.7 STIL MCPH7, SIL ENSG00000123473 SCL/TAL1 interrupting locus 1 47250139-47314147 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA046543 Approved Plasma membrane
Cytosol Pancreatic cancer:1.33e-4 (unfavourable) Mixed Mixed testis: 12.5 STK17A DRAK1 ENSG00000164543 Serine/threonine kinase 17a 7 43582758-43626786 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA018138, HPA037979 Uncertain Approved Nuclear speckles
Plasma membrane Expressed in all Expressed in all lymph node: 49.9 STK17B DRAK2 ENSG00000081320 Serine/threonine kinase 17b 2 196133566-196176503 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034858 Approved Uncertain Plasma membrane
Cytosol Renal cancer:5.72e-8 (unfavourable) Expressed in all Tissue enhanced bone marrow: 248.9 lymph node: 135.0 STOML2 HSPC108, SLP-2 ENSG00000165283 Stomatin (EPB72)-like 2 9 35099776-35103195 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB015944, HPA062016 Approved Supported Plasma membrane
Cytosol Renal cancer:3.00e-5 (favourable), Liver cancer:4.77e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 97.5 STXBP4 MGC50337, Synip ENSG00000166263 Syntaxin binding protein 4 17 54968727-55173632 Predicted intracellular proteins Evidence at protein level CAB007760, HPA022138, HPA022888, HPA024227 Approved Approved Plasma membrane
Cytosol Mixed Mixed parathyroid gland: 12.2 STYK1 DKFZp761P1010, NOK, SuRTK106 ENSG00000060140 Serine/threonine/tyrosine kinase 1 12 10618939-10674318 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040468, HPA048569 Uncertain Approved Nucleus
Plasma membrane Mixed Mixed rectum: 17.8 SUCLG1 ENSG00000163541 Succinate-CoA ligase, alpha subunit 2 84423523-84460045 Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA036683, HPA036684 Supported Supported Plasma membrane
Mitochondria Renal cancer:2.21e-8 (favourable), Endometrial cancer:5.23e-4 (unfavourable) Expressed in all Expressed in all kidney: 467.4 SUCLG2 ENSG00000172340 Succinate-CoA ligase, GDP-forming, beta subunit 3 67360460-67654614 Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA046705, HPA051998 Supported Supported Plasma membrane
Mitochondria Renal cancer:2.79e-10 (favourable), Colorectal cancer:1.08e-4 (favourable) Expressed in all Expressed in all colon: 171.4 SUMF2 DKFZp566I1024 ENSG00000129103 Sulfatase modifying factor 2 7 56064002-56080670 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA024040, CAB025743, HPA074892 Supported Uncertain Vesicles
Plasma membrane Cervical cancer:6.58e-6 (unfavourable), Endometrial cancer:3.96e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 159.3 SYT4 HsT1192, KIAA1342 ENSG00000132872 Synaptotagmin IV 18 43267878-43277650 Predicted intracellular proteins Evidence at protein level HPA010574 Approved Supported Vesicles
Plasma membrane Tissue enhanced Tissue enhanced adrenal gland: 20.5;cerebral cortex: 82.7 seminal vesicle: 11.1 TBC1D10A AC004997.C22.2, EPI64, TBC1D10 ENSG00000099992 TBC1 domain family, member 10A 22 30291990-30327046 Predicted intracellular proteins Evidence at protein level HPA007725, HPA008142, HPA076041 Approved Supported Nucleoplasm
Plasma membrane Expressed in all Mixed esophagus: 31.3 TBC1D24 DFNA65, DFNB86, KIAA1171, TLDC6 ENSG00000162065 TBC1 domain family, member 24 16 2475118-2505734 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA044712, HPA068080 Uncertain Supported Plasma membrane
Cell Junctions Breast cancer:3.22e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 23.4 TBC1D30 KIAA0984 ENSG00000111490 TBC1 domain family, member 30 12 64781193-64881032 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039772, HPA040043 Approved Approved Plasma membrane
Cytosol Endometrial cancer:3.61e-5 (favourable), Lung cancer:5.08e-4 (favourable) Mixed Mixed parathyroid gland: 12.3 TBXA2R ENSG00000006638 Thromboxane A2 receptor 19 3594506-3606840 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA077366 Supported Nuclear speckles
Plasma membrane Renal cancer:1.45e-4 (unfavourable), Pancreatic cancer:7.17e-4 (favourable) Expressed in all Mixed spleen: 5.3 TDO2 TDO, TPH2 ENSG00000151790 Tryptophan 2,3-dioxygenase 4 155854738-155920406 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039611 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Tissue enriched 17 liver: 277.5 appendix: 16.2 TDP1 FLJ11090, SCAN1 ENSG00000042088 Tyrosyl-DNA phosphodiesterase 1 14 89954939-90044768 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA071317 Supported Nucleus
Plasma membrane Liver cancer:8.99e-5 (unfavourable) Expressed in all Mixed testis: 41.7 TEK CD202b, TIE-2, TIE2, VMCM, VMCM1 ENSG00000120156 TEK tyrosine kinase, endothelial 9 27109141-27230175 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010359, HPA073265 Approved Supported Plasma membrane
Microtubule organizing center Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable) Expressed in all Tissue enhanced placenta: 65.3 lung: 42.7 TEX9 ENSG00000151575 Testis expressed 9 15 56244009-56445997 Predicted intracellular proteins Evidence at protein level HPA039415 Uncertain Approved Plasma membrane
Cytosol Mixed Mixed fallopian tube: 44.1 TGFBR1 ACVRLK4, ALK-5, ESS1, MSSE ENSG00000106799 Transforming growth factor, beta receptor 1 9 99104038-99154192 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002441, CAB031481, HPA056473 Uncertain Supported Vesicles
Plasma membrane Expressed in all Expressed in all placenta: 69.3 TGM2 TGC ENSG00000198959 Transglutaminase 2 20 38127387-38166578 Enzymes, Predicted intracellular proteins Evidence at protein level CAB002598, HPA021019, HPA029518 Approved Approved Plasma membrane
Cytosol Renal cancer:1.67e-7 (unfavourable), Pancreatic cancer:2.97e-4 (unfavourable) Expressed in all Tissue enhanced cervix, uterine: 456.8 placenta: 317.8 THY1 CD90 ENSG00000154096 Thy-1 cell surface antigen 11 119417378-119424985 CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003733, CAB068243, CAB068244 Supported Approved Nucleus
Plasma membrane Renal cancer:2.40e-6 (unfavourable), Glioma:9.64e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 422.9;smooth muscle: 428.6 gallbladder: 161.7 TIGD7 Sancho ENSG00000140993 Tigger transposable element derived 7 16 3298832-3305729 Predicted intracellular proteins Evidence at protein level HPA041357, HPA041474 Uncertain Supported Plasma membrane
Cytosol Mixed Mixed testis: 13.6 TIMD4 ENSG00000145850 T-cell immunoglobulin and mucin domain containing 4 5 156919282-156963255 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA015625, CAB026027 Approved Approved Plasma membrane
Cytosol Renal cancer:3.37e-4 (favourable) Tissue enriched Group enriched 6 lymph node: 64.4;testis: 161.6 adipose tissue: 17.7 TM4SF20 FLJ22800, TCCE518 ENSG00000168955 Transmembrane 4 L six family member 20 2 227362156-227381995 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051838, HPA063184, HPA065531 Uncertain Supported Plasma membrane
Focal adhesion sites Group enriched Group enriched 36 duodenum: 285.0;small intestine: 167.3 testis: 6.3 TM4SF4 il-TMP ENSG00000169903 Transmembrane 4 L six family member 4 3 149473974-149503281 Predicted membrane proteins, Transporters Evidence at protein level HPA046430 Supported Approved Plasma membrane
Cytosol Group enriched Group enriched 34 duodenum: 595.8;gallbladder: 1326.5;liver: 343.7;small intestine: 515.2 stomach: 20.3 TMC5 FLJ13593 ENSG00000103534 Transmembrane channel-like 5 16 19410496-19499113 Predicted membrane proteins Evidence at protein level HPA040810, HPA042037 Approved Approved Nucleus
Plasma membrane Liver cancer:7.96e-4 (unfavourable) Mixed Tissue enhanced small intestine: 60.2 duodenum: 46.6 TMEM101 FLJ23987, MGC4251 ENSG00000091947 Transmembrane protein 101 17 44011188-44023946 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039739 Approved Nucleoplasm
Plasma membrane Renal cancer:4.10e-5 (favourable), Endometrial cancer:4.29e-4 (favourable), Liver cancer:7.10e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 156.9 TMEM139 FLJ90586 ENSG00000178826 Transmembrane protein 139 7 143279957-143288048 Predicted membrane proteins, Transporters Evidence at protein level HPA036982, HPA036983 Approved Approved Plasma membrane
Focal adhesion sites Renal cancer:3.05e-5 (favourable), Pancreatic cancer:1.66e-4 (unfavourable) Mixed Tissue enhanced duodenum: 34.9;kidney: 34.4 small intestine: 21.2 TMEM218 ENSG00000150433 Transmembrane protein 218 11 125096545-125111763 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038489 Uncertain Approved Plasma membrane
Cytosol Liver cancer:1.93e-5 (unfavourable), Stomach cancer:5.50e-4 (favourable) Expressed in all Expressed in all fallopian tube: 21.7 TMEM222 C1orf160, DKFZP564D0478 ENSG00000186501 Transmembrane protein 222 1 27322145-27336400 Predicted membrane proteins Evidence at protein level HPA016579, HPA059374 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all fallopian tube: 47.4 TMEM245 C9orf5, CG-2 ENSG00000106771 Transmembrane protein 245 9 109015152-109119945 Predicted membrane proteins Evidence at protein level HPA023892 Approved Approved Plasma membrane
Cytosol Renal cancer:4.46e-9 (favourable) Expressed in all Expressed in all thyroid gland: 123.5 TMEM254 bA369J21.6, C10orf57, FLJ13263 ENSG00000133678 Transmembrane protein 254 10 80078646-80092557 Predicted membrane proteins Evidence at protein level HPA029105 Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all skin: 85.9 TMEM258 C11orf10 ENSG00000134825 Transmembrane protein 258 11 61768501-61792802 Predicted membrane proteins Evidence at protein level HPA044602 Approved Approved Plasma membrane
Cytosol Ovarian cancer:4.37e-4 (favourable) Expressed in all Expressed in all epididymis: 429.6 TMEM266 C15orf27, FLJ38190 ENSG00000169758 Transmembrane protein 266 15 76059837-76229121 Predicted membrane proteins Evidence at protein level HPA041921 Uncertain Supported Plasma membrane
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 1.9;skeletal muscle: 1.5 placenta: 1.1 TMEM63B C6orf110, dJ421H19.2, DKFZp434P0531 ENSG00000137216 Transmembrane protein 63B 6 44126914-44155519 Predicted membrane proteins, Transporters Evidence at protein level HPA029249, HPA029250, HPA029251 Uncertain Validated Plasma membrane
Actin filaments Expressed in all Expressed in all lung: 59.2 TNFRSF10D CD264, DcR2, TRAILR4, TRUNDD ENSG00000173530 Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain 8 23135588-23164030 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA070971 Approved Plasma membrane
Actin filaments Cervical cancer:1.70e-4 (unfavourable) Expressed in all Mixed gallbladder: 12.7 TNFRSF11A CD265, FEO, LOH18CR1, PDB2, RANK ENSG00000141655 Tumor necrosis factor receptor superfamily, member 11a, NFKB activator 18 62325287-62391292 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010391, HPA027728, HPA047976 Uncertain Supported Plasma membrane
Cytosol Mixed Tissue enhanced duodenum: 31.2 small intestine: 20.9 TNFRSF12A CD266, FN14, TweakR ENSG00000006327 Tumor necrosis factor receptor superfamily, member 12A 16 3018445-3022383 Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007853 Approved Approved Plasma membrane
Cytosol Head and neck cancer:5.50e-4 (unfavourable), Renal cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 195.6 TNFRSF9 4-1BB, CD137, ILA ENSG00000049249 Tumor necrosis factor receptor superfamily, member 9 1 7915894-7943165 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA071425 Approved Nucleoli
Plasma membrane Renal cancer:2.69e-8 (unfavourable) Mixed Tissue enhanced lymph node: 11.2;tonsil: 7.4 appendix: 5.3 TOLLIP IL-1RAcPIP ENSG00000078902 Toll interacting protein 11 1274371-1309654 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038621, HPA038622 Supported Approved Plasma membrane
Cytosol Renal cancer:1.11e-16 (favourable), Glioma:4.57e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 132.7 TRAF7 DKFZp586I021, MGC7807, RFWD1, RNF119 ENSG00000131653 TNF receptor-associated factor 7, E3 ubiquitin protein ligase 16 2155698-2178129 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA041229 Approved Supported Vesicles
Plasma membrane Expressed in all Expressed in all duodenum: 41.1 TRAIP RNF206, TRIP ENSG00000183763 TRAF interacting protein 3 49828599-49856574 Predicted intracellular proteins Evidence at protein level HPA036261, HPA036262 Approved Supported Plasma membrane
Cytosol Liver cancer:8.77e-5 (unfavourable) Expressed in all Mixed testis: 11.3 TRAPPC13 C5orf44, FLJ13611, FLJ26957, MGC48585 ENSG00000113597 Trafficking protein particle complex 13 5 65624716-65666233 Predicted intracellular proteins Evidence at protein level HPA037777 Approved Approved Nucleus
Plasma membrane Renal cancer:8.66e-4 (favourable) Expressed in all Expressed in all prostate: 30.0 TRDN ENSG00000186439 Triadin 6 123216339-123637093 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038226, HPA058226 Supported Approved Plasma membrane
Cytosol Tissue enhanced Group enriched 25 heart muscle: 254.8;skeletal muscle: 650.4 prostate: 18.2 TRIM16 EBBP ENSG00000221926 Tripartite motif containing 16 17 15627960-15684311 Predicted intracellular proteins Evidence at protein level HPA023623, HPA066431 Uncertain Supported Plasma membrane
Cytosol Liver cancer:3.94e-4 (unfavourable), Urothelial cancer:6.71e-4 (unfavourable) Expressed in all Expressed in all esophagus: 118.3 TRIM16L TRIM70 ENSG00000108448 Tripartite motif containing 16-like 17 18697998-18736118 Predicted intracellular proteins Evidence at protein level HPA066431 Approved Plasma membrane
Cytosol Thyroid cancer:2.29e-5 (unfavourable), Liver cancer:2.87e-4 (unfavourable) Expressed in all Mixed gallbladder: 22.7 TRIM4 RNF87 ENSG00000146833 Tripartite motif containing 4 7 99876958-99919600 Predicted intracellular proteins Evidence at protein level HPA019356, HPA029461 Approved Supported Plasma membrane
Cytosol Renal cancer:7.36e-6 (favourable) Expressed in all Expressed in all ovary: 50.7 TRIM44 DIPB, MC7 ENSG00000166326 Tripartite motif containing 44 11 35662805-35818007 Predicted intracellular proteins Evidence at protein level HPA049053, HPA057633 Approved Approved Vesicles
Plasma membrane Liver cancer:5.24e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 30.8 TRIML2 FLJ25801, SPRYD6 ENSG00000179046 Tripartite motif family-like 2 4 188091273-188109603 Predicted intracellular proteins Evidence at protein level HPA043838 Uncertain Approved Plasma membrane
Cytosol Tissue enriched Group enriched 25 placenta: 5.9;testis: 3.4 cerebral cortex,lung: 0.1 TRMT10B bA3J10.9, FLJ31455, RG9MTD3 ENSG00000165275 TRNA methyltransferase 10B 9 37753803-37778972 Predicted intracellular proteins Evidence at transcript level HPA021800 Uncertain Approved Nucleoplasm
Plasma membrane Lung cancer:3.91e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable) Expressed in all Mixed skin: 13.0 TRPM4 FLJ20041 ENSG00000130529 Transient receptor potential cation channel, subfamily M, member 4 19 49157741-49211836 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA041169 Supported Supported Nucleoplasm
Plasma membrane Renal cancer:2.53e-7 (favourable), Endometrial cancer:2.88e-7 (favourable) Expressed in all Mixed colon: 27.5 TTC17 FLJ10890 ENSG00000052841 Tetratricopeptide repeat domain 17 11 43358932-43494933 Predicted intracellular proteins Evidence at protein level HPA038508 Approved Supported Plasma membrane
Cytosol Renal cancer:4.75e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 61.6 TTC23 FLJ12572, HCC-8 ENSG00000103852 Tetratricopeptide repeat domain 23 15 99136323-99251223 Predicted intracellular proteins Evidence at protein level HPA039806, HPA040369 Uncertain Approved Plasma membrane
Cytosol Endometrial cancer:1.07e-4 (favourable), Breast cancer:3.17e-4 (favourable) Expressed in all Mixed testis: 24.2 TTLL12 KIAA0153 ENSG00000100304 Tubulin tyrosine ligase-like family member 12 22 43166622-43187133 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003054, CAB046029 Approved Approved Plasma membrane
Cytosol Liver cancer:2.84e-4 (unfavourable) Expressed in all Expressed in all esophagus: 74.6 TTLL5 KIAA0998 ENSG00000119685 Tubulin tyrosine ligase-like family member 5 14 75633625-75955078 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA032128 Uncertain Approved Plasma membrane
Cytosol Expressed in all Tissue enriched 5 testis: 103.3 parathyroid gland: 20.2 TXNDC11 EFP1 ENSG00000153066 Thioredoxin domain containing 11 16 11679080-11742878 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041174, HPA041390 Supported Supported Plasma membrane
Cytosol Endometrial cancer:2.12e-5 (favourable), Glioma:8.01e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 83.0 TXNIP EST01027, HHCPA78, THIF, VDUP1 ENSG00000265972 Thioredoxin interacting protein 1 145992435-145996600 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA031085, HPA053694 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all adipose tissue: 1573.3 TYW3 C1orf171, FLJ40918 ENSG00000162623 TRNA-yW synthesizing protein 3 homolog (S. cerevisiae) 1 74733152-74766678 Enzymes, Predicted intracellular proteins Evidence at protein level HPA029641 Approved Approved Plasma membrane
Cytosol Liver cancer:1.49e-7 (unfavourable) Expressed in all Expressed in all ovary: 32.6 UBAP1 UBAP ENSG00000165006 Ubiquitin associated protein 1 9 34179005-34252523 Predicted intracellular proteins Evidence at protein level HPA019804, HPA041590 Approved Validated Plasma membrane
Cytosol Renal cancer:7.49e-6 (favourable) Expressed in all Expressed in all testis: 88.4 UBE2C UBCH10 ENSG00000175063 Ubiquitin-conjugating enzyme E2C 20 45812576-45816957 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB011464, HPA034569, CAB035990, HPA054975 Approved Validated Plasma membrane
Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.24e-6 (unfavourable), Pancreatic cancer:6.91e-4 (unfavourable) Expressed in all Mixed tonsil: 59.1 UBE2D1 E2(17)KB1, SFT, UBC4/5, UBCH5, UbcH5A ENSG00000072401 Ubiquitin-conjugating enzyme E2D 1 10 58334975-58370753 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003920 Approved Approved Plasma membrane
Cytosol Renal cancer:8.04e-6 (unfavourable), Liver cancer:5.58e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 47.8 UBE2D2 UBC4, UbcH5B ENSG00000131508 Ubiquitin-conjugating enzyme E2D 2 5 139526431-139628433 Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA003920 Approved Approved Plasma membrane
Cytosol Liver cancer:9.63e-7 (unfavourable), Renal cancer:2.09e-5 (unfavourable), Colorectal cancer:5.09e-5 (favourable), Endometrial cancer:5.90e-4 (favourable) Expressed in all Expressed in all testis: 237.4 UBE2D3 UbcH5C ENSG00000109332 Ubiquitin-conjugating enzyme E2D 3 4 102794383-102868896 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003920 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.51e-4 (favourable) Expressed in all Expressed in all bone marrow: 301.5 UBE2D4 HBUCE1 ENSG00000078967 Ubiquitin-conjugating enzyme E2D 4 (putative) 7 43926438-43956136 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003920 Approved Approved Plasma membrane
Cytosol Pancreatic cancer:4.86e-4 (favourable), Prostate cancer:5.77e-4 (favourable), Renal cancer:6.51e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 12.6 UBE2QL1 FLJ25076 ENSG00000215218 Ubiquitin-conjugating enzyme E2Q family-like 1 5 6448623-6494909 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA057414 Supported Nucleus
Plasma membrane Renal cancer:6.81e-8 (favourable) Mixed Tissue enhanced cerebral cortex: 42.0 seminal vesicle: 10.3 UBE2S E2-EPF ENSG00000108106 Ubiquitin-conjugating enzyme E2S 19 55399745-55407777 Enzymes, Predicted intracellular proteins Evidence at protein level CAB015228, HPA057150 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:8.16e-8 (unfavourable), Liver cancer:8.00e-6 (unfavourable), Endometrial cancer:2.05e-4 (unfavourable) Expressed in all Expressed in all testis: 120.1 UBQLN2 Chap1, CHAP1/DSK2, Dsk2, LIC-2, N4BP4, PLIC-2, PLIC2, RIHFB2157 ENSG00000188021 Ubiquilin 2 X 56563639-56567868 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006431, CAB013481 Supported Validated Plasma membrane
Cytosol Liver cancer:2.29e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 53.9 UBR2 bA49A4.1, C6orf133, dJ392M17.3, KIAA0349 ENSG00000024048 Ubiquitin protein ligase E3 component n-recognin 2 6 42564062-42693504 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027869, HPA027880 Approved Approved Nucleoplasm
Plasma membrane Ovarian cancer:1.65e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 30.0 ULBP2 RAET1H ENSG00000131015 UL16 binding protein 2 6 149942000-149949235 Predicted membrane proteins Evidence at protein level CAB018974 Approved Supported Vesicles
Plasma membrane Glioma:3.69e-4 (unfavourable), Cervical cancer:8.07e-4 (unfavourable) Expressed in all Mixed cerebral cortex,esophagus: 3.0 UNC5A KIAA1976, UNC5H1 ENSG00000113763 Unc-5 netrin receptor A 5 176810477-176880895 Predicted membrane proteins Evidence at protein level HPA071450 Approved Plasma membrane
Cytosol Endometrial cancer:2.23e-4 (unfavourable) Tissue enhanced Group enriched 22 adrenal gland: 10.4;cerebral cortex: 35.5 lymph node: 1.0 USP2 UBP41 ENSG00000036672 Ubiquitin specific peptidase 2 11 119355215-119381726 Enzymes, Predicted intracellular proteins Evidence at protein level HPA006777, HPA007222 Approved Supported Plasma membrane
Cytosol Renal cancer:3.09e-11 (favourable) Expressed in all Tissue enhanced testis: 119.2 skeletal muscle: 59.3 USP4 UNP, Unph ENSG00000114316 Ubiquitin specific peptidase 4 (proto-oncogene) 3 49277831-49340712 Enzymes, Predicted intracellular proteins Evidence at protein level HPA018499 Approved Supported Plasma membrane
Cytosol Renal cancer:4.29e-5 (favourable), Lung cancer:4.46e-5 (favourable) Expressed in all Expressed in all testis: 56.7 UTP20 1A6/DRIM, DRIM ENSG00000120800 UTP20 small subunit (SSU) processome component 12 101280109-101386616 Predicted intracellular proteins Evidence at protein level HPA049341 Supported Nucleoli
Plasma membrane Liver cancer:1.15e-5 (unfavourable), Renal cancer:8.87e-4 (favourable) Expressed in all Mixed parathyroid gland: 12.2 UTRN DMDL, DRP, DRP1 ENSG00000152818 Utrophin 6 144285701-144853034 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB016348, HPA018894 Supported Approved Nucleoplasm
Plasma membrane Renal cancer:7.61e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 171.0 VAMP5 ENSG00000168899 Vesicle-associated membrane protein 5 2 85584408-85593412 Predicted membrane proteins Evidence at protein level HPA035082 Supported Approved Nucleoplasm
Plasma membrane Renal cancer:1.28e-5 (unfavourable) Expressed in all Expressed in all lung: 120.0 VPS50 CCDC132, DKFZp313I2429, FLJ20097, KIAA1861, VPS54L ENSG00000004766 VPS50 EARP/GARPII complex subunit 7 93232340-93361121 Predicted intracellular proteins Evidence at protein level HPA026679 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.35e-6 (favourable), Liver cancer:7.21e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 25.5 VPS8 FLJ32099, KIAA0804 ENSG00000156931 Vacuolar protein sorting 8 homolog (S. cerevisiae) 3 184812143-185052614 Predicted intracellular proteins Evidence at protein level HPA036871 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all testis: 31.0 VWA7 C6orf27, G7c, NG37 ENSG00000204396 Von Willebrand factor A domain containing 7 6 31765590-31777294 Predicted secreted proteins Evidence at transcript level HPA046954, HPA054262, HPA055033 Approved Approved Plasma membrane
Cytosol Renal cancer:4.35e-8 (favourable) Mixed Tissue enhanced fallopian tube: 9.0 parathyroid gland: 1.9 WARS2 TrpRS ENSG00000116874 Tryptophanyl tRNA synthetase 2, mitochondrial 1 119031216-119140671 Enzymes, Predicted intracellular proteins Evidence at protein level HPA069692 Supported Supported Plasma membrane
Mitochondria Renal cancer:1.45e-4 (favourable) Expressed in all Expressed in all fallopian tube: 15.2 WASF2 SCAR2, WAVE2 ENSG00000158195 WAS protein family, member 2 1 27404226-27490158 Predicted intracellular proteins Evidence at protein level CAB022632, HPA045288 Supported Approved Plasma membrane
Cytosol Liver cancer:5.29e-8 (unfavourable), Ovarian cancer:8.48e-4 (unfavourable) Expressed in all Expressed in all esophagus: 88.5 WDR53 MGC12928, MGC64882 ENSG00000185798 WD repeat domain 53 3 196554177-196568674 Predicted intracellular proteins Evidence at protein level HPA016420, HPA019332 Approved Approved Plasma membrane
Cytosol Liver cancer:1.57e-6 (unfavourable), Melanoma:3.09e-4 (unfavourable) Expressed in all Tissue enriched 6 testis: 112.1 parathyroid gland: 19.5 WDR6 ENSG00000178252 WD repeat domain 6 3 49007062-49015953 Predicted intracellular proteins Evidence at protein level HPA042622 Approved Supported Plasma membrane
Cytosol Liver cancer:2.97e-6 (unfavourable), Renal cancer:4.52e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 199.7 WDR66 CaM-IP4, MGC33630 ENSG00000158023 WD repeat domain 66 12 121917862-122003927 Predicted intracellular proteins Evidence at protein level HPA039902, HPA040005 Supported Uncertain Plasma membrane
Cytosol Endometrial cancer:3.11e-4 (favourable) Mixed Tissue enhanced fallopian tube: 32.2;testis: 30.6 thyroid gland: 7.4 WIPF1 WASPIP, WIP ENSG00000115935 WAS/WASL interacting protein family, member 1 2 174559572-174682916 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA003739, CAB009737, HPA070706 Supported Approved Plasma membrane
Cytosol Renal cancer:1.14e-4 (unfavourable) Expressed in all Expressed in all lymph node: 159.5 WNT8A WNT8D ENSG00000061492 Wingless-type MMTV integration site family, member 8A 5 138083892-138092365 Predicted secreted proteins Evidence at transcript level HPA038539 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Not detected testis: 0.7 XPC RAD4, XPCC ENSG00000154767 Xeroderma pigmentosum, complementation group C 3 14145147-14178783 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009932, HPA035707, HPA069673 Supported Validated Nucleus
Plasma membrane Renal cancer:4.14e-7 (favourable), Urothelial cancer:2.46e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 51.3 XRN1 SEP1 ENSG00000114127 5'-3' exoribonuclease 1 3 142306607-142448062 Predicted intracellular proteins Evidence at protein level HPA035005, HPA035006 Approved Supported Plasma membrane
Cytosol Pancreatic cancer:9.43e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 21.9 YES1 c-yes, HsT441, Yes ENSG00000176105 YES proto-oncogene 1, Src family tyrosine kinase 18 721588-812546 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004370, HPA026480 Approved Supported Plasma membrane
Cytosol Pancreatic cancer:2.46e-4 (unfavourable) Expressed in all Expressed in all placenta: 61.6 YTHDC1 KIAA1966, YT521, YT521-B ENSG00000083896 YTH domain containing 1 4 68310387-68350089 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036462 Supported Approved Nucleoplasm
Plasma membrane Urothelial cancer:7.29e-5 (favourable) Expressed in all Expressed in all bone marrow: 75.2 ZBED3 MGC15435 ENSG00000132846 Zinc finger, BED-type containing 3 5 77072072-77087323 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA055995 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:1.68e-4 (favourable) Expressed in all Mixed thyroid gland: 18.7 ZGPAT dJ583P15.3, FLJ14972, GPATC6, GPATCH6, KIAA1847, MGC44880, ZC3H9, ZC3HDC9, ZIP ENSG00000197114 Zinc finger, CCCH-type with G patch domain 20 63707465-63736142 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA056705 Supported Nucleus
Plasma membrane Head and neck cancer:6.17e-5 (favourable) Expressed in all Expressed in all liver: 26.9 ZMYND10 BLU, CILD22 ENSG00000004838 Zinc finger, MYND-type containing 10 3 50341110-50346852 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035255 Uncertain Approved Plasma membrane
Cytosol Renal cancer:6.75e-5 (favourable) Tissue enhanced Group enriched 16 fallopian tube: 228.5;testis: 284.3 lung: 15.8 ZNF20 KOX13 ENSG00000132010 Zinc finger protein 20 19 12092843-12140407 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA020887 Uncertain Approved Nucleoplasm
Plasma membrane Not detected Mixed testis: 9.3 ZNF229 ENSG00000278318 Zinc finger protein 229 19 44417519-44448578 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA001494 Uncertain Approved Vesicles
Plasma membrane Renal cancer:8.43e-5 (favourable) Mixed Tissue enhanced parathyroid gland: 6.5 fallopian tube,thyroid gland: 3.1 ZNF277 NRIF4, ZNF277P ENSG00000198839 Zinc finger protein 277 7 112206588-112343096 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA027307 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:9.47e-4 (favourable) Expressed in all Expressed in all thyroid gland: 33.4 ZNF337 dJ694B14.1 ENSG00000130684 Zinc finger protein 337 20 25674215-25696841 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA044303, HPA064219 Uncertain Approved Nuclear speckles
Plasma membrane Renal cancer:2.87e-6 (unfavourable) Mixed Expressed in all parathyroid gland: 28.7 ZNF407 FLJ13839, FLJ20307, KIAA1703 ENSG00000215421 Zinc finger protein 407 18 74597870-75065671 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA028255, HPA041673 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:9.79e-5 (favourable) Expressed in all Mixed parathyroid gland: 8.8 ZNF510 KIAA0972 ENSG00000081386 Zinc finger protein 510 9 96755865-96778129 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA049139 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:5.94e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 12.2 ZNF598 FLJ00086 ENSG00000167962 Zinc finger protein 598 16 1997654-2009823 Predicted intracellular proteins Evidence at protein level HPA041760, HPA041896 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed spleen: 12.4 ZNF655 VIK, VIK-1 ENSG00000197343 Zinc finger protein 655 7 99558406-99576453 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029534, HPA050750 Uncertain Supported Nucleoplasm
Plasma membrane Breast cancer:7.12e-4 (favourable), Melanoma:7.24e-4 (unfavourable) Expressed in all Expressed in all lymph node: 21.5 ZNF783 DKFZp667J212 ENSG00000204946 Zinc finger family member 783 7 149262171-149297302 Predicted intracellular proteins Evidence at protein level HPA020375 Uncertain Approved Plasma membrane
Cytosol Renal cancer:2.24e-7 (unfavourable), Urothelial cancer:4.11e-4 (favourable) Expressed in all Mixed spleen: 9.4 ZNF785 FLJ32130 ENSG00000197162 Zinc finger protein 785 16 30573740-30585771 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA030510 Approved Nucleoplasm
Plasma membrane Pancreatic cancer:2.03e-5 (favourable), Lung cancer:8.99e-4 (favourable) Expressed in all Expressed in all endometrium: 11.8 ZNF839 C14orf131 ENSG00000022976 Zinc finger protein 839 14 102317377-102342702 Predicted intracellular proteins Evidence at protein level HPA020434 Uncertain Approved Nucleoplasm
Plasma membrane Pancreatic cancer:4.57e-4 (favourable), Renal cancer:5.00e-4 (favourable) Expressed in all Expressed in all testis: 36.9 ZSWIM1 C20orf162, dJ337O18.5 ENSG00000168612 Zinc finger, SWIM-type containing 1 20 45881227-45885266 Predicted intracellular proteins Evidence at protein level HPA041147, HPA046751 Uncertain Approved Plasma membrane
Cytosol Pancreatic cancer:1.77e-4 (favourable), Liver cancer:5.47e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 10.6 ZSWIM8 4832404P21Rik, KIAA0913 ENSG00000214655 Zinc finger, SWIM-type containing 8 10 73785582-73801797 Predicted intracellular proteins Evidence at protein level HPA041244 Approved Approved Plasma membrane
Cytosol Head and neck cancer:5.61e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 62.8